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Chapter 1 
Health-Related Quality of Life (HRQOL), Human Immunodeficiency 
Virus (HIV) and Highly Active Anti-Retroviral Therapy (HAART): The 
Example of the US Military HIV Natural History Study (NHS) 
 
Part A: General Introduction to HIV, HAART and HRQOL 
 
1.1: Introduction and Background 
   According to the World Health Organization (WHO), there were over 34 million people 
living with the human immunodeficiency virus/acquired immunodeficiency syndrome 
(HIV/AIDS) globally at the end of 20111 .WHO also estimated that about 2.5 million new 
HIV infections occurred in 20111. The parts of the world most severely affected by the 
HIV/AIDS pandemic are Sub-Saharan Africa (by far the most), the Caribbean, Eastern 
Europe and Central Asia1. It is worth noting that although the regional prevalence of HIV 
infection is about 25 times higher in sub-Saharan Africa than in Asia, almost 5 million 
people are living with HIV in South, South-East and East Asia combined1. AIDS-related 
mortality accounted for about 1.7 million deaths globally. While this represents a 24% 
decline from the 2005 peak, it sheds light on the burden of the disease at the global level. 
The greatest burden of the disease is felt in resource-poor countries where a significant 
number of infected persons still lack access to care despite a worldwide scale-up of anti-
retroviral therapy (ART)1. 
   In resource-rich countries, such as the United States of America, there is widespread 
availability of ARTs. The estimated annual number of persons aged 13 or older with 
newly diagnosed AIDS grew from 318 to 75,457 between 1981 and 19922. Deaths from 
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AIDS also increased steadily from 451 to 50,628 between 1981 and 19952. Following the 
introduction of highly active antiretroviral therapy (HAART), AIDS diagnoses and 
deaths declined significantly from 1995 to 1998, and remained stable from 1999 to 2008 
at an average of 38,279 AIDS diagnoses and 17,489 deaths per year, respectively2.  In the 
US men who have sex with men (MSM) and blacks bear the greatest burden of the 
disease2,3.  At the end of 2008, there were over 1.1 million people living with HIV/AIDS 
in the United States2. The incidence of new HIV infections has remained stable at about 
50,000 yearly2. Factors contributing to this are multiple and include continued high risk 
behavior among high risk groups – injection drug users (IDU), men who have sex with 
men (MSM), and sex workers; lack of awareness of infection status, access to or retention 
in HIV care and HIV-drug resistance4.    
1.2: Human Immunodeficiency Virus (HIV) 
1.2.1: HIV Life Cycle 
   Figures 1 and 2 respectively show the structure of HIV and the HIV lifecycle. HIV is a 
retrovirus, a double-stranded ribonucleic acid (RNA) that employs the reverse 
transcriptase (RT) enzyme to transcribe the RNA into DNA in the cytoplasm of infected 
host’s cell. Reverse transcription of the RNA core yields proviral DNA that may either 
reside in the cytoplasm in circular form or enter the cell nucleus and become integrated 
into host DNA5. Integrated viral DNA genes may remain latent, or, in response to viral 
and host regulatory proteins, may become activated. When the proviral DNA genes are 
activated, messenger RNA is transcribed leading to the formation of regulatory proteins 
such as tat and rev. These proteins, together with viral genomic RNA transcribed from 
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the integrated viral DNA, are assembled to form new HIV-1 viruses, which leave the 
infected cell and are available to attack new cells5.  
   The major (glycol)-proteins to which humans infected with HIV produce antibodies are 
gp120, gp41, p16/p14, p27/p25 and p24. Both gp120 and gp41 are external envelope 
proteins that bind to receptors of host cells including CD4+ lymphocytes, macrophages, 
and monocytes; they are necessary for infectivity. However, gp120 attachment to CD4+ 
requires the presence of chemokine co-receptors such as CXCR4 or CCR5, which 
facilitate the process of cell binding and entry5. The p16/p14 tat proteins are found mostly 
in the nucleus and nucleolus of infected cells and function as an activator of viral 
transcription. The p19 rev protein is responsible for the transport and stability of the viral 
RNA, and travels between the cytoplasm and nucleolus of the infected cell. The p27/p25 
nef proteins are active in the down regulation of CD4+ cells. They reside in the plasma 
membrane as well as the cytoplasm. The p24 gag protein functions in the core capsid and 
is found in the virion5.  
1.2.2: HIV Natural History  
   HIV infection is characterized by an acute (primary) phase, a clinical latency phase and 
a chronic infection phase including development of symptomatic disease and acquired 
immune disease (AIDS). Transmitted either sexually or parenterally, the HIV virus is 
detectable within 7-10 days of initial infection and viral antibodies detectable in 7-21 
days later5. During this acute stage (acute HIV infection syndrome), viral load is usually 
high and infected individuals may present with flu-like symptoms such as fever, 
adenopathy, pharyngitis, and rash. Some may present with systemic symptoms including 
meningitis, Guillain-Barre syndrome, peripheral neuropathy and Bell’s palsy5. 
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Subsequent to and after destruction of gut-associated lymphoid tissue (GALT) that occurs 
a few weeks after the initial infection, the body’s immune system responds via B-cell 
produced antibodies and CD8+ cells directed against the virus. At this point, the HIV 
viral level in the blood declines with a new viral set-point set in 3 to 4 months5. 
   The clinical latency period is defined by a gradual decline in the level of CD4+ cells 
along with an increase in the CD8+ cells such that the ratio of CD4+/CD8+ drops below 
1.0; the number of CD3+ cells remains relatively stable for several years. Destruction of 
the immune system continues and CD4+ cell level further declines as more viral particles 
are produced. Generally, CD4+ count indicates the degree of immunosuppression while 
the plasma viral load indicates the level of immune control versus viral replication and 
pathogenesis5. 
   Several months prior to the development of clinical AIDS, a loss in T-cell homeostasis 
occurs as reflected by the rapid decline in CD3+ cells5. The above process is often 
accompanied by a change in the co-receptor utilization from CCR5 to CXCR-4 cell type. 
In rare situations where CXCR-4 predominates early in the infection, progression to 
clinical AIDS occurs more rapidly5. The median time from initial infection to 
development of clinical AIDS is about 10 years5. The Centers for Disease Control and 
Prevention (CDC) definition of AIDS include a laboratory confirmed HIV-infection and 
CD4+ T-lymphocyte count of less than 200cells/µL or with one of the AIDS defining 
opportunistic infections listed in table 16. Pneumocystis jiroveci pneumonia, HIV wasting 
syndrome, Kaposi’s sarcoma, oropharyngeal and esophageal candidiasis, extrapulmonary 
Cryptococcus, and tuberculosis are the commonly encountered opportunistic infections in 
the US5.            
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1.3: Highly Active Anti-Retroviral Therapy (HAART) 
   There are currently over 25 antiretroviral drugs approved by the United States’ Food 
and Drug Administration (Table 1.2). The six distinct classes of antiretroviral drugs are 
nucleoside reverse transcriptase inhibitors (NRTIs), Non-Nucleoside reverse 
Transcriptase Inhibitors (NNRTI), Protease Inhibitors (PIs), Integrase Inhibitors (INIs), 
Fusion Inhibitors and Small-Molecule CCR5 Antagonists7. Both fusion inhibitors and 
small-molecule CCR5 antagonists are referred to as Entry Inhibitors7.  
   Before 1996, HIV/AIDS was treated with a single drug in the earlier period and later 
with two drugs. Because of resistance and the resultant treatment failure, and following 
the approval of the first protease inhibitors, combination therapy requiring at least two 
different classes of 3 different drugs were introduced with great success at maintaining 
virologic suppression beyond levels detectable by laboratory assays (< 50 copies per 
mL). The 3 drugs regimens came to be referred to as highly active antiretroviral therapy 
(HAART), usually requiring a protease inhibitor but because of toxicities non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) were also used. Currently, HAART may be 
defined as a combination of at least three antiretroviral drugs from at least two classes. 
Preferred regimes include NNRTI-based regimen, PI-based regimes and INIs-based 
regimen8.  
   NRTIs are reverse transcriptase (RT) inhibitors. They act by inhibiting DNA strand 
synthesis after being incorporated into the growing viral chain. Zidovudine (AZT, 
Retrovir), an NRTI, was the first anti-retroviral drug approved by the FDA in 1986. Other 
examples of NRTIs include stavudine (d4T, Zerit), didanosine, emtricitabine (FTC, 
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Emtriva), tenofovir disoprovil fumarate (TDF, Viread), abacavir (ABC, Ziagen), 
lamivudine (3TC, Epivir).  
   NNRTIs inhibit HIV-1 RT by binding and inducing the formation of a hydrophobic 
pocket proximal to, but not overlapping the active site7. The binding of NNTRIs changes 
the spatial conformation of the substrate-binding site and reduces polymerase activity7. 
Examples of NNRTIs are efavirenz, nevirapine, delaviridine, etravirine, and rilpivirine. 
   PIs block proteolysis of the viral polyprotein, a step required for the production of 
infectious particles7. PIs are among the most potent agents developed to date, but are 
large, peptide-like compounds that generally required co-administration of a boosting 
agent to inhibit their metabolism and enhance drug levels7. The HIV protease enzyme is 
responsible for the cleavage of the viral gag and gag-pol polyprotein precursors during 
virion maturation. Currently approved PIs include atazanavir (ATZ, Reyataz), darunavir 
(TMC114, Prezista), fosamprenavir (Lexiva), indinavir (IDV, Crixivan), lopinavir (LPV), 
nelfinavir (NFV, Viracept), ritonavir (RTV, Norvir), saquinavir (SQV, 
Fortovase/Invirase) and tipranavir (TPV, Aptivus)    
   First approved in 2007, integrase inhibitors (INIs or InSTIs) are the newest class of 
ARTs approved by the FDA7. They specifically inhibit strand transfer and block 
integration of the HIV DNA into the cellular DNA. All InSTIs are made up of two 
essential components: a metal-binding pharmacophore, which sequesters the active site 
magnesiums, and a hydrophobic group, which interacts with the viral DNA as well as the 
enzyme in the complex7. Examples of InSTIs are raltegravir and dolutegravir. 
Dolutegravir was approved in August, 20139. 
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   Peptide fusion inhibitors were designed based on the discovery that two homologous 
domains in the viral gp41 protein must interact with each other to promote fusion, and 
that mimicry of one of one of these domains by a heterologous protein can bind and 
disrupt the intra-molecular interactions of the virus protein7. The only currently available 
fusion inhibitor is enfuvirtide (T-20) and is given by subcutaneous injection. 
   Small-molecule CCR5 antagonists carry out their anti-retroviral activity by binding to 
the hydrophobic pockets within the transmembrane helices of CCR57. Also approved for 
the first time in 2007 by the FDA, maraviroc is the only available co-receptor CCR5 
antagonist in the market. 
   There is drug resistance to virtually all available ARTs with cross-resistance among 
many of the drugs in the same class7. For the co-receptor CCR5 antagonist, resistance 
detection may be difficult to notice at the time of treatment failure making their use in 
clinical practice more complex compared to the other ARTs7. Because of resistance and 
drug toxicities, HIV-infected individuals may need to change medications from time to 
time5. 
1.4: Health-Related Quality of Life (HRQOL) 
1.4.1: Definitions 
   The term health-related quality of life (HRQOL) is traceable to the 1948 definition of 
health10 by the World Health Organization, which defined health as “a state of complete 
physical, mental and social well-being and not merely the absence of disease or 
infirmity”11. It is not surprising then that currently used definitions have towed similar 
concept of health. For example, Coons et al defined HRQOL as to “how well a person 
functions and to his or her perceptions of well-being in the physical, mental, and social 
8 
 
domains of life”12.  The definition proposed by Wenger and Furberg and adopted by 
Naughton and Shumaker refers to HRQOL as “encompassing those attributes valued by 
patients, including their resultant comfort or sense of well-being; the extent to which they 
are able to maintain reasonable physical, emotional, and intellectual function; and the 
degree to which they retain their ability to participate in valued activities in the family, in 
the work-place, and in the community”13,14. The Centers for Disease Control and 
Prevention simply defines HRQOL as “encompassing those aspects of overall quality of 
life that can be clearly shown to affect health – either physical or mental”15. HRQOL 
therefore encompasses both the actual capabilities of the individual and his or her 
perceptions of activities the individual value as critical to assess13. Although quality of 
life (QOL) is often used synonymously with HRQOL in the literature (the older ones 
especially), QOL is an inclusive, broad concept that incorporates all factors affecting a 
person including economic status, social functioning, health status, life satisfaction and 
well-being, HRQOL focuses specifically on QOL as it relates to health. 
1.4.2: Relevance of HRQOL 
    HRQOL is of particular importance in chronic illnesses, such as HIV/AIDS in which 
current therapeutic goals are not aimed at a cure but in halting disease progression, 
alleviating symptoms, improving functional capabilities and mitigating the adverse 
psychosocial consequences that may be associated with the disease14. Although often 
assessed in research settings, routine clinical assessment of health-related quality of life 
in persons with HIV infection has the potential to improve care by assessing and 
monitoring treatment effects, enhancing communication between patient and the 
provider, and tracking changes in functional status over time10.  
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   Given that there are HIV-naïve individuals who will eventually be requiring HAART, 
there is need to monitor the untreated course of the disease in order to allow intervention 
when it will be most beneficial to the infected individual. Also, the increased lifespan 
from HAART therapy also means that people living with HIV/AIDS (PLHA) are at 
potentially increased risk of prolonged morbidity due to medication adverse effects and 
age-associated comorbidity, such as diabetes, cancers, chronic obstructive pulmonary 
disease and heart diseases. HRQOL measures reflect the overall health status of the 
individual and with the increased survival in the HAART era non-AIDS comorbidities 
are now the principal diagnoses among those with HIV. Furthermore, resistance to 
medication, non-compliance, and future high risk behavior with acquisition of more 
virulent strains of the virus may further complicate the natural history of the disease with 
varying impact on the individual’s well-being and quality of life. Finally, studies on 
HRQOL data can help identify subgroups with relatively poor perceived health and guide 
interventions to improve their situations and avert more serious consequences15. The 
interpretation and publication of these findings can help identify needs for health policies 
and legislation, help to allocate resources based on unmet needs, guide the development 
of strategic plans, and monitor the effectiveness of broad community interventions15.  
1.4.3: HRQOL Dimensions 
   The primary HRQOL dimensions are physical functioning, social functioning, 
psychological functioning, overall life satisfaction/well-being, and perception of health 
status13. Physical functioning refers to an individual’s daily life activities. Social 
functioning is defined as a person’s ability to interact with family, friends and the 
community13. Psychological functioning of a person refers to the individual’s emotional 
10 
 
well15. Overall life satisfaction represents a person’s perception of his or her overall sense 
of well-being15. Perceptions of health status is different from actual health but chronic 
illnesses or the acquisition of potentially deadly infection such as HIV may come with a 
period of adjustment, with individuals resetting their expectations and adapting to their 
new life situation. For HIV/AIDS, stigma and societal acceptability may all affect this 
process, as well as the availability and accessibility of therapy including psychological 
therapy.   
   Additional HRQOL dimensions that have been studied in the literature include 
neuropsychological functioning, personal productivity, intimacy and sexual functioning, 
sleep disturbance, pain and symptoms15. Neuropsychological functioning refers to the 
cognitive abilities of a person, such as memory, recognition, spatial skills and motor 
coordination13. HIV/AIDS may directly affect neurocognitive functioning, for example 
HIV dementia or it may be the complication of opportunistic infections such as 
toxoplasmosis or leukemia. Personal productivity includes paid and unpaid activities the 
individual is engaged in. Employment status is often affected by the disease. Sleep 
disturbance is often related to anxiety and depression and is a common finding among 
HIV-infected individuals; it has been shown to affect HRQOL10. Pain is a commonly 
assessed domain in HRQOL. HIV/AIDS patients may be plagued with chronic and 
debilitating pains such as HIV distal neuropathic pain that may significantly affect 
HRQOL16. Symptomatic HIV patients have poorer HRQOL compared to asymptomatic 
patients and symptom burden is a recognized contributor to the HRQOL of life of HIV-
infected individuals4,12,17-20.        
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1.4.4: HRQOL Instruments 
    Over the years several HRQOL instruments have been developed. There are two broad 
groups of HRQOL instruments – generic and disease specific. The generic instruments 
are designed to assess HRQOL in a broad range of populations and diseases while 
specific HRQOL instruments are designed to assess HRQOL in specific diseases such as 
HIV/AIDS. Examples of validated generic instruments include Medical Outcome Studies 
Short Form – 36 (MOS SF-36), Quality of Well-Being (QWB) Scale, Sickness Impact 
Profile (SIP), Nottingham Health Profile (NHP), the Cooperative Information Project 
(COOP) Charts, Time Trade Off (TTO), Standard Gamble (SG), Spitzer QL index, the 
World Health Organization Quality of Life Assessment Instrument (WHOQOL), the 
EuroQol – 5 Dimensions – 5 Levels (EQ-5D-5L), and Quality-Adjusted Time Without 
Symptoms or Toxicity (Q-TWiST)4,10. Q-TWiST is regarded as a generic tool but was 
initially developed for HRQOL assessment in cancer clinical trials21. Examples of 
validated HIV-disease specific HRQOL instruments include Medical Outcome Study-
HIV Health Survey (MOS-HIV), HIV Overview of Problems/Evaluation Systems 
(HOPES), HIV/AIDS-Targeted Quality of Life (HAT-QOL) and the AIDS Clinical Trial 
Group QOL Health survey (ACTG-QOL)4,10,22. Tables 3 and 4 respectively display the 
generic and HIV-disease specific HRQOL instruments, the dimensions examined by 
these tools, the approximate completion time, mode of administration as well as some of 
their advantages and disadvantages10.  
   A good HRQOL instrument must be both valid and reliable4,10. Both the construct 
validity and the content validity must be established4. While the construct validity 
ensures that the instrument measures what it purports to measure the content validity 
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ensures that the tool measures all aspect of a given question23. Reliability refers to the 
degree to which the results obtained by a measurement, procedure can be replicated23. 
Reliability of the instruments is measured through their internal consistency using 
Cronbach’s Alpha. A Cronbach’s alpha of 0.7 and above is considered acceptable. Apart 
from validity and reliability, Grossman et al have proposed that an ideal instrument be 
self-administered, brief yet reasonably comprehensive, evaluates the most relevant 
aspects of HIV-related HRQOL, appropriate for the entire spectrum of the disease 
severity, responsive to clinically important changes in health status over time, easy to 
understand/appropriate for all literacy levels, sensitive to a wide range of patient cultural 
and ethnic backgrounds, available in appropriate translated versions, has wide patient 
acceptance/adherence, and allows easy data collection, scoring, and interpretation without 
the need to use a computer10. Finally, an ideal HRQOL tool must avoid the floor and 
ceiling effects in their scores4. Because no instrument meets all these criteria tradeoffs are 
usually made between the breadth and depth of the measuring tool24. Whereas breadth 
deals with the comprehensiveness of the tool, depth is concerned with the concept the 
instrument purportedly measures25.  
   In our cohort, the SF-36 was used for obtaining HRQOL data. The SF-36 instrument 
has extensive usage in both cross-sectional and cohort studies. However, because it is a 
generic instrument its use in clinical trials is somewhat limited. In a systemic review of 
24 clinical trials studies carried out by Gakhar et al, only 2 studies used the MOS SF-36 
instrument while the MOS-HIV was used in 12 of those studies4. Shahriar et al compared 
the SF-36 and the MOS-HIV but did not find any unique value of the MOS-HIV over the 
SF-36. They concluded that although the SF-36 was a generic instrument, it may be a 
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preferable over the MOS-HIV because of the fewer ceiling effects, availability of 
national norms, and the vast amount of data for other populations in the U.S. and around 
the world26.     
1.4.5: The Medical Outcomes (MOS) Survey Short Form 36 (SF-36) 
   The precursor of the MOS SF-36 is the MOS Functioning and Well-Being Profile 
(MOSFWBP), an instrument that contains 149 items and requires 30 to 40 minutes to 
complete10. Because of its length, shorter versions of the instrument such as MOS SF-20, 
MOS SF-12, MOS SF-56, and the MOS SF-21 were developed from it10,27. An HIV-
disease specific instrument is the MOS-HIV. The MOS was a 4 year observational study 
of the influence of characteristics of providers, patients, and health systems on outcomes 
of care10. The SF-36 is a generic, multi-purpose, short-form health survey with only 36 
questions. It is a preference-based health utility index that has been used extensively in 
the US and internationally.  
   The SF-36 utilizes eight health concepts, namely physical functioning (PF), bodily pain 
(BP), role limitations due to physical health (RP), role limitations due to personal or 
emotional problems (RE), emotional well-being or mental health (MH), social 
functioning (SF), energy/fatigue or vitality (VT), and general health (GH) 
perceptions4,10,22,28.  These concepts are further combined to form two summary scores 
known as the physical component summary (PCS) score (PF, BP, RP, and GH) and the 
mental component summary (MCS) score (MH, SF, RE and VT)24. Among the HRQOL 
domains that are included in other widely used surveys but not included in the SF-36 are 
sleep adequacy, cognitive functioning, sexual functioning, health distress, family 
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functioning, self-esteem, eating, recreation/hobbies, communication, and, by its generic 
nature, symptoms specific to one disease condition24. 
   The MOS SF-36 is self-administered, takes about 10 minutes to complete and has been 
adapted in many cultures and translated into over 50 languages10. Table 5 shows the 
number of items in each concept, the levels and meaning of low and high scores of each 
concept27. The SF-36 instrument is displayed in Table 628.  The means and standard 
deviations of the PCSS and MCSS are both 50 and 10 respectively for the general US 
population. Table 722,28 shows the number of items in each subscale, their reliability 
(Cronbach’s Alpha), means, and corresponding standard deviations for the general US 
population.    
1.4.6: An Overview of Analytical Methods Used on HRQOL Research 
   HRQOL scores are generated as continuous variables usually in the global categories as 
mental component summary scale and physical component summary scale. In most cross-
sectional studies on HRQOL, HRQOL is the outcome variable. Typically, in such studies 
HRQOL score is a continuous variable and analyses involves multivariate linear 
regression models to compute the beta coefficients of the explanatory variables. Because 
the SF-36 is a norm based scoring system, the HRQOL scores generated from this 
instrument for any given group can be directly compared to that of the US general 
population using the Z-test. In clinical trials, the baseline HRQOL scores are compared to 
that obtained at the end of follow-up using the t-test. The general approach in clinical 
trials is to use an intention-to-treat (ITT) analysis. In prospective cohort studies, t-test 
analysis are also used especially if when there are only two measurement points but 
studies using t-tests with more than two measurement points have also been done29. A 
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few prospective studies have used random effects regression model30 in analyzing the 
impact of various explanatory variables on HRQOL, therefore accounting for time-
varying covariates in the model which the earlier described approaches ignored.   
   Much fewer studies have used HRQOL as the explanatory variable in the literature, and 
such studies were mainly concerned with the ability of HRQOL to predict the utilization 
of healthcare resources31,32 or mortality33,34. Survival analysis (Cox Proportional Hazard 
Regression models) has been used in assessing predictive value of HRQOL on 
survival33,34. Descriptive statistics have included Kaplan-Meier curves and the log-rank 
tests in these studies. In both studies HRQOL was divided into quartiles with the first 
quartile indicating worse HRQOL scores and the 4th quartile the best33,34. Cook et al31 
used random effects logistic regression model for their analysis while Royal et al32 used 
multivariable logistic regression model in their analysis.          
1.5: HIV, HAART and HRQOL 
    The diagnosis of HIV infection, in and of itself, can have deleterious impact on the 
psychological state of the individual and may negatively affect HRQOL especially for 
those with poor coping skills and with limited social support10.  Both HIV-related 
symptoms and adverse effects from medications affect a wide range of the individual’s 
quality of life and well-being35. Studies in the pre-HAART era generally revealed that 
HRQOL deteriorated over time for PLHA, especially for those who progressed to 
develop AIDS35-37. Others have found that HRQOL in asymptomatic HIV infection is 
comparable to that of the general population but as symptoms develop the HRQOL 
gradually declines38. Those with symptomatic AIDS generally have a much poorer 
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HRQOL score compared to asymptomatic HIV infected individuals or the general 
population38,39.  
   Because those on HAART typically have a longer lifespan, they are potentially at 
increased risk of experiencing the adverse effects of the medications including diarrhea, 
anemia and lipodystrophy. Other side effects are peripheral neuropathy, insulin 
resistance, renal tubular toxicity, osteopenia, hepatotoxicity, pancreatitis, hypersensitivity 
reaction, hyperprolactinemia and neuropsychiatric disturbances35. It is estimated that 
three symptoms or side effects would result in deterioration in HRQOL by one standard 
deviation35. Assessing HRQOL in individuals with HIV disease on treatment is therefore 
very important as it is one of the only methods of reconciling the risks and benefits of 
prolonged therapies against a complex background of diverse morbidity40. 
1.6: Gaps in the Literature 
   The greater majority of research conducted on HRQOL in people living with 
HIV/AIDS are cross-sectional studies29,38,41-48, and most of the longitudinal studies have 
been carried over relatively short periods of time, usually no longer than 1-year36,49-54 or 
2-year duration55-57. Also, most of these longitudinal studies were carried out in clinical 
trial settings as against a prospective cohort setting. Clinical trials findings may not 
always apply to non-clinical trial studies and the general population because of limited 
representation of minorities and disadvantaged groups in clinical trials. More so, clinical 
trials have strict inclusion criteria in order to decrease the probability of attrition or 
toxicity and maximize the likelihood of detecting a treatment effect. In their study to 
directly compare the HRQOL scores between clinical trial sample and non-clinical trial 
sample, Cunningham et al found that HRQOL scores were significantly lower in the non-
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clinical trial group compared to the clinical trial group by about one standard deviation, 
even after direct adjustment for clinical and demographic characteristics, and also after 
comparison of the non-trial sample with the most symptomatic in the trial sample58. Some 
of the longitudinal studies involved the switching of drugs and did not have appropriate 
control group but uses the individual’s baseline HRQOL score as basis for comparison54. 
   The few prospective cohort studies on HRQOL also had problems with generalizability 
because they addressed specific groups or populations or had issues with sample size or 
were non-US based studies. For example, the work by Burgoyne et al had a 4-year 
follow-up but had only 41 patients making sub-analysis and the ability to detect effect 
size changes difficult29. They had enrolled 56 patients but lost 15 to follow-up and so 
issues of selection bias due to attrition may very well affect the interpretation of their 
results. The authors did not account for time varying covariates in their analysis. The 
study by Cook et al had only women31. Although the investigators used a random effects 
regression model, they only studied the impact of mental health quality of life on 
healthcare utilization31. The study by Liu et al studied only men who have sex with men, 
and so may not be generalizable to heterosexual men and women. The studies by Jia et 
al53 and Lorenz et al59 had only two measurement points, baseline and 12 months and 
baseline and 18 months respectively. Another study by Jia et al60 also had two 
measurement points (baseline and 12 months), had only male participants and was drawn 
from 3 infectious disease clinics in one southern state, and would therefore not be 
considered representative of the entire country.  The study by Cunningham et al used the 
Cox proportional hazards regression model to analyze the predictive value of HRQOL on 
mortality in a large representative HIV cohort but that study is over 9 years old and the 
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data was collected between January 1996 and December 199933. Given that mortality is 
no longer a very common outcome among HIV-infected individuals in the US and other 
developed countries, other important end-points such as emergency room utilization and 
hospitalization may appear to be more relevant studies today. Another study that used the 
Cox regression model was that by De-Boer-van-der-Kolk et al; however, unlike the study 
by Cunningham et al, this study was based on a French population34. 
   Protopopescu et al carried out a 5-year longitudinal study of the APROCO-COPILOTE 
cohort (ANRS CO-8) in which they compared the results of a random effect model 
(REM) to that of a joint model in their cohort when there is non-ignorable missing data30. 
They found similar results from both analytical models. The study evaluated the change 
in HRQOL (physical and mental component summary scores) in 1,000 participants who 
are on a PI-based HAART regime over a 5-year period. At the time of HAART initiation, 
42.3% were HAART-naïve. Enrollment into this French cohort started in 1997 but the 
authors did not specify the time period they considered. These authors found that 
immune-depression and self-reported side effects were negative predictors of both 
physical and mental component summary scores. They also found that HRQOL improved 
after the first year of follow-up but stabilized thereafter. Because this was a PI-based 
HAART cohort, inferences may not be applicable to non-PI HAART cohort/population.  
   In the light of the aforementioned gaps in the literature, our proposed study provides us 
a unique opportunity to answer many of the questions on HRQOL in the HAART era in 
the United States, especially in the setting of equal access to health care. It allows us to 
compare the baseline predictors of HRQOL in our cohort to that of the general military 
population as reported in the Millennium cohort by Smith et al61. Other obvious 
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advantages the cohort provides us are its comprehensive and extensive follow-up periods 
and the large sample size. We would therefore be able to conduct analysis of the impact 
of specific HAART on HRQOL62; the impact of medical and mental comorbidities and 
AIDS-defining events on HRQOL40, and the relationship between HRQOL and 
healthcare utilization, specifically hospitalizations. 
 Part B: A General Descriptive Statistics of HRQOL of the NHS Cohort at Baseline 
1.7: Methods 
1.7.1: Study Cohort 
The U.S. Military HIV Natural History Study (NHS) is a prospective multicenter 
continuous enrollment observational cohort of HIV-infected active duty military 
personnel and other beneficiaries (spouses, adult dependents, and retired military 
personnel) from the Army, Navy/Marines and Air Force enrolled since 198663-66.  
Participants are followed at five medical centers in the United States.  Demographic data 
are collected at baseline and updated while medical and medication histories and standard 
laboratory studies are collected biannually. Blood samples obtained from participants in 
this cohort from scheduled visits are stored in a repository.  Demographic information 
captured includes race/ethnicity (Caucasian, African American, Hispanic or Puerto Rican, 
Mexican, Asian, or Pacific Islander, Native American or Alaskan native, or other), age, 
gender, active duty, retired or dependent, and rank in military. Although not captured in 
the NHS database, injection drug use (IDU) has been reported to be very rare in this 
cohort64,67.  All NHS participants provided informed consent, and approval for this 
research was obtained from the institutional review board at each participating site. 
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1.7.2: Study Participants  
   The RAND Short Form 36 (SF-36) questionnaires were administered annually to NHS 
participants from April 2006 to September 2010. However, a few participants had more 
than one completed questionnaire in a year, and for these participants the last completed 
questionnaire for that year was used. There were 1731 participants who completed the 
questionnaires over the period of the study. We used the CD4 count and HIV RNA levels 
closest in time to the HRQOL measure used. 
1.7.3: Definitions and Variable Selections 
1.7.3.1: Health-Related Quality of Life Scores 
   Baseline is defined as the first ever HRQOL measure irrespective of when the 
participant was enrolled in the study. As previously stated, there are eight health domains 
measured in the SF-36 questionnaires. These domains are further combined to produce 
two component summary scores – a physical component summary score (PCSS) and a 
mental component summary score (MCSS). We used the RAND 36-Item Health Survey 
1.068 scoring system. This scoring system also includes a single item that provides an 
indication of perceived change in health but this item does not contribute to the score. 
The Rand Scoring System is a two-step process that is much easier to compute and 
differs from the MOS SF-36 Scoring System68, although the instruments are the same. 
The first step is recoding of the pre-coded numeric values as shown in the scoring key in 
Table 1.8. All items are scored so that a high score defines a more favorable health state 
(see Table 1.3). Each item is scored on a 0 to 100 range so that the lowest and highest 
possible scores are set at 0 and 100, respectively (Table 1.9). Scores represent the 
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percentage of total possible scores achieved. In the second step, items in the same scale 
are averaged together to create the eight scale scores68. Only non-missing values are 
considered in calculating the scale scores68. For our dataset, we computed the eight health 
domain scores as well as the United States norm-based physical and mental components 
summary scores using the codes written by Ron Hays and available in his website69. 
1.7.3.2: HAART (Treatment) Variable 
   HAART is defined as a combination of at least three antiretroviral agents similar to 
previous investigations for this cohort64. HAART treatment is further divided into three 
groups: a protease inhibitor-based HAART (PI-HAART), for HAART with at least one 
protease inhibitor in the combined HAART regimen; a non-protease-inhibitor-based 
HAART (NPI-HAART), for HAART with at no protease inhibitor in the combined 
HAART regimen; and a HAART-naïve group (HAART-N) for those not on HAART. By 
HAART-naïve we mean participants had never been on HAART prior to completing the 
SF-36 questionnaire at baseline.  
1.7.3.3: Other Variables  
   Variables considered for inclusion in the descriptive statistics and for the final models 
of the hypothesis-driven aims include HRQOL scores (PCSS and MCSS) and HAART 
treatment already defined above, gender (male/female), age, military rank 
(officer/warrant officer, enlisted and civilian/retired),  marital status (married, not 
married), race/ethnicity, HIV RNA viral levels (measured in log base 10), CD4+ count, 
medical comorbidity, mental comorbidity, AIDS-defining illnesses, medication 
adherence, HIV duration, and calendar year. Calendar year is the year in which the 
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participant first completed the SF-36 questionnaire irrespective of when the participant 
was enrolled in the NHS. 
   Although AIDS-defining illnesses have declined significantly in the post-HAART era, 
AIDS definition will be in line with 1993 Centers for Disease Control and Prevention 
criteria, with the exception of an isolated CD4 count <200 cells/mm3 as CD4 count will 
be analyzed separately.  Race/ethnicity will be classified as non-Hispanic white, non-
Hispanic African-American/black, and Others/Hispanic. Medical co-morbidity refers to 
chronic medical conditions, and will be classified as having no comorbidity or having one 
or more comorbidity. Mental comorbidity will be classified similarly. Adherence was 
classified as ‘good’ (yes) or ‘poor’ (no) with at least 90% adherence level required for 
classifying as good56 
1.7.4: Inclusion and Exclusion Criteria 
   All participants in the US Military HIV NHS cohort who completed at least one 
HRQOL survey between 2006 and 2010 were included in the study.  Exclusions will 
depend on the particular analysis and will be discussed in the relevant section.  
1.7.5: Data Analysis 
   We computed scores of the eight health domains of HRQOL and the two norm-based 
summary scores (PCSS and MCSS) using the SAS codes provided Ron D. Hays.69 We 
provided descriptive statistics using the proportions for count variables and 
means/standard deviations as well as the median/interquartile ranges for numeric 
variables including those for the eight health domains and the summary scores of the 
computed HRQOL measures. All statistical analyses were carried out using SAS version 
9.3 [SAS Institute Inc., Cary, NC]. 
23 
 
1.8: Results and Discussion 
   Figures 1.3.a and 1.3.b show the returns of completed survey questionnaires by month 
and year. There were 827 completed surveys in 2006 but returns were above 1000 from 
2007 to 2010, with 2009 recording the highest number of completed surveys at 1284. 
Table 1.10 shows the descriptive statistics of the participants. Out of the 1730 
participants who met our eligibility criteria, 826 (48%) were enrolled in the study for the 
first time in 2006, another 486 (28%) were enrolled in 2007 while the remaining 418 
(24%) were enrolled in the study between 2008 and 2010. 42.54% were non-Hispanic 
African Americans, 41.79% non-Hispanic Whites and 15.66% comprising of other 
races/ethnic groups including Hispanics. Only 7% of the participants were female. 
14.51% of the participants had one or more medical comorbidities while 25.78% had one 
or more mental comorbidities. By far the most common mental comorbidity in the cohort 
was major depressive disorder (60.59%) followed by general anxiety and bipolar 
disorders (17.53%) and alcohol abuse (11.98%). The common medical conditions were 
diabetes mellitus (33%), cancers (31%), cardiovascular diseases including coronary 
artery disease (11%) and kidney disease (9%). 11.56% of participants had AIDS at 
baseline with the median duration for the development of an AIDS-defining event being 
7 years (interquartile range [IQR] of 1-12 years). About 24% of the cohort were HAART 
naïve at baseline while another 9% were off HAART at baseline, making the total percent 
of participants ‘not on HAART’ at baseline 35% (567). 529 participants (30.58%) were 
on a protease inhibitor based HAART (PI-HAART) while 35% of participants were on a 
non-protease inhibitor HAART (NPI-HAART). Of the 610 participants on NPI-HAART, 
85% were on a non-nucleoside reverse transcriptase inhibitor (NNRTI) combination 
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therapy. 1.39% of participants were on a non-HAART antiretroviral therapy. Among 
those on HAART, 90% were adherent to their medication. The mean age of the 
participants was 40 years with about 38% being between 35 and 44 years, 3.64% older 
than 60 years, and about 8% being between 18 and 24 years. The mean CD4 count for the 
cohort was high at 537 cells/mm3 with those having CD4 count <200 cells/mm3 making 
up 7.5% of the cohort. The mean HIV RNA level was 2.74 in log10, with 50% of the 
cohort having a plasma viral load greater than 50 copies/mL. The median time from HIV 
diagnosis to baseline was 8 years (IQR: 2-15 years).  
   In table 1.11 we present the raw HRQOL scores of the eight health domain of the 
participants as well as their two summary scores, the physical component summary score 
(PCSS) and the mental component summary score (MCSS). Although the domain scores 
are linearly transformed T-scores, they were still highly skewed in our cohort (table 
1.11), making the summary scores preferable in linear regression analyses. Furthermore, 
using the summary scores avoids the floor and ceiling effects associated with the domain 
scores27. Both PCSS and MCSS are norm-based scores and are comparable to the general 
US population which have a mean of 50 and a standard deviation of 10. At baseline, the 
NHS participants had a slightly higher physical functional health (51.52 vs. 50) and 
slightly lower mental functional health (47.58 vs. 50) when compared to the 1990 general 
US population. Compared to the Millennium Cohort of the US military, the NHS 
participants’ physical components score was slightly lower (PCSS: 51.52 vs. 53.4) while 
the difference in the mental component score was more marked with a difference of over 
5 (MCSS: 47.58 vs. 52.8). In general, it has been suggested that differences in HRQOL 
scores of 5 points or more in the health domains or 2 to 3 in the summary scores are 
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clinically and socially relevant61,70; however, even smaller point differences may be 
useful in risk stratification especially among those with advance disease71.   
   The choice of HRQOL survey instrument has long been debated with many clinical 
trial studies preferring the HIV-specific HIV-MOS tool over the MOS SF-36 instrument 
that was used in our cohort. Earlier studies have demonstrated a high reliability of the 
MOS SF-36 in HIV population as well as in HIV-infected populations. In table 1.12 we 
displayed the reliability of the RAND SF-36 in NHS cohort as well as that of the general 
US population. The NHS participants’ had slightly higher reliability (higher Cronbach 
alpha) in all eight health conceptual areas of the SF-36 questionnaire with the exception 
of emotional well-being.  
1.9: Conclusion  
   In chapter 2 we will look at the baseline factors associated with health-related quality of 
life in the cohort. In chapter 3 we will take a longitudinal look at the changes in HRQOL 
measures for a nested cohort of the HRQOL study who were followed from 2006 to 
2010. Finally, in chapter 4 we will examine whether HRQOL measures can predict 
hospitalization among cohort members using the Cox proportional hazard regression 
model. In chapter 5, our concluding chapter, we will summarize our major findings and 
make recommendations based on those. When we first conceived our various aims and 
hypotheses we thought the questionnaires were administered from the mid-1990s, and so 
we hoped to also examine the impact that serious non-AIDS and AIDS-defining events 
will have on HRQOL measures but those studies will no longer be meaningful since 
majority of the comorbidities and AIDS-defining events had already occurred at baseline. 
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1.10: Tables 
 
 
 
Table 1.1: AIDS defining opportunistic infections  
No Infections 
1 Candidiasis of bronchi, trachea, or lungs  
2 Candidiasis, esophageal  
3 Cervical cancer, invasive  
4 Coccidioidomycosis, disseminated or extrapulmonary  
5 Cryptococcosis, extrapulmonary  
6 Cryptosporidiosis, chronic intestinal (greater than 1 month's duration)  
7 Cytomegalovirus disease (other than liver, spleen, or nodes)  
8 Cytomegalovirus retinitis (with loss of vision)  
9 Encephalopathy, HIV-related  
10 Herpes simplex: chronic ulcer(s) (greater than 1 month's duration); or bronchitis, pneumonitis, or 
esophagitis  
11 Histoplasmosis, disseminated or extrapulmonary  
12 Isosporiasis, chronic intestinal (greater than 1 month's duration)  
13 Kaposi's sarcoma  
14 Lymphoma, Burkitt's (or equivalent term)  
15 Lymphoma, immunoblastic (or equivalent term)   
16 Lymphoma, primary, of brain  
17 Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary  
18 Mycobacterium tuberculosis, any site (pulmonary or extrapulmonary)  
19 Mycobacterium, other species or unidentified species, disseminated or extrapulmonary  
20 Pneumocystis carinii pneumonia  
21 Pneumonia, recurrent 
22 Progressive multifocal leukoencephalopathy  
23 Salmonella septicemia, recurrent  
24 Toxoplasmosis of brain  
25 Wasting syndrome due to HIV  
Source: CDC 
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Table 1.2: Antiretroviral Drugs Approved by the FDA 
Brand 
Name 
Generic Name Manufacturer 
Name 
Approval 
Date 
Time to 
Approval 
Multi-class Combination Products (Combinatorial Pills) 
Atripla Efavirenz, emtricitabine 
and tenofovir disoproxil 
fumarate 
Bristol-Myers 
Squibb and Gilead 
Sciences 
12-July-06 2.5 months 
Complera Emtricitabine, rilpivirine, 
and tenofovir disoproxil 
fumarate 
Gilead Sciences 10-August-11 6 months 
Stribild Elvitegravir, cobicistat, 
emtricitabine, tenofovir 
disoproxil fumarate 
Gilead sciences 27-August-12 6 months 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
Emtriva Emtricitabine, FTC Gilead sciences 02-Jul-03 10 months 
Epivir Lamivudine, 3TC GlaxoSmithKline 17-Nov-95 4.4 months 
Hivid Zalcitabine, 
dideoxycytidine, ddC (no 
longer marketed) 
Hoffmann-La Roche 19-Jun-92 7.6 months 
Retrovir Zidovudine, 
azidothymidine, AZT 
GlaxoSmithKline 19-Mar-87 3.5 months 
Videx Didanosine, 
dideoxyinosine, ddI 
Bristol Myers-
Squibb 
9-Oct-91 6 months 
Viread Tenofovir disoproxil 
fumarate, TDF 
Gilead 26-Oct-01 5.9 months 
Zerit Stavudine, d4T Bristol Myers-
Squibb 
24-Jun-94 5.9 months 
Ziagen Abacavir sulfate, ABC GlaxoSmithKline 17-Dec-98 5.8 months 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
Edurant Rilpivirine Tibotec Therapeutics 20-May-11 10 months 
Intelence Etravirine Tibotec Therapeutics 18-Jan-08 6 months 
Rescriptor Delavirdine, DLV Pfizer 4-Apr-97 8.7 months 
Sustiva Efavirenz, EFV Bristol Myers-
Squibb 
17-Sep-98 3.2 months 
Viramune Nevirapine, NVP  Boehringer 
Ingelheim 
21-Jun-96 3.9 months 
Protease Inhibitors (PIs) 
Agenerase Amprenavir, APV (no 
longer marketed) 
GlaxoSmithKline 15-Apr-99 6 months 
Aptivus Tipranavir, TPV Boehringer 
Ingelheim 
22-Jun-05 6 months 
Crixivan Indinavir, IDV Merck 13-Mar-96 1.4 months 
Invirase Saquinavir mesylate, SQV Hoffmann-La Roche 6-Dec-95 3.2 months 
Kaletra Lopinavir and ritonavir, 
LPV/RTV 
Abbott Laboratories 15-Sep-00 3.5 months 
Lexiva Fosamprenavir Calcium, 
FOS-APV 
GlaxoSmithKline 20-Oct-03 10 months 
Norvir Ritonavir, RTV Abbott Laboratories 1-Mar-96 2.3 months 
Prezista Darunavir Tibotech, Inc. 23-Jun-06 6 months 
Reyataz Atazanavir sulfate, ATV Bristol Myers-
Squibb 
20-Jun-03 6 months 
Viracept Nelfinavir mesylate, NFV Aguoron 
Pharmaceuticals 
14-Mar-97 2.6 months 
Fusion Inhibitors 
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Fuzeon Enfuvirtide, T-20 Hoffmann-La Roche 
& Trimeris 
13-Mar-03 6 months 
Entry Inhibitors – CCR5 co-receptor antagonist  
Selzentry Miraviroc Pfizer 06-August-07 8 months 
HIV Integrase Strand Transfer Inhibitors 
Isentress Raltegravir Merck & Co., Inc. 12-Oct-07 6 months 
Source: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm118915.htm 
Last updated: 02/08/2013; Accessed 08/07/2013 
 
 
Table 1.3. Generic Measures of Health-Related Quality of Life (Source : Grossman)   
   
Instrument Dimensions 
examined 
Length; 
time to 
complete 
Administration Advantages Disadvantages 
SIP Physical: 
ambulation, 
mobility, body care 
 
Psychosocial: social 
interaction, 
communication, 
alertness, emotional 
behavior 
 
Other: sleep/rest, 
eating, work, home 
management, 
recreation and 
pastimes 
136 
items; 
≈20 min 
Self-
administered or 
interviewer 
Results can be 
presented as 
subscale 
 
and summary 
scores; no 
floor effects 
Not HIV-
specific; takes 
longer to 
administer; 
emphasis on 
physical 
dysfunction 
QWB Self-care, mobility, 
institutionalization, 
social activities, 
reports of symptoms 
and problems 
(physical and 
mental) 
50 items; 
≈20 min 
Interviewer; 
self-
administered 
version 
Can be used 
to calculate 
cost-utility 
Not HIV-
specific; takes 
longer to 
administer; 
single score 
only 
MOS SF-36 Physical 
functioning, role 
limitations caused 
by physical 
problems, social 
functioning, body 
pain, general mental 
health, role 
limitations caused 
by emotional 
problems, vitality, 
general health 
perceptions 
36 items; 
10 min 
Self-
administered 
Culturally 
adapted and 
translated into 
> 50 
languages 
Not HIV-
specific 
LASA Energy level, daily 
activity, overall 
QOL 
3 items; 1 
- 2 min 
Self-
administered 
Short 
administration 
time; easy to 
administer 
Not HIV-
specific; not as 
reliable as 
multi-item 
measures; may 
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SIP, Sickness Impact Profile; QWB, Quality of Well-Being scale; MOS SF-36, Medical Outcomes Study Short Form-36; LASA, 
Linear Analogue Self-Assessment; QOL, quality of life; NHP, Nottingham Health Profile; MHIQ, McMaster Health Index 
Questionnaire; COOP, Cooperative Information Project; HRQOL, health-related quality of life. 
not be truly 
linear 
NHP  6 domains of 
experience: pain, 
physical mobility, 
sleep, emotional 
reactions, energy, 
social isolation 
 
7 domains of daily 
life: employment, 
household work, 
relationships, 
personal life, sex, 
hobbies, vacations 
45 items; 
5 - 15 
min 
Self-
administered 
Evaluates 
areas 
pertinent to 
HIV disease 
Not HIV-
specific; items 
negatively 
worded 
Spitzer QOL 
index 
Activity, daily 
living, health, 
support, outlook on 
life 
5 items; 
10 min 
Self-
administered 
Relatively 
short 
administration 
time 
Not HI-specific; 
questionable 
reliability and 
sensitivity in 
HIV patients 
MHIQ Physical: mobility, 
self-care, 
communication, 
global physical 
functioning 
 
Social: general well-
being, work/social 
role performance, 
social support and 
participation, global 
social functioning 
≈ 59 
items; 20 
minutes 
Self-
administered or 
interviewer 
Has been used 
in a variety of 
disease states 
and settings 
Not HIV-
specific; takes 
longer to 
administer; 
limited 
reliability 
COOP 
Charts 
Physical condition, 
emotional condition, 
daily work, social 
activities, overall 
condition, change in 
condition, pain, 
general HRQOL 
9 items; 5 
minutes 
Interviewer Short 
administration 
time; easy to 
administer to 
patients with 
limited 
education 
Not HIV-
specific 
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Table 1.4: HIV Disease-Specific HRQOL Instruments (Source: Grossman10) 
Instrument Dimensions 
Examined 
Length; 
Time to 
Complete 
Administration Advantages Disadvantages 
MOS-HIV General health 
perceptions, physical 
functioning, role 
functioning, pain, 
social functioning, 
mental health, energy, 
health distress, 
cognitive functioning, 
QOL, health transition 
35 items; 
5 min 
Self-
administered or 
interview 
Shorter 
administrati
on time; 
available in 
> 20 
languages 
Does not 
evaluate all 
areas pertinent 
to HIV; some 
ceiling and 
floor effects 
HIV-QL31 Sexual life/activity, 
pain, psychological 
aspects (general 
feeling of well-being, 
depression), 
relationships, aspects 
connected with disease 
activities (denial of 
disease, obsession with 
disease), somatic 
aspects (diet, fatigue, 
sleep), impact of 
treatment and care 
(housing/accommodati
on and finance) 
31 items; 
moderate 
Self-
administered 
Based on 
patient-
reported 
concerns 
Not widely 
studied; 
responsiveness 
to change 
unknown 
FAHI  Physical well-being, 
function and global 
well-being, emotional 
well-being/living with 
HIV, social well-
being, cognitive 
functioning 
44 items; 
lengthy 
Self-
administered 
None 
beyond 
being HIV-
specific 
Takes longer to 
administer; not 
extensively 
used 
HAT-QOL  Overall function 
(combination of 
physical, role, and 
social function), sexual 
function, disclosure 
worries, health 
worries, financial 
worries, HIV mastery, 
life satisfaction, 
medication concerns, 
provider trust 
42 items; 
lengthy 
Self-
administered 
Based on 
patient-
reported 
concerns 
Takes longer to 
administer; 
lower reliability 
EORTC 
QLQ-C30 
Physical functioning, 
role functioning, 
emotional functioning, 
cognitive functioning, 
social functioning, 
pain, fatigue, nausea 
and vomiting, overall 
HRQOL + AIDS 
module 
30 items 
+ 20 
(AIDS 
module); 
lengthy 
Self-
administered 
Widely 
used; 
translated 
into several 
languages 
Takes longer to 
administer 
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GHSA  General health 
perception, physical 
functioning, role/social 
functioning, HIV-
related symptoms, 
health care utilization 
49 items; 
moderate 
Self-
administered or 
interview 
None 
beyond 
being HIV-
specific 
Not studied 
longitudinally 
HOPES  Physical: 8 subscales 
related to physical and 
daily functioning 
problems 
 
Psychosocial: 9 
subscales related to 
emotional functions, 
communication, 
interaction problems 
 
Medication interaction: 
3 subscales related to 
communication and 
interaction with health 
care providers 
 
Sexuality: 2 subscales 
related to sexual 
interest, activities, 
functioning 
 
Partner: 5 subscales 
related to 
communication and 
interaction problems 
with partner(s) 
Miscellaneous: 6 
subscales 
142 items; 
15 - 30 
min 
Self-
administered 
Assesses 
many 
dimensions 
Takes longer to 
administer; 
possible 
response bias 
AIDS-HAQ  Disability, general 
health perception, 
social functioning, 
mental health, 
cognitive functioning, 
energy/fatigue, pain, 
disease worry, 
symptoms 
30 items; 
lengthy 
Self-
administered 
Studied 
longitudinall
y 
Long 
administration 
time; not used 
extensively 
since the advent 
of HAART 
MQOL-HIV Mental health, physical 
health, physical 
functioning, social 
functioning, social 
support, cognitive 
functioning, financial 
status, partner 
intimacy, sexual 
functioning, medical 
care 
40 items; 
10 min 
 
Self-
administered or 
interview 
Studied 
longitudinall
y; less 
susceptible 
to ceiling 
effects 
Less reliable 
and less 
responsive to 
change than 
MOS-HI 
MOS-HIV, Medical Outcomes Study HIV; QOL, quality of life; HIV-QL31, HIV-QOL Questionnaire; FAHI, Functional Assessment of HIV Infection; HAT-QOL, 
HIV/AIDS Quality of Life; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire; HRQOL, health-
related quality of life; GHSA, General Health Self-Assessment; HOPES, HIV Overview Problems Evaluation System; AIDS-HAQ, AIDS Health Assessment 
Questionnaire; MQOL-HIV, Multidimensional Quality of Life Questionnaire for HIV/AIDS. 
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Table 1.5: SF-36 Health Status Scales and the Interpretation of Low and High Score& 
&(Source: Ware25) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concepts No. of 
Items 
No. of 
Levels 
Meaning of Scores 
Low High 
Physical functioning 
(PF)  
10  21 Limited a lot in performing 
all physical activities 
including bathing or 
dressing 
Performs all types of physical 
activities including the most 
vigorous without limitations 
due to health 
Role limitations due 
to physical 
problems (RP)  
4 5 Problems with work or 
other daily activities as a 
result of physical health 
No problems with work or 
other daily activities as a 
result of physical health, past 
4 weeks  
Social Functioning 
(SF)  
2 9 Extreme and frequent 
interference with normal 
social activities due to 
physical and emotional 
problems 
Performs normal social 
activities without interference 
due to physical or emotional 
problems, past 4 weeks  
Bodily pain (BP)  2 11 Very severe and extremely 
limiting pain 
No pain or limitations due to 
pain, past 4 weeks 
General mental 
health (MH)  
5 26 Feelings of nervousness 
and depression all of the 
time 
Feels peaceful, happy, and 
calm all of the time, past 4 
weeks 
Role limitations due 
to emotional 
problems (RE)  
3 4  Problems with work or 
other daily activities as a 
result of emotional 
problems 
No problems with work or 
other daily activities as a 
result of emotional problems, 
past 4 weeks 
Vitality (VT) 4 21 Feels tired and worn out all  Feels full of pep and energy 
of the time all of the time, 
past 4 weeks 
General health 
perceptions (GH) 
 5  21 Believes personal health is 
poor and likely to get worse  
Believes personal health is 
excellent 
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Table 1.6: Short Form – 36 (SF-36) (Source: www.rand.org/health/survey_tools/mos) 
1.  In general, would you say your health is:  
Excellent 1 
Very good 2 
Good 3 
Fair 4 
Poor 5 
2. Compared to one year ago, how would you rate your health in general now?  
Much better now than one year ago 1 
Somewhat better now than one year ago 2 
About the same  3 
Somewhat worse now than one year ago 4 
Much worse now than one year ago 5 
The following items are about activities you might do during a typical day. Does your health now limit you in these 
activities? If so, how much  
 Yes, limited 
a lot 
Yes, limited a little No, not 
limited 
at all 
3. Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports 
1 2 3 
4. Moderate activities, such as moving a table, pushing a 
vacuum, bowling, or playing golf 
1 2 3 
5. Lifting or carrying groceries 1 2 3 
6. Climbing several flights of stairs 1 2 3 
7. Climbing one flight of stairs 1 2 3 
8. Bending, kneeling, or stooping 1 2 3 
9. Walking more than a mile  1 2 3 
10. Walking several blocks 1 2 3 
11. Walking one block 1 2 3 
12. Bathing or dressing yourself 1 2 3 
During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities 
as a result of your physical health? (Circle One Number on Each Line) 
     Yes No 
13. Cut down the amount of time you spent on work or other activities 1 2 
14. Accomplished less than you would 1 2 
15. Were limited in the kind of work of other activities 1 2 
16. Had difficulty performing the work or other activities (for example, it took extra 
effort) 
1 2 
During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities 
as a result of any emotional problems (such as feeling depressed or anxious)?  (Circle One Number on Each 
Line) 
 Yes No 
17. Cut down the amount of time you spent on work or other activities 1 2 
18. Accomplished less than you would 1 2 
19. Didn’t do work or other activities as carefully as usual 1 2 
20. During the past 4 weeks, to what extent has your physical health or emotional problems interfered with 
your normal social activities with family, friends, neighbors, or groups? (Circle One Number) 
Not at all 1 
Slightly 2 
Moderately 3 
Quite a bit 4 
Extremely 5 
21. How much bodily pain have you had during the past 4 weeks? (Circle One Number) 
None 1 
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Very mild 2 
Mild 3 
Moderate 4 
Severe 5 
Very severe 6 
22. During the past 4 weeks, how much did pain interfere with your normal work (including both work 
outside the home and housework)? (Circle One Number) 
Not at all 1 
Slightly 2 
Moderately 3 
Quite a bit 4 
Extremely 5 
These questions are about how you feel and how things have been with you during the past 4 weeks. For each 
question, please give the one answer that comes closest to the way you have been feeling. 
How much of the time during the past 4 weeks . . . (Circle One Number on Each Line) 
 All of 
the 
Time 
Most of 
the 
Time 
A Good 
Bit of the 
Time 
Some 
of the 
Time 
A Little 
of the 
Time 
None 
of the 
Time 
23. Did you feel full of pep? 1 2 3 4 5 6 
24. Have you been a very nervous person 1 2 3 4 5 6 
25. Have you felt so down in the dumps that 
nothing could cheer you up 
1 2 3 4 5 6 
26. Have you felt calm and peaceful? 1 2 3 4 5 6 
27. Did you have a lot of energy? 1 2 3 4 5 6 
28. Have you felt downhearted and blue? 1 2 3 4 5 6 
29. Did you feel worn out? 1 2 3 4 5 6 
30. Have you been a happy person? 1 2 3 4 5 6 
31. Did you feel tired? 1 2 3 4 5 6 
32. During the past 4 weeks, how much of the time has your physical health or emotional problems interfered 
with your social activities (like visiting with friends, relatives, etc.)? (Circle One Number) 
All of the time 1 
Most of the time 2 
Some of the time 3 
A little of the time 4 
None of the time 5 
How TRUE or FALSE is each of the following statements for you. (Circle One Number on Each Line) 
 Definitely 
True 
Mostly 
True 
Don’t 
Know 
Mostly 
False 
Definitely 
False 
33. I seem to get sick a little easier than other 
people 
1 2 3 4 5 
34. I am as healthy as anybody 1 2 3 4 5 
35. I expect my health to get worse 1 2 3 4 5 
36. My health is excellent 1 2 3 4 5 
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Table 1.7: Reliability, Central Tendency and Variability of Scales in the Medical 
Outcome Studies (Source: Ware) 
Scale Item Alpha Mean SD 
Physical Functioning 10 0.93 70.61 27.42 
Role limitations due to physical health 4 0.84 52.97 40.78 
Role limitations due to emotional problems 3 0.83 65.78 40.71 
Energy/Fatigue 4 0.86 52.15 22.39 
Emotional well-being 5 0.90 70.38 21.97 
Social functioning 2 0.85 78.77 25.43 
Pain 2 0.78 70.77 25.46 
General health 5 0.78 56.99 21.11 
Health Change 1 ----- 59.14 23.12 
Physical Component Summary Score 36 0.92 50.00 10.00 
Mental Component Summary Score 36 0.88 50.00 10.00 
 
 
 
 
 
 
 
Table 1.8: Recoding Items (Step 1) (Source: RAND) 
Items Numbers Change Original response Category* To Recoded Value of: 
1, 2, 20, 22, 34, 36 1 100 
2 75 
3 50 
4 25 
5 0 
3, 4, 5, 6, 7, 8, 9, 10, 11, 12 1 0 
2 50 
3 100 
13, 14, 15, 16, 17, 18, 19 1 0 
2 100 
21, 23, 26, 27, 30 1        100 
 2 80 
 3 60 
 4 40 
 5 20 
 6 0 
24, 25, 28, 29, 31 1 0 
 2 20 
 3 40 
 4 60 
 5       80 
 6    100 
32, 33, 35 1  0 
 2 25 
 3 50 
 4 75 
 5       100 
*Precoded response choices as printed in the questionnaire 
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Table 1.9: Averaging Items to Form Scales (Step 2) (Source: RAND) 
Scale Number of 
Items 
After Recoding Per Table, 
Average the Following Items: 
Physical Functioning 10 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 
Role limitations due to physical health 4 13, 14, 15, 16 
Role limitations due to emotional problems 3 17, 18, 19 
Energy/Fatigue 4 23, 27, 29, 31 
Emotional well-being 5 24, 25, 26, 28, 30 
Social functioning 2 20, 32 
Pain 2 21, 22 
General health 5 1, 33, 34, 35, 36 
 
 
 
 
Table 1.10: Baseline Characteristics of the Cohort 
Characteristics N (%) 
Gender 
Male 
Female 
 
1610 (93.06) 
  120 (6.94) 
Race 
Non-Hispanic White 
Non-Hispanic African American 
Hispanic/Others 
 
723 (41.79) 
736 (42.54) 
271 (15.66) 
Rank 
Officer/Warrant Officer 
Enlisted 
             Others (Retired/Dependents) 
Missing 
 
128 (7.40) 
920 (53.18) 
680 (39.31) 
    2 (0.12) 
Marriage 
Yes 
No 
 
  557 (32.20) 
1173 (67.80) 
Medical Comorbidity 
Yes 
No 
 
  251 (14.51) 
1479 (85.49) 
Mental Comorbidity 
Yes 
No 
 
  446 (25.78) 
1284 (74.22) 
AIDS 
Yes 
No 
 
  200 (11.56) 
1530 (88.44) 
HAART 
PI-Based 
Non-PI-Based 
HAART-Naïve 
Off-HAART 
Non-HAART ART  
 
529 (30.58) 
610 (35.26) 
411 (23.76) 
156 (9.02) 
  24 (1.39) 
Adherence (≥ 90%) 
Yes 
No 
Missing 
 
1036 (90.96) 
  97 (8.52) 
   6 (0.53) 
Age Groups 
Between 18 and 24 years 
 
137 (7.92) 
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Between 25 and 34 years 
Between 35 and 44 years 
Between 45 and 60 years 
Greater than 60 years 
375 (21.68) 
656 (37.92) 
499 (28.84) 
  63 (3.64) 
CD4 Count Groups 
CD4 Count Less than 200 
CD4 Count Between 200 and 499 
CD4 Count Greater Than 499 
Missing 
 
115 (6.65) 
748 (43.24) 
865 (50.00) 
2 (0.12) 
HIV RNA Level Greater than 50 Copies 
Yes 
No 
Missing 
 
865 (50.00) 
864 (49.94) 
1 (0.06) 
Calendar Year 
2006 
2007 
2008 
2009 
2010 
 
826 (47.75) 
486 (28.09) 
147 (8.50) 
172 (9.94) 
99 (5.72) 
Age (years) 
Mean ± SD (N) 
Median  (IQR) 
 
40.09  ± 10.59 (1730) 
40.00 (32.00 – 47.00 ) 
CD4 Count (x 106/L) 
Mean ± SD (N) 
Median  (IQR) 
 
537.29 ± 266.79 (1728) 
500.00 (359.00 – 677.00) 
HIV RNA Level (Log10) 
Mean ± SD (N) 
Median  (IQR) 
 
2.75 ± 1.27 (1729) 
1.71 (1.70 – 3.98) 
Time from HIV Diagnosis (years)  
Mean ± SD (N) 
              Median (IQR) 
 
8.86 ± 7.17 (1730) 
8.00 (2.00 – 15.00) 
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Table 1.11: Health Related Quality of Life Scores of Participants at Baseline 
HRQOL Scores Mean ± SD (N) 
Physical Functioning (PHYFUN10) 
Mean ± SD (N) 
Median  (IQR) 
 
85.48 ± 24.57 (1730) 
100.00 (80.00 – 100.00) 
Role Limitations Due to Physical Health (ROLEP4) 
Mean ± SD (N) 
Median  (IQR) 
 
82.34 ± 32.99 (1724) 
100.00 (75.00 – 100.00) 
Bodily Pain (PAIN2) 
Mean ± SD (N) 
Median  (IQR) 
 
81.00 ± 22.97 (1727) 
90.00 (67.50 – 100.00) 
General Health (GENH5) 
Mean ± SD (N) 
Median  (IQR) 
 
70.34 ± 21.12 (1730) 
75.00 (60.00 – 85.00) 
Emotional Well Being (EMOT5) 
Mean ± SD (N) 
Median  (IQR) 
 
67.92 ± 14.36 (1727) 
72.00 (60.00 – 80.00) 
Role Limitations Due to Emotional Problems (ROLEE3) 
Mean ± SD (N) 
Median  (IQR) 
 
83.02 ± 33.47 (1726) 
100.00 (100.00 – 100.00) 
Energy/Fatigue (ENFAT4) 
Mean ± SD (N) 
Median  (IQR) 
 
59.30 ± 16.96 (1728) 
60.00 (50.00 - 70.00 ) 
Social Functioning (SOCFUN2) 
Mean ± SD (N) 
Median  (IQR) 
 
81.54 ± 24.03 (1727) 
100.00 (62.50 – 100.00) 
Physical Component Summary Score (PCSS)$ 
Mean ± SD (N) 
Median  (IQR) 
 
51.52 ± 9.08 (1719) 
54.88 (46.94 – 57.97) 
Mental Component Summary Score (MCSS)# 
Mean ± SD (N) 
              Median (IQR) 
 
47.58 ± 9.18 (1719) 
50.31 (43.44 – 53.85) 
$PCSS (norm-based T score derived from PHYFUN10, ROLEP4, PAIN2 and GENH5) 
# MCSS (norm-based T score derived from EMOT5 ROLEE3 ENFAT4 SOCFUN2) 
 
 
 
 
 
 
Table 1.12: Comparison of Reliability of HRQOL Scores in the NHS Cohort and the US 
Gen. Population 
HRQOL Scores  Items Alpha (NHS Cohort) Alpha (US Population) 
Physical Functioning  10 0.96 0.93 
Role Limitations – PH  4 0.89 0.84 
Bodily Pain  2 0.86 0.78 
General Health  5 0.83 0.78 
Emotional Well-Being  5 0.84 0.98 
Role Lim – Emot. Prob.  3 0.88 0.83 
Energy/Fatigue  4 0.87 0.86 
Social Functioning 2 0.86 0.85 
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1.11: Figures 
 
 
Figure 1.1: Structure of HIV 
 
 
 
Source: http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/Biology/Pages/hivVirionLargeImage.aspx 
Last updated: 01/05/2009; Accessed: 08/17/2013 
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Figure 1.2: Life cycle of HIV 
 
 
 
Source: http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/Biology/Pages/hivReplicationCycle.aspx 
Last updated: 04/03/2009; Accessed: 08/17/2013 
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Fig 1.3.a: Monthly Return of Completed SF-36 By Calendar Year (2006-2008) 
 
 
Fig 1.3.b: Monthly Return of Completed SF-36 By Calendar Year (2009 and 2010) 
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Chapter 2 
Baseline Factors Associated with Health-Related Quality of Life among 
HIV-infected Individuals in the HAART Era 
Abstract 
Objective: The aims of this study were: (i). to determine the factors associated with HRQOL at baseline in 
our cohort, and (ii). to evaluate if there are differences in baseline HRQOL measures by HAART groups. 
Methods: The RAND Short Form 36 (SF-36) was administered between 2006 and 2010 among members of 
the NHS cohort, and participants who completed the SF-36 were included in the study. Physical component 
summary (PCSS) and mental component summary (MCSS) scores were computed based on standard 
algorithms. Multivariate linear regression models were constructed for PCSS and MCSS to estimate the 
association between highly active anti-retroviral therapy (HAART) and HRQOL scores while controlling 
for demographic characteristics and other covariates.  
Results: HAART was not independently associated with HRQOL scores. Factors independently associated 
with PCSS were CD4 count < 200 cells/mm3 (β= -5.87, 95% CI: -7.66, -4.08), mental comorbidity (β= -
2.77, 95% CI: -3.73, -1.80), medical comorbidity (β= -2.68, 95% CI: -3.92, -1.44), AIDS diagnosis (β= -
3.32, 95% CI: -3.72, -0.92). Others were  gender, rank, marital status, and age. Factors independently 
associated with MCSS were CD4 count < 200 cells/mm3 (β= -2.77, 95% CI: -3.73, -1.80), mental 
comorbidity (β= -6.24, 95% CI: -7.24, -5.24), age and being African American.  
Conclusion: Modifiable factors associated with HRQOL measures at baseline were mental comorbidity, 
low CD4 count, medical comorbidity and AIDS diagnosis. Efforts should be made to address these risk 
factors in order to improve the functional status of HIV-infected individuals in the NHS cohort.     
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Chapter 2 
Baseline Factors Associated with Health-Related Quality of Life among 
HIV-infected Individuals in the HAART Era 
 
2.1: Introduction and Background 
    The annual estimated rate of new human immunodeficiency virus (HIV) infections in 
the United States between 2008 and 2011 remained stable at 15.8 per 100,000 while the 
rate for HIV stage 3 or acquired immune deficiency syndrome (AIDS) was 10.3 per 
100,000 in the same period1. Death from HIV/AIDS has continued to decline since the 
mid-1990s with the introduction of highly active antiretroviral therapy (HAART)2,3. By 
2010, the Centers for Disease Control and Prevention (CDC) estimated that the all-cause 
mortality in people infected with HIV in the United States was 6.3 per 100,000 and the 
all-cause mortality in those with a diagnosis of AIDS was 5.0 per 100,0001. Given the 
stable incidence of HIV/AIDS in the US and the declining mortality among infected 
individuals, greater reliance is now being placed on other end-point measures both in 
clinical and public health settings, such as health-related quality of life, in assessing the 
well-being of individuals living with HIV/AIDS4,5.  
   Health-related quality of life (HRQOL) is a multidimensional and dynamic concept that 
is well recognized as an end-point in assessing the well-being of individuals living with 
HIV/AIDS5-9. Several factors have been established as determinants of HRQOL in HIV-
infected populations but these determinant are partly influenced by the population being 
studied, the HRQOL instrument used and the country of study among other factors10,11. 
Some of the determinants of HRQOL in HIV-infected individuals in the United States 
and other high-income countries12 are age13,14, race/ethnicity13, gender7,8,12,15, educational 
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level13, income level13,14, socioeconomic status16, access to health insurance17, being on 
antiretroviral therapy (ART) or highly active antiretroviral therapy (HAART)9,10, 
injection drug use18, the presence of mental and medical comorbidities14,19, presence of 
AIDS-defining illnesses13,20, CD4 count13,21, viral load21, and less frequently captured 
variables such as coping style/ability17,22,23 and social support22 among others.   
    The relationship between HIV/AIDS, HAART and HRQOL is a complex one. While 
HAART helps to prevent disease progression and results in better quality of life and well-
being in HIV-infected individuals, the prolonged use of medication that is necessary to 
continually keep viral suppression below detection levels, often leads to adverse effects 
that may then worsens the individual’s quality of life. Some of the recognized side effects 
of HAART are diarrhea, anemia, lipodystrophy, peripheral neuropathy, insulin resistance 
and metabolic syndrome, renal tubular toxicity, pancreatitis, and hypersensitivity 
reaction. Lipodystrophy, diarrhea and other medication-related symptoms have been 
shown to affect quality of life24-26. Although, side effects are not specific to one class of 
HAART medications, protease inhibitors have been implicated as having greater adverse 
effects including morphological changes and metabolic disturbances27. However, most 
studies evaluating the impact of different HAART regimen on HRQOL have been in 
clinical trials10,28-31 or following a switch from protease inhibitor-based regimen to a non-
protease-inhibitor regimen without the benefit of an appropriate control group27.  
   We also note that some of the predictors of HRQOL in HIV-infected individuals in the 
general US population, such as lack of access to healthcare due to lack of insurance, 
access to and maintenance of anti-retroviral medications, and  injection drug use may not 
play an equally important role as determinants of HRQOL of HIV-infected individuals in 
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the United States Military. This is because of the universal access to healthcare in this 
population and the rarity of injection drug use among military personnel32,33.  The aims of 
this study were: (i). to determine the factors associated with HRQOL at baseline in our 
cohort, and (ii). to evaluate if there are differences in baseline HRQOL measures by 
HAART groups.     
2.2: Methods 
2.2.1: Study Cohort 
The U.S. Military HIV Natural History Study (NHS) is a prospective multicenter 
continuous enrollment observational cohort of HIV-infected active duty military 
personnel and other beneficiaries (spouses, adult dependents, and retired military 
personnel) from the Army, Navy/Marines and Air Force enrolled since 198632,34-36.  
Participants are followed at five medical centers in the United States.  Demographic data 
are collected at baseline and updated while medical and medication histories and standard 
laboratory studies are collected biannually. Blood samples obtained from participants in 
this cohort from scheduled visits are stored in a repository.  Demographic information 
captured includes race/ethnicity (Caucasian, African American, Hispanic or Puerto Rican, 
Mexican, Asian, or Pacific Islander, Native American or Alaskan native, or other), age, 
gender, active duty, retired or dependent, and rank in military. Although not captured in 
the NHS database, injection drug use (IDU) has been reported to be very rare in this 
cohort32,33.  All NHS participants provided informed consent, and approval for this 
research was obtained from the institutional review board at each participating site. 
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2.2.2: Study Participants  
The RAND Short Form 36 (SF-36) questionnaires were administered annually to NHS 
participants from April 2006 to September 2010. However, a few participants  had more 
than one completed questionnaire in a year, and for these participants the last completed 
questionnaire for that year was used. We used the CD4 count and viral load values closest 
in time to the HRQOL measure used. Baseline was defined as the first ever HRQOL 
measure irrespective of when the participant was first enrolled in the NHS. 
2.2.3: Definitions and Variable Selections 
Variable selection was based on the literature on HRQOL in HIV-infected individuals in 
the United States and other high income countries5,10, on HRQOL in the US Military37 
and on variables captured in our cohort32-35.  
2.2.3.1: Health-Related Quality of Life Scores 
   We computed  the norm-based the physical (PCS) and mental (MCS) component 
summary scores from the eight health domains in the SF-36 questionnaire in line with the 
recommended scoring algorithm for the RAND 36-item health survey 1.038,39. The PCS 
and MCS scores were the outcome variables in our analyses. Although we also calculated 
the raw and transformed T-scores of the eight health domain scores, we have reported 
only the summary scores here for ease of results interpretation and for comparison with 
other studies.  
2.2.3.2: HAART (Treatment) Variable 
   HAART was defined as a combination of at least three antiretroviral agents similar to 
previous investigations for this cohort32. HAART treatment was the main explanatory 
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variable. HAART treatment was divided into four groups: protease inhibitor-based 
HAART (PI-HAART),  for HAART with at least one protease inhibitor in the combined 
HAART regimen; non-protease-inhibitor-based HAART (NPI-HAART), for HAART 
with no protease inhibitor in the combined HAART regimen; HAART-naïve group 
(HAART-N) for those not on HAART; and, OFF-HAART group made up of participants 
who were not on HAART at the time of completing the survey but had prior use of 
HAART. We separated this group from the HAART-naïve group because of their 
different demographic and clinical characteristics (see result section).   
2.2.3.3: Covariates  
   Covariates considered for inclusion in our models were based on previous studies as 
well as on the demographic and clinical characteristics that were captured in the NHS 
cohort.  These covariates included gender (male/female), age, military rank 
(officer/warrant officer, enlisted and civilian/retired),  marital status (married, not 
married), race/ethnicity, plasma viral load, CD4+ cell count, medical comorbidity, mental 
comorbidity, AIDS-defining illnesses, medication adherence, HIV duration, and calendar 
year. CD4 was categorized as ‘<200 cells/mm3,’ ‘200-499 cells/mm3’ and ‘>499 
cells/mm3’ while plasma viral load was categorized as >50 copies/mL or ≤50 copies/mL.   
Although most of the participants were not new to the HIV Natural History Study (NHS) 
of the US Military, enrollment into the HRQOL study specifically began in 2006 and 
continued until 2010. We therefore included calendar year in order to adjust for any 
temporal variations in participants’ entry into the HRQOL study. 
   Although AIDS-defining illnesses have declined significantly in the HAART era, AIDS 
definition was in line with the 1993 Centers for Disease Control and Prevention criteria, 
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with the exception of an isolated CD4 cell count <200 cells/mm3 as CD4 was analyzed 
separately.  Race/ethnicity was classified as non-Hispanic white, non-Hispanic African-
American, and Others (including Hispanics). Medical co-morbidity referred to chronic 
medical conditions, and was classified as having no comorbidity or having one or more 
comorbidity. Mental comorbidity was classified similarly. Adherence was classified as 
good (yes) or poor (no) with an adherence level of at least 90%30 required for classifying 
as good. 
 2.2.4: Inclusion and Exclusion Criteria 
All participants aged 18 years and above who completed the HRQOL survey 
questionnaires between 2006 and 2010 were included. We excluded participants who had 
been on treatment for less than four weeks prior to taking the HRQOL survey since some 
of the questions in the questionnaire specifically asked for participants’ functional health 
in the past four weeks. We further excluded participants who were on both PI-HAART 
and NPI-HAART within four weeks of taking the survey. We also excluded participants 
who were on a non-HAART antiretroviral therapy at the time of survey.   
2.2.5: Statistical Analyses 
   We summarized the baseline characteristics of the participants who met our inclusion 
criteria by four HAART groups (PI-HAART, NPI-HAART, HAART-Naïve, and 
HAART-Missing). Proportions of participant’s characteristics were compared using Chi-
square tests and exact statistics while the medians of the numeric variables were 
compared using the Kruskal Wallis tests. Separate multivariate regression models were 
constructed for PCS and MCS scores. We tested the effect of covariates on participants’ 
PCS and MCS scores in univariate analyses, and included those which achieved a 
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significance p-value of less than 0.2 in the multivariate analyses. Race/ethnicity, and 
gender were forced into all models. Using these criteria, calendar year, marital status, 
medical comorbidity, and duration of HIV (years) were not included in the multivariate 
MCS model. All covariates were eligible for inclusion into the multivariate PCS model. 
Furthermore, for variables that were not significant in the multivariate models we 
manually removed and re-entered them (one at a time) to determine the most 
parsimonious models by comparing their adjusted R-square and Mallow’s cp. We also 
tested the effect on adherence on both physical and mental health scores of participants. 
In doing so we excluded participants in the HAART-naïve and OFF-HAART groups. In 
the final models chosen, we checked for evidence of multi-collinearity, and for 
interaction between the main independent variable, HAART Treatment, and the 
covariates. All statistical analyses were performed using SAS 9.3 [SAS Institute Inc., 
Cary, NC]. 
2.3: Results 
   Baseline demographic and clinical characteristics by HAART group for participants 
with SF-36 data are displayed in table 2.1. Of the 1730 eligible participants, 24 (1.4%) on 
a non-HAART antiretroviral therapy were excluded. We also excluded another 38 (2.2%) 
who were either on HAART for less than 4 weeks prior to the survey or on both PI/NPI-
HAART within 4 weeks of survey completion. Participants were different on all 
demographic characteristics with the exception of gender and marital status (Table 2.1). 
Participants were also significantly different on all clinical characteristics, namely CD4 
cell count, plasma viral load, time from HIV diagnosis, medical and mental 
comorbidities, AIDS diagnosis, and medication adherence.  
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   Participants scores on both their physical and mental HRQOL measures (PCS and MCS 
scores) were also different by HAART groups. The HAART-Naïve group had the highest 
median PCS score while the PI-HAART group had the lowest median PCS score. On the 
other hand, the NPI-HAART group had the highest median MCS score and the HAART-
Naïve group had the lowest median MCS score. The median age of participants on PI-
HAART was 44 years (interquartile range [IQR]: 39-50) followed by the NPI-HAART 
group with a median age of 41 years (IQR: 35-47) while the HAART-naïve group was 
much younger with a median age of 29 years (IQR: 25-38). The median age for the 
HAART-off group was 40.5 years (IQR: 36-45). Because the initial definition of HAART 
required that at least a protease inhibitor in the combination therapy, the PI-HAART 
group had the longest duration of HIV infection (median 15 years, IQR of 10-19 years).  
  Table 2.2 shows the univariate and multivariate analyses for the physical HRQOL 
scores (PCS score). Compared to the PI-HAART, HAART-naivety was associated with a 
higher PCS scores by 4.59 (95% Confidence Limits [95% CL]: 3.44, 5.74) in the 
unadjusted model but this was no longer significant after adjusting for covariates (β = 
0.11, 95% CL: -1.57, 1.78). Also, the PCS scores of participants in the NPI-HAART 
group were significantly higher than those in the PI-HAART group in the unadjusted 
model (β = 2.53, 95% CL: 1.48, 3.58) but not in the adjusted model. There were no 
statistical difference in PCS scores between the PI-HAART and the Off-HAART groups 
both in the unadjusted and adjusted models. Being male was significantly associated with 
higher PCS scores (β = 2.11, 95% CL: 0.49, 3.73). Compared to participants enrolled into 
the HRQOL study in 2006, those enrolled in 2007 had significantly higher PCs scores by 
1.56 (95% CL: 0.59, 2.53).  
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   Factors associated with lower physical HRQOL scores (PCS scores) were age, CD4 
count <200 cells/mm3, lower military rank or being civilian/retired, presence of medical 
and mental comorbidities, AIDS diagnosis, and being married. Every 5-year increment in 
age was associated with 0.51 point reduction in PCS score (95% CL: -0.78, -0.24). 
Compared to officers, the PCS scores of active duty enlisted participants was lower by 
l.90 (95% CL: -3.53, -0.27) and that for civilians/retired military personnel was lower by 
3.30 (95% CL: -5.03, -1.56). Being married was also associated with a reduction in PCS 
score by 1.24 points (95% CL: -2.13, -0.36) in the adjusted model. Medical and mental 
comorbidities, and AIDS diagnosis were significantly associated with a reduction in PCS 
scores by 2.72 (95% CL: -3.96, -1.47), 2.84 (95% CL: -3.82, -1.86) and 2.34 (95% CL: -
3.75, -0.93) respectively. After adjusting for covariates, the PCS score of participants 
with CD4 count <200 cells/mm3 was lower than those with CD4 count >500 cells/mm3 
by 5.12 points (95% CL: -6.91, -3.33) but there was no difference between the PCS 
scores of participants with CD4 count of 200-499 cells/mm3 and those whose CD4 count 
>500 cells/mm3 either in the unadjusted or adjusted models. There was no statistically 
significant difference in PCS scores by plasma viral load category. Race/ethnicity was 
also not associated with PCS scores. Although duration of HIV (in years) was 
significantly associated with a reduction in PCS score by 0.29 points for every unit 
increase in years in the unadjusted model, there was no significant association after 
adjusting for covariates.   
   Table 3.3 shows the univariate and multivariate analyses for the mental HRQOL scores. 
There were no statistically significant differences between the four treatment groups on 
their mental HRQOL scores before and after adjusting for covariates. Increasing age and 
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being African American were associated with relatively higher mental HRQOL score 
(MCS scores). In the multivariate model, we found that every 5-year increment in age 
was associated with a 0.48 point higher MCS scores (95% CL: 0.22, 0.74). Compared to 
Caucasians, being African-American was associated with a 1.54 point increase in MCS 
scores  (95% CL: 0.61, 2.48). Having a CD4 count <200 cells/mm3 (β = 2.19; 95% CL: -
4.08, -0.31) significantly associated with lower MCS scores but not CD4 count of 200-
499 cells/mm3 (β = -0.78; 95% CL: -1.70, 0.10) when compared to CD4 count >499 
cells/mm3. Mental comorbidities were significantly associated with lower MCS scores by 
6.12 points after adjusting for covariates (95% CL: -7.32, -5.30). AIDS diagnosis and 
plasma vial load were only significantly associated with lower MCS scores in the 
unadjusted models but were no longer significant after adjusting for covariates. Gender, 
military rank, medical comorbidities, and HIV duration were not associated with MCS 
scores in the unadjusted models.  
   In separate models restricted to the PI/NPI-HAART groups, we tested the association 
between adherence to HAART medication and HRQOL measures. In the unadjusted 
models medication adherence was significantly associated with both PCS and MCS 
scores but in the adjusted models there was no longer a significant association between 
adherence and PCS scores or MCS scores (Tables 2.2 and 2.3). There were no evidence 
of multi-collinearity and no evidence of interaction. In table 2.4 we displayed the most 
parsimonious PCS and MCS models with results similar to the ones already provided 
above.  
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2.4: Discussion 
   Health-related quality of life (HRQOL) has not been previously evaluated in the U.S. 
Military HIV Natural History Study (NHS), which is one of the oldest open-enrollment 
dynamic HIV cohorts in the country. Our aims were therefore to assess factors associated 
with HRQOL at baseline and to determine whether HRQOL measures were different 
among the HAART groups including those not on HAART. Because the HAART-naïve 
group were very different from the Off-HAART group both in demographic and clinical 
characteristics we treated them as a separate groups (table 2.1). In this study we found 
that being HAART-naïve was associated with a higher perceived physical functional 
health in the unadjusted model but after controlling for covariates there was no 
significant difference between HAART-naivety and being on a PI-HAART, a finding that 
is similar to that of Preau et al40. We also did not find any differences in physical 
functional health between the Off-HAART and PI-HAART groups. NPI-HAART was 
associated with higher perceived physical health in the univariate model but not in the 
adjusted model. In a cross-sectional study of 159 participants by Armon et al17 found that 
use of efavirenz based HAART (NPI-HAART) was associated with higher physical 
functional health but also found inverse relationship between nevirapine based HAART 
(also an NPI-HAART) and physical functional health. The authors argued that the lower 
physical functional health reported with nevirapine may be due to it being reserved for 
participants with more severe disease17, an argument we believe should hold true for PI-
HAART.  
   There are very few studies on the relationship between HRQOL and specific 
antiretroviral therapy (ART) regimens in the literature and most of these are in clinical 
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trials10. Comparison of study findings is further complicated by the various instruments 
used, some being HIV-disease specific while others are generic. Of the 26 articles 
recently reviewed by Gakhar et al only two articles used the SF-36 questionnaire, 12 used 
the MOS-HIV with other disease-specific and generic instruments making the rest10. The 
study by Hodder et al41 which used the SF-36 investigated the benefit of switching from 
either a PI-based or an NNRTI-based HAART to a single tablet regimen of efavirenz, 
emtricitabine, and tenofovir DF, and the other study that used the MOS SF-36 had 
participants on a PI-based HAART regimen alone6. While these studies showed 
improvement in HRQOL they are not directly comparable to ours. However, two other 
studies27,29 reported better HRQOL after switching from a PI-based HAART to an 
NNRTI-based HAART (specifically efavirenz and nevirapine), but these studies did not 
control for the PI-comparison group. Fumaz et al28, on the other hand, reported better 
quality of life in participants who switched from PI-HAART to NNRTI (efavirenz) in 
comparison to those who remained on PI-HAART; however, they used a 5-point 
adaptation of the MOS-HIV questionnaire28 making direct comparison difficult. It has 
been suggested that the better physical health found in the NPI-HAART group was 
attributable to the simpler regimen of the NPI-HAART regimen, fewer adverse events, 
and better physical and emotional status28. It is worth noting here that efavirenz is 
associated with high central nervous system side effects especially in the initial 2 to 3 
weeks of treatment42, and this was case with some of the participants in the study 
reported by Fumaz et al28.  
   The other factors independently associated with physical HRQOL (PCS) scores in our 
cohort were age, military rank, marital status, gender, CD4 count less than 200, medical 
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and mental comorbidities, AIDS diagnosis, and baseline enrollment year being 2007. 
However, only age, being African-American, CD4 count <200 cell/mm3, and mental 
comorbidity were independently associated with mental HRQOL (MCS) scores in our 
cohort. We did not find any differences in mental health by HAART group either in the 
unadjusted or adjusted models. Age has been reported in the literature to be negatively 
associated with PCS score in HIV-infected populations14,15,18,40,43,44. Also, Smith et al 
found age to be negatively associated with PCS in a non-HIV military population37 which 
is consistent with our findings. There was, however, a positive association between 
increasing age and MCS in our cohort similar to that in the military37 and in HIV-infected 
individuals13. The relationship between age and HIV is a complex one but it is clear that 
both increasing age and HIV infection lead to a gradual decline in immunity, and that 
older individuals have slower immune recovery and achieve less CD4 cell restoration 
with HAART45. Also, both HIV infection and aging are associated with increased 
medical comorbidities that could further negatively impact physical functional health19. 
Beyond that, physical senescence associated with older age may also contribute poorer 
physical functional health5.   
   Akin to the literature, we found that CD4 count <200 cells/mm3 was significantly 
associated with lower physical HRQOL score13,21,46. There was no significant difference 
in PCS scores of participants with CD4 count of 200-499 cells/mm3 when compared to 
those with CD4 count >499 cells/mm3, similar to findings by others13,14. The negative 
impact of CD4 count <200 cells/mm3 on perceived physical health is likely attributable to 
the greater burden of the disease associated with CD4 counts <200 cells/mm3, including 
the fact these individuals are more likely to have had HIV-infection for a longer period of 
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time, be older and may have more associated comorbidities as was the case in our cohort 
(data not shown). We also found that CD4 counts <200 cells/mm3 independently 
associated with lower mental HRQOL score similar to the findings by others8,17,47 but 
unlike the findings by Hays et al13, which found a positive association between lower 
CD4 count and mental HRQOL scores. It has been suggested that because CD4 count 
<200 cells/mm3 is associated with faster disease progression in HIV-infected individuals, 
this will tend to cause distress that may negatively impact perceived mental health8. In 
line with several studies in the HAART era we did not find any difference in both the 
PCS and MCS scores of participants of the NHS to be affected by viral load14,48,49. This is 
not entirely surprising since the effect of viral load on HRQOL may be partly explained 
by its effect on CD4 count, and as previously noted by other investigators, CD4 count is a 
better prognostic marker for disease progression for HIV-infected individuals on 
HAART48,49. Moreover, slightly over half of the NHS participants had plasma viral load 
≤50 copies/mL, a level that reflects significantly suppressed viral activity.   
   The presence of medical comorbidities was negatively associated with physical 
functional health but not mental functional health similar to findings by 
others7,14,19,20,22,40. The presence of mental comorbidities, on the other hand, was 
negatively associated with both physical and mental functional health of participants, 
although the dramatic influence of mental comorbidity on MCS in our cohort (β: -6.12; 
95% CL: -7.32, -5.30) clearly shows the need for greater attention by both clinicians and 
policy makers in addressing this issue in this population of military personnel. The need 
for frequent and regular evaluation of the mental health of participants is further 
supported by the high prevalence of mental comorbidity in our cohort (over 25%) (please 
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see chapter 1, table 1.10.). Although diverse psychological comorbidities have been 
shown to influence HRQOL, depression, which accounted for over 60% of the 
psychological comorbidity in our cohort, is by far the most predictive of physical and 
mental functional health7,14,40.  
   Having ever been diagnosed with AIDS was negatively associated with  physical health 
in our cohort similar to findings by others13,40,50 The median duration of AIDS diagnosis 
in our cohort was 8 years (IQR: 2-12 years). In our cohort, only 12 participants (6.12% of 
all those with AIDS at baseline) had a recent AIDS diagnosis in the one year preceding 
enrollment into the study. In sensitivity analyses, we did not find any differences in result 
when we excluded these participants with a recent AIDS diagnosis. Also, similar to 
findings by others17,51 we did not find the presence of AIDS diagnosis to be 
independently associated with mental functional health, which may further support the 
view that with time HIV-infected individuals may develop more effective coping 
strategies that could enhance their mental health5,22.  
   Although HIV duration was negatively associated with perceived physical health in the 
unadjusted model, the association was no longer significant after adjusting for age and 
other covariates. Most likely, the apparent negative association may have been explained 
by other factors such as medical comorbidity and AIDS that are more likely with longer 
duration of the disease. Furthermore age is often correlated with duration of HIV 
infection in our cohort (correlation coefficient 0.62, p<.0001). Race/ethnicity was not 
associated with physical functional health in our cohort which may give credence to the 
view that with employment and/or equal access to healthcare (more likely to be skewed 
by race/ethnicity in the general population), race/ethnicity is not a significant predictor of 
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PCSS. In our cohort, being African-American was positively associated with higher 
mental functional health which is similar to the findings in a non-HIV Military cohort 
which reported a higher MCS score among African-Americans compared to 
Caucasians37. While there may be need for further validation of this finding we are not 
sure if this has any clinical correlations. We also found gender differences in physical 
functional health in our cohort. This is similar to what has been reported in other 
studies7,8,12,15,52 including the US Military37.   
   Some of the limitations of our study include its cross-sectional nature, which may 
preclude conclusions on causality. Our study population was also predominantly male 
(over 90%) so generalizability to female should be applied cautiously. We also did not 
control for variables such as route of transmission as this was not captured at the time the 
surveys were administered due to fear of participants’ violation of the Uniform Code of 
Military Justice36. It is worth noting that previous studies have however, not found route 
of transmission to be independently associated with HRQOL16,17,19,40. Finally, the use of 
the RAND SF-36 questionnaire, a generic HRQOL instrument, does not allow us to 
capture some important HIV-disease specific dimensions on quality of life such as 
cognitive functioning or sleep problems.   
   Our study had some major advantages. One, we simultaneously examined the 
differences in HRQOL measures in a large cohort of individuals on PI-HAART and NPI-
HAART, as well as those who were HAART-naïve or Off-HAART. Because of the large 
sample size, we were able to adjust for many important variables in our models. Other 
advantages of the cohort are its representation of minority groups including African-
Americans, Hispanics and other races. Also, the use of a norm-based generic HRQOL 
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questionnaire (RAND SF-36) makes it easy for direct comparisons with different 
populations and settings including the general US population, non-HIV-infected US 
military population, other HIV cohorts as well as those of other chronic diseases that 
have used similar instruments.  
2.5: Conclusion 
   In conclusion, there are several important findings from our study. One, physical 
functional health was better than mental functional health in our cohort. Two, our study 
showed no differences in both physical and mental functional health of participants by 
HAART groups. Three, the high negative impact of mental comorbidities on mental 
functional health in our cohort deserves the attention of both clinicians and policy makers 
in order to improve the self-reported health of HIV-infected individuals in the United 
States Military. Also, the complex interplay between age/HIV and HRQOL needs to be 
further studied in order for us to better understand why older age is negatively associated 
with physical functional health but positively associated with mental functional health. 
Finally, we believe this current study will serve as a reference for future longitudinal 
studies on HRQOL in our cohort.   
 
 
 
 
2.6: Tables 
 
Table 2.1: Baseline Characteristics of Participants by Highly Active Anti-Retroviral Therapy Group 
Characteristics PI-Based HAART  
N (%) 
Non-PI-Based HAART 
N (%) 
HAART-Naïve  
N (%) 
Off-HAART  
N (%) 
P-Value* 
Gender 
Male 
Female 
 
485 (93.45) 
34 (6.55) 
 
533 (91.58) 
49 (8.42) 
 
390 (94.89) 
 21 (5.11) 
 
144 (92.31)  
12 (7.69) 
0.2257 
Race/Ethnicity 
Non-Hispanic White 
Non-Hispanic African American 
Hispanic/Others 
 
234 (45.09) 
223 (42.97) 
62 (11.95) 
 
253 (43.47) 
251 (43.13) 
78 (13.40) 
 
145 (35.28) 
164 (39.90) 
102 (24.82) 
 
69 (44.23) 
65 (41.67) 
22 (14.10) 
<.0001 
Rank 
Officer/Warrant Officer 
Enlisted 
Civilian/Retired 
 
25 (4.83) 
177 (34.17) 
316 (61.00) 
 
44 (7.56) 
290 (49.83) 
248 (42.61) 
 
41 (10.00) 
340 (82.93) 
29 (7.07) 
 
11 (7.05)  
76 (48.72)  
69 (44.23)  
<.0001 
Marriage 
Yes 
No 
 
165 (31.79) 
354 (68.21) 
 
201 (34.54) 
381 (65.46) 
 
115 (27.98) 
296 (72.02) 
 
52 (33.33)  
104 (66.67) 
0.1784 
CD4 Groups  
CD4 Less Than 200 
CD4 Between 200 and 499 
CD4 Greater Than 499  
 
62 (11.95) 
213 (41.04) 
244 (47.01) 
 
18 (3.10) 
192 (33.05) 
371 (63.86) 
 
8 (1.95) 
227 (55.37) 
175 (42.68) 
 
14 (8.97) 
81 (51.92) 
61 (39.10) 
 
<.0001 
Viral Load Copies > 50 copies/mL 
Yes 
No 
 
176 (33.98) 
342 (66.02) 
 
103 (17.70) 
479 (82.30) 
 
405 (98.54) 
6 (1.46) 
 
139 (89.10) 
17 (10.90) 
<.0001 
Mental Comorbidity 
Yes 
No 
 
190 (36.61) 
329 (63.39) 
 
150 (25.77) 
432 (74.23) 
 
36 (8.76) 
375 (91.24) 
 
54 (34.62) 
102 (65.38) 
<.0001 
Medical Comorbidity 
Yes 
No 
 
126 (24.28) 
393 (75.72) 
 
84 (14.43) 
498 (85.57) 
 
6 (1.46) 
405 (98.54) 
 
24 (15.38) 
132 (84.62) 
<.0001 
AIDS 
Yes 
No 
 
123 (23.70) 
396 (76.30) 
 
55 (9.45) 
527 (90.55) 
 
2 (0.49) 
409 (99.51) 
 
12 (7.69)  
144 (92.31) 
<.0001 
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Adherence (90%) 
Yes 
No 
 
453 (87.62) 
64 (12.38) 
 
550 (94.66) 
31 (5.34) 
 
N/A 
N/A 
 
N/A 
N/A 
<.0001 
Calendar Year 
Baseline Year 2006 
Baseline Year 2007 
Baseline Year 2008 
Baseline Year 2009 
Baseline Year 2010 
 
286 (55.11) 
168 (32.37) 
33 (6.36) 
24 (4.62) 
8 (1.54) 
 
313 (56.09) 
157 (31.73) 
34 (5.84) 
48 (8.25) 
30 (5.15) 
 
106 (25.79) 
107 (26.03) 
67 (16.30) 
79 (19.22) 
52 (12.65) 
 
100 (64.10) 
35 (22.44) 
8 (5.13) 
10 (6.41) 
3 (1.92) 
<.0001 
 
Age (years) 
Median (IQR) 
 
44.0 (39.0 – 50.0) 
 
41.0 (35.0 – 47.0)  
 
29.0 (25.0 – 38.0)  
 
40.5 (36.0 – 45.0) 
 
<.0001 
CD4 Cell Count (x 106/L) 
Median (IQR) 
 
477.0 (316.0 – 678.0) 
 
570.0 (435.0 – 776.0) 
 
466.0 (374.0 – 606.0) 
 
450.0 (338.0 – 622.0) 
 
<.0001 
Viral Load (Log10) 
 Median (IQR) 
 
1.70 (1.70 – 2.26) 
 
1.70 (1.70 – 1.70) 
 
4.25 (3.73 – 4.73) 
 
4.03 (3.29 – 4.46) 
 
<.0001 
Time from HIV Diagnosis (years)  
 Median (IQR) 
 
15.0 (10.0 – 19.0) 
 
8.0 (4.0 – 14.0) 
 
0.0 (0 – 1.0) 
 
11.0 (7.0 – 15.0) 
 
<.0001 
Physical Component Summary Score 
Median (IQR) 
 
 52.90 (43.89 – 57.18) 
 
55.45 (48.11 – 58.19) 
 
56.26 (51.26 – 58.72) 
 
(53.04, 45.15 – 57.39) 
 
<.0001 
Mental Component Summary Score  
Median (IQR) 
 
50.36 (42.35 – 54.08) 
 
51.26 (44.89 – 54.39) 
 
48.81 (43.45 – 53.35) 
 
50.12 (42.34 – 52.87) 
 
0.0003 
*Chi-square test for count variable and Kruskal Wallis for numeric variable. N/A = Not Applicable. IQR = Interquartile Range
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Table 2.2:  Factors Associated with Physical Component Summary Scores at Baseline  
 
Variable 
 Physical Component Summary Scores (n = 1652) 
Unadjusted Model Multivariate Model 
β SE 95% CI P-Value β SE 95% CI P-Value 
HAART Status  
HAART Naïve  
Non-PI-Based HAART 
Off-HAART  
PI-Based HAART 
 
4.59 
2.53 
0.81 
- 
 
0.59 
0.54 
0.81 
- 
 
3.44,  5.74 
1.48,  3.58 
-0.78, 2.40 
- 
 
<.0001 
<.0001 
0.32 
- 
 
0.11 
0.68 
-0.50 
- 
 
0.85 
0.54 
0.84 
- 
 
-1.57, 1.78 
-0.38, 1.75 
-2.15, 1.15 
- 
 
0.90 
0.21 
0.56 
- 
Age (5-yearly Increment) -1.03 0.10 -1.23, -0.83 <.0001 -0.51 0.14 -0.78, -0.24 0.0002 
Race/Ethnicity 
Non-Hispanic African American 
Hispanic/Others 
Non-Hispanic White 
 
0.12 
0. 38 
- 
 
0.484 
0.653 
- 
 
-0.83, 1.07 
-0.90, 1.66 
- 
 
0.81 
0.56 
- 
 
-0.373 
-0.736 
- 
 
0.462 
0.618 
- 
 
-1.28, 0.53 
-1.95, 0.48 
- 
 
0.42 
0.23 
- 
Gender 
Male 
Female 
 
2.97 
- 
 
0.87 
- 
 
1.27, 4.67 
- 
 
0.0006 
- 
 
2.11 
- 
 
0.83 
- 
 
0.49, 3.73 
- 
 
0.01 
- 
Rank 
Enlisted 
Civilian  
Officer/Warrant Officer 
 
-2.07 
-6.20 
- 
 
0.84 
0.86 
- 
 
-3.72, -0.42 
-7.89, -4.52 
- 
 
0.01 
<.0001 
- 
 
-1.90 
-3.30 
- 
 
0.83 
0.88 
- 
 
-3.53, -0.27 
-5.03, -1.57 
- 
 
0.02 
0.0002 
- 
Marital Status 
Married 
Single 
 
-1.814  
- 
 
0.473 
- 
 
-2.74, -0.89 
- 
 
0.0001 
- 
 
-1.24 
- 
 
0.45 
- 
 
-2.13, -0.36 
- 
 
0.006 
- 
CD4 Count Groups 
<200 cells/mm3 
200-499 cells/mm3 
>499 cells/mm3 
 
-7.75 
-0.64 
- 
 
0.93 
0.45 
- 
 
-9.58, -5.92 
-1.53, 0.24 
- 
 
<.0001 
0.15 
- 
 
-5.94 
-0.76 
- 
 
0.94 
0.44 
- 
 
-7.78, -4.09 
-1.62, 0.10 
- 
 
<.0001 
0.08 
- 
Viral Load >50 copies/mL 
Yes 
No 
 
0.61 
- 
 
0.44 
- 
 
-0.26, 1.48 
- 
 
0.17 
- 
 
0.17 
- 
 
0.59 
- 
 
-0.99, 1.32 
- 
 
0.78 
- 
Medical Comorbidity 
Yes 
No 
 
-5.21 
- 
 
0.62 
- 
 
-6.42, -4.00 
- 
 
<.0001 
- 
 
-2.72 
- 
 
0.63 
- 
 
-3.96, -1.47 
- 
 
<.0001 
- 
Mental Comorbidity 
Yes 
No 
 
-4.57 
- 
 
0.49 
- 
 
-5.54, -3.60 
- 
 
<.0001 
- 
 
-2.84 
- 
 
0.50 
- 
 
-3.82, -1.86 
- 
 
<.0001 
- 
AIDS 
Yes 
 
-6.07 
 
0.682 
 
-7.40, -4.73 
 
<.0001 
 
-2.34 
 
0.72 
 
-3.75, -0.93 
 
0.001 
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##Model with only PI-HAART and NPI-HAART. SE = Standard Error. β = Beta coefficient. CI = Confidence Interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No - - - - - - - - 
Duration of HIV (years)  -0.30 0.03 -0.36, -0.24 <.0001 0.02 0.05 -0.07, 0.11 0.66 
Adherence## 2.14 1.01 0.16, 4.12 0.03 1.58 0.95 -0.29, 3.44 0.10 
Calendar Year 
2010 
2009 
2008 
2007 
2006 
 
1.91 
0.78 
2.62 
1.10 
- 
 
0.99 
0.78 
0.82 
0.52 
- 
 
-0.02, 3.85 
-0.74, 2.31 
1.01, 4.24 
0.07, 2.13 
- 
 
0.05 
0.31 
0.001 
0.04 
- 
 
-0.37 
-0.35 
1.48 
1.56 
- 
 
0.96 
0.75 
0.79 
0.49 
- 
 
-2.24, 1.51 
-1.83, 1.13 
-0.07, 3.02 
0.59, 2.53 
- 
 
0.70 
0.64 
0.06 
0.002 
- 
Intercept NA NA NA NA 57.84 1.70 54.52, 61.16 <.0001 
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Table 2.3:  Factors Associated with Mental Component Summary Scores at Baseline  
 
Variable 
 Mental Component Summary Scores (n = 1652) 
Unadjusted Model Multivariate Model 
β SE 95% CI P-Value β SE 95% CI P-Value 
HAART Status  
HAART Naïve  
Non-PI-Based HAART 
HAART Holiday 
PI-Based HAART 
 
-0.51 
0.94 
-1.41 
- 
 
0.61 
0.55 
0.83 
- 
 
-0.15, 2.02 
-0.15,  0.68 
-3.04, 0.23 
- 
 
0.40 
0.09 
0.09 
- 
 
-1.27 
0.02 
-1.07 
- 
 
0.80 
0.55 
0.87 
- 
 
-2.85, 0.30 
-1.05, 1.11 
-2.78, 0.64 
- 
 
0.11 
0.96 
0.22 
- 
Age (5-yearly Increment) 0.25 0.11 0.04, 0.46 0.02 0.48 0.13 0.22, 0.74 0.0003 
Race/Ethnicity 
Non-Hispanic African American 
Hispanic/Others 
Non-Hispanic White 
 
  1.84 
  -0.81 
- 
 
0.49  
0.66 
- 
 
0.88, 2.79 
-2.10, 0.48 
- 
 
0.0002 
0.22 
- 
 
1.54 
-0.71 
- 
 
0.48 
0.64 
- 
 
0.61, 2.48 
-1.97, 0.55 
- 
 
0.001 
0.27 
- 
Gender 
Male 
Female 
 
0.84 
- 
 
0.88 
- 
 
-0.89, 2.57 
- 
 
0.34 
- 
 
1.11 
- 
 
0.85 
- 
 
-0.56, 2.78 
- 
 
0.19 
- 
Rank 
Enlisted 
Civilian  
Officer/Warrant Officer 
 
-0.36 
-1.19 
- 
 
0.88 
0.90 
- 
 
-2.08, 1.37 
-2.95, 0.57 
- 
 
0.68 
0.18 
- 
 
0.73 
-0.32 
- 
 
0.87 
0.90 
- 
 
-0.97, 2.45 
-2.08, 1.45 
- 
 
0.40 
0.72 
- 
Marital Status 
Married 
Single 
 
-0.31  
- 
 
0.48 
- 
 
-1.26, 0.63 
- 
 
0.52 
- 
    
CD4 Count Groups 
<200 cells/mm3 
200-499 cells/mm3 
>499 cells/mm3 
 
-3.07 
-1.04 
- 
 
0.96 
0.46 
- 
 
-4.95, -1.19 
-1.95, -0.13 
- 
 
0.001 
0.02 
- 
 
-1.96 
-0.80 
- 
 
0.98 
0.46 
- 
 
-3.87, -0.04 
-1.70, 0.10 
- 
 
0.04 
0.08 
- 
Viral Load >50 copies/mL 
Yes 
No 
 
-1.46 
- 
 
0.45 
- 
 
-2.34, -0.58 
- 
 
0.001 
- 
 
-0.420 
- 
 
0.611 
- 
 
-1.62 – 0.78 
- 
 
0.49 
- 
Medical Comorbidity 
Yes 
No 
 
0.71  
- 
 
0.64 
- 
 
-0.54, 1.97 
- 
 
0.26 
- 
    
Mental Comorbidity 
Yes 
No 
 
-5.99  
- 
 
0.49 
- 
 
-6.96, -5.03 
- 
 
<.0001 
- 
 
-6.12 
- 
 
0.52 
- 
 
-7.13, -5.10 
- 
 
<.0001 
- 
AIDS 
Yes 
 
-1.97 
 
0.71 
 
-3.36, -0.59 
 
0.005 
 
-0.79 
 
0.73 
 
-2.23, 0.64 
 
0.28 
70 
 
 
 
 
 
 
 
 
 
##Model with only PI-HAART and NPI-HAART. SE = Standard Error. β = Beta coefficient. CI = Confidence Interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No - - - - - - - - 
Duration of HIV (years)  0.003 0.03 -0.06, 0.06 0.91     
Adherence## 2.30 0.98 0.37, 4.23 0.02 1.77 0.93 -0.06, 3.59 0.06 
Calendar Year 
2010 
2009 
2008 
2007 
2006 
 
0.59 
-0.28 
-0.30 
-0.45 
- 
 
1.00 
0.79 
0.84 
0.53 
- 
 
-1.37, 2.56 
-1.73, 1.34 
-1.83, 1.34 
-1.49, 0.60 
- 
 
0.55 
0.72 
0.72 
0.40 
- 
    
Intercept NA NA NA NA 44.69 1.73 41.29, 48.09 <.0001 
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Table 2.4:  Factors Associated with Physical/Mental Component Summary Scores at Baseline  
 
Variable 
 Physical/Mental Component Summary Scores (n = 1652) 
Most Parsimonious Multivariate PCSS Model Most Parsimonious Multivariate MCSS Model 
β SE 95% CI P-Value β SE 95% CI P-Value 
HAART Status  
HAART Naïve  
Non-PI-Based HAART 
HAART Holiday 
PI-Based HAART 
 
0.07 
0.61 
-0.42 
- 
 
0.68 
0.53 
0.77 
- 
 
-1.25, 1.40 
-0.42, 1.64 
-1.94, 1.09 
- 
 
0.91 
0.25 
0.58 
- 
 
-1.14 
0.08 
-1.05 
- 
 
0.79 
0.55 
0.87 
- 
 
-2.69, 0.41 
-0.99, 1.16 
-2.76, 0.67 
- 
 
0.15 
0.88 
0.23 
- 
Age (5-yearly Increment) -0.48 0.13 -0.73, -0.22 0.0002 0.38 0.12 0.14, 0.61 0.002 
Race/Ethnicity 
Non-Hispanic African American 
Hispanic/Others 
Non-Hispanic White 
     
1.60 
 -0.70 
- 
 
0.47 
0.64 
- 
 
0.67, 2.52 
-1.95, 0.56 
- 
 
0.0007 
0.28 
- 
Gender 
Male 
Female 
 
2.14 
- 
 
0.82 
- 
 
0.53, 3.76 
- 
 
0.009 
- 
 
1.22 
- 
 
0.84 
- 
 
-0.43, 2.88 
- 
 
0.15 
- 
Rank 
Enlisted 
Civilian  
Officer/Warrant Officer 
 
-1.99 
-3.31 
- 
 
0.82 
0.85 
- 
 
-3.60, -0.39 
-4.98, -1.64 
- 
 
0.02 
0.0001 
- 
    
Marital Status 
Married 
Single 
 
-1.27 
- 
 
0.45 
- 
 
-2.16, -0.41 
- 
 
0.0041 
- 
    
CD4 Count Groups 
<200 cells/mm3 
200-499 cells/mm3 
>499 cells/mm3 
 
-5.87 
-0.74 
- 
 
0.91 
0.43 
- 
 
-7.66, -4.08 
-1.59, 0.11 
- 
 
<.0001 
0.09 
- 
 
-1.96 
-0.76 
- 
 
0.98 
0.46 
- 
 
-3.88, -0.05 
-1.66, 0.14 
- 
 
0.04 
0.10 
- 
Viral Load >50 copies/mL 
Yes 
No 
     
-0.42 
- 
 
0.61 
- 
 
-1.61 – 0.78 
- 
 
0.50 
- 
Medical Comorbidity 
Yes 
No 
 
-2.68 
- 
 
0.63 
- 
 
-3.92, -1.44 
- 
 
<.0001 
- 
    
Mental Comorbidity 
Yes 
No 
 
-2.77 
- 
 
0.49 
- 
 
-3.73, -1.80 
- 
 
<.0001 
- 
 
-6.24 
- 
 
0.51 
- 
 
-7.24, -5.24 
- 
 
<.0001 
- 
AIDS 
Yes 
 
-2.32 
 
0.71 
 
-3.72, -0.92 
 
0.001 
 
-0.90 
 
0.73 
 
-2.33, 0.53 
 
0.22 
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##Model with only PI-HAART and NPI-HAART. SE = Standard Error. β = Beta coefficient. CI = Confidence Interval 
 
 
 
 
 
No - - - - - - - - 
Duration of HIV (years)          
Adherence## 1.59 0.95 -0.27, 3.46 0.09 1.73 0.93 -0.09, 3.55 0.06 
Calendar Year 
2010 
2009 
2008 
2007 
2006 
 
-0.47 
-0.44 
1.40 
1.52 
- 
 
0.95 
0.75 
0.78 
0.49 
- 
 
-2.24, 1.51 
-1.90, 1.03 
-0.13 2.94 
0.56, 2.49 
- 
 
0.62 
0.56 
0.07 
0.002 
- 
    
Intercept 57.61 1.67 54.34, 60.87 <.0001 45.63 1.48 42.72, 48.53 <.0001 
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Chapter 3 
Predictors of Health-Related Quality of Life among HIV-infected 
Individuals in the HAART Era 
Abstract 
Objective: The aims of this study were: (i). to determine the long-term predictors of HRQOL in our cohort, 
and (ii). to evaluate the impact of HAART use on changes in HRQOL measures on the long-term. 
Methods: Study participants were a nested cohort of the NHS that responded to the SF-36 questionnaire in 
2006 and annually thereafter until 2010. Physical component summary (PCSS) and mental component 
summary (MCSS) scores were computed based on standard algorithms. Mixed linear random effects model 
was used to estimate the changes in PCSS and MCSS over the four year period of follow-up.  
Results: There was no beneficial effect of being in one HAART group compared to the other, and HAART 
did not lead to changes in HRQOL scores over the period of follow-up. Factors independently predictive of 
PCSS were being on NPI-HAART (β= 1.13, 95% CI: 0.20, 2.05), being HAART-naïve (β= 1.55, 95% CI: 
0.15, 2.95), CD4 count < 200 cells/mm3 (β= -2.62, 95% CI: -4.31, -0.93), CD4 count 200-499 cells/mm3 
(β= -0.90, 95% CI: -1.57, -0.23), mental comorbidity (β= -3.24, 95% CI: -4.19, -2.29), medical 
comorbidity (β= -3.80, 95% CI: -5.38, -2.23), AIDS diagnosis (β= -3.38, 95% CI: -4.98, -1.78),  5-yearly 
increment in age (β= -0.83, 95% CI: -1.12, -0.54 ) and being married. Every one-year of follow-up also led 
to an improvement in PCSS for those with medical comorbidity.  Factors independently associated with 
MCSS were CD4 count < 200 cells/mm3 (β= -2.42, 95% CI: -4.13, -0.71), mental comorbidity (β= -4.38, 
95% CI: -5.32, -3.43),  and being African American (β= 2.45, 95% CI: 1.35, 3.56).  
Conclusion: There is an urgent need to address the modifiable factors predictive of physical and mental  
HRQOL measures in our cohort specifically mental comorbidity and low CD4 count. Our study did not find 
any treatment benefit of  NPI-HAART over PI-HAART in the long term. Our study supports the frequency 
of testing for HIV-disease indicators, which informs the need for those not on treatment being placed on 
treatment or the need to change treatment among those already on treatment. 
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Chapter 3 
Predictors of Health-Related Quality of Life among HIV-infected 
Individuals in the HAART Era 
 
3.1: Introduction and Background 
    In an earlier study (chapter 2), we determined the factors associated with health-related 
quality of life (HRQOL) measures at baseline for our cohort. In this current study we 
further investigate the long-term predictors of HRQOL in our cohort, and also examine 
the changes in HRQOL among participants on different classes of highly active anti-
retroviral therapy (HAART) including those who were not on HAART. One major 
advantage of doing so is that it will be enable us to evaluate the HRQOL trajectory both 
for those on HAART and those not on HAART, assess the benefit of the frequency of 
testing for HIV disease indicators (CD4 cell count and plasma viral load) and compare 
treatment modalities in order to maximize HRQOL in HIV-infected individuals1.     
3.2: Methods 
3.2.1: Study Participants and Cohort 
   The participants for the current study are a nested cohort of the larger Natural History 
Study cohort, which has been described elsewhere2-5 (please see chapter 2). Briefly, the 
United States Military HIV Natural History Study (NHS) is a dynamic cohort of military 
personnel and their dependents who are followed at five medical centers. Participants 
included in the current study were those who completed the RAND Short Form 36 (SF-
36) at baseline in 2006, and were subsequently followed through September, 2010. All 
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participants provided informed consent, and approval for this research was obtained from 
the institutional review board at each participating site. 
3.2.2: Definitions and Variable Selections 
3.2.2.1: Health-Related Quality of Life Scores 
   The norm-based the physical (PCS) and mental (MCS) component summary scores 
were computed from the eight health domains in the SF-36 questionnaire in line with the 
recommended scoring algorithm for the RAND 36-item health survey 1.06,7. The PCS 
and MCS scores were the outcome variables in our analyses, and were measured over 5 
yearly time points, 2006 to 2010.  
3.2.2.2: HAART (Treatment) Variable 
   We defined HAART as a combination of at least three antiretroviral agents in line with 
previous investigations for this cohort3. In line with our baseline study, HAART 
treatment was categorized into four groups: (i) protease inhibitor-based HAART (PI-
HAART),  for HAART with at least one protease inhibitor in the combined HAART 
regimen; (ii) non-protease-inhibitor-based HAART (NPI-HAART), for HAART with no 
protease inhibitor in the combined HAART regimen; (iii) HAART-naïve group 
(HAART-N) for those who had never been on HAART; and (iv) an Off-HAART group, 
for those who were not on HAART at the time of survey but have had HAART in the 
past.  
3.2.2.3: Covariates  
   Covariates selected were in line with those included for the cross-sectional study 
(please see chapter 2).  These covariates included gender (male/female), age, military 
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rank (officer/warrant officer, enlisted and civilian/retired),  marital status (married, not 
married), race/ethnicity (non-Hispanic white, non-Hispanic African-American, and 
Others), viral load, CD4+ count, medical comorbidity, mental comorbidity, AIDS 
diagnosis, and HIV duration. CD4 cell count was categorized as ‘<200 cells/mm3, ‘200-
499 cells/mm3’ and ‘>499 cells/mm3’, while plasma viral load was categorized as >50 
copies/mL (yes) or ≤50 copies/mL (no). The definition of AIDS was in line with the 1993 
Centers for Disease Control and Prevention criteria, with the exception of an isolated 
CD4 cell count <200 cells/mL as CD4 was analyzed separately.  Medical co-morbidity 
referred to chronic medical conditions, and was classified as having no comorbidity or 
having one or more comorbidity. Mental comorbidity was classified similarly.  
3.3: Inclusion and Exclusion Criteria 
All participants aged 18 years and above who completed the HRQOL survey 
questionnaires in 2006 for the first time were considered for inclusion into the current 
study. Similar to the baseline study we excluded 14 participants on a non-HAART anti-
retroviral therapy.   
3.4: Statistical Analyses 
   We tabulated the baseline (2006) characteristics of participants using proportions for 
count variables and medians and interquartile ranges for numeric variables while we used 
bar charts and graphs to summarize the longitudinal data from 2006 to 2010. Bar charts 
were used to display percentages of participants by HAART groups for categorical 
variables while graphs displayed the means and their corresponding 95% confidence 
intervals for numeric variables. We used random effects model (REM) to estimate the 
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beta (β) coefficients and corresponding 95% confidence intervals for the variables. We 
used the restricted maximum likelihood (REML) estimation method to estimate β, and 
used an unstructured covariance structure8 to account for correlation of the random 
effects. Like in the baseline study, we constructed different models for PCSS and MCSS. 
For each outcome variable, we first conducted univariate analysis for the explanatory 
variables and only variables that achieved <0.2 significance level were included for the 
final multivariate analyses. We further utilized the minus 2 log likelihood ratio (-2LLR) 
test to determine the number of variables that made the most parsimonious models. 
Variables with significant interaction with time in the univariate analyses were tested for 
significant interaction in the multivariate models. All variables, with the exception of race 
and gender, were treated as time-dependent variables. Time was treated as a numeric 
variable although we also compared the results with treating it as a discrete variable. All 
statistical analyses and graphs were performed using SAS 9.3 [SAS Institute Inc., Cary, 
NC]. 
3.3: Results 
   There were 812 participants in 2006 (baseline) who met the study eligibility criteria, 
and their characteristics are displayed in table 3.1a. Participants were mostly male (95%), 
with Caucasian and African-American making up 48% and 40% respectively. 27% of 
participants had mental comorbidity, 16% medical comorbidity and 10% had AIDS at 
baseline. The median age at baseline was 42 years (interquartile range [IQR]: 34-47), and 
the median physical and mental component summary scores were respectively 54.41 
(IQR, 45.95 – 57.48) and 50.77 (IQR, 44.06 – 54.05). Table 3.1b shows the number of 
participants per HAART group per year of follow-up, the total number of participants 
who responded to the SF-36 questionnaire in any given year, the number of non-
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responders, and the number of participants with missing values for one or more variables 
among responders.   
   In the univariate PCSS analyses, there was no significant interaction between the 
treatment (HAART) and time variables, p=0.6 (table 3.2.a, figures 3.1.a-d). Also, there 
was no significant effect of treatment on changes in PCS scores over the period of 
follow-up (p=0.7). Compared to participants in the PI-HAART group, the PCS scores of 
participants in the NPI-HAART and HAART-naïve groups were respectively higher by 
3.6 (95% confidence interval [CI]: 2.11-5.94) and 2.11 (95%CI: 0.65-3.38) (tables 3.2.a. 
and figures 3.1.a-c). In the multivariate model (most parsimonious), the differences in 
scores were respectively 1.55 and 1.13 for HAART-naïve and NPI-HAART but remained 
statistically significant (table 3.3.a). There was no significant difference in PCS scores 
between the Off-HAART and PI-HAART groups both in the univariate and multivariate 
models (tables 3.2.a, 3.3.a, fig. 3.1.a, 3.1.d). The change in PCS scores for every one year 
increment from baseline in the multivariate PCSS model was -0.03 (p=0.8). In the 
univariate MCSS model, no significant interaction was noted between the treatment 
(HAART) and time variables, and there were no significant treatment effects on changes 
in MCS scores over the follow-up period (table 3.2.b and fig. 3.1.b). There was also no 
significant difference in MCS scores by HAART group.  
   Other factors that were independently predictive of physical functional health were 
CD4 count <200 cells/mm3 (β: -2.62; 95%CI: -4.31 – -0.93), CD4 count 200-499 
cells/mm3 (β: -0.90; 95%CI: -1.57 – -0.23), AIDS diagnosis (β: -3.38; 95%CI: -4.98 –  
-1.78),  medical (β: -3.80; 95%CI: -5.38 – -2.23),  and mental (β: -3.24; 95%CI: -4.19 –  
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-2.29), comorbidities, being married (β: 0.99; 95%CI: -1.88 – -0.11), and age of 
participants with every 5 year increment in age leading to a reduction in PCS scores by -
0.83 (95%CI: -1.12 – -0.54),  . There was also significant interaction between medical 
comorbidity and time (β: 0.72, 95% CI: 0.32 – 1.13). Although the duration of HIV 
infection was predictive of physical functional health in the univariate analysis, it was not 
significantly predictive of physical functional health after adjusting for in the multivariate 
model. Factors that were independently predictive of mental functional health were being 
African American (β: 2.45, 95% CI: 1.35 – 3.56), CD4 count <200 cells/mm3 (β: -2.42, 
95% CI: -4.13 – -0.71), and mental comorbidity (β: -4.38, 95% CI: -5.32 – -3.43). 
Although plasma viral load >50 copies/mL was predictive of mental functional health in 
the univariate REM, this was no longer statistically significant in the multivariate model 
(β: -0.61, 95% CI: -1.28 – 0.05).  
3.4: Discussion 
   The goals of this study were two-fold: 1) to determine the long-term predictors of 
HRQOL, and 2) to evaluate if there were differences in HRQOL measures by HAART 
groups. Studies on HRQOL in HIV-infected individuals have generally been used to 
address whether HAART improves HRQOL9,10, and while it is generally agreed that 
HAART improves HRQOL in the short-term9-11, the evidence of the impact of HAART 
on HRQOL on the long term is not clear9. The overall effect of HAART on HRQOL has 
been described as a balance between improvements in HIV-related morbidity and better 
life-expectancy on the one hand and medication adverse effects on the other hand1,11. 
This picture is further complicated by the increasing age-associated comorbidities12,13 in 
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HIV-infected populations, the differential handling of HAART by older individuals14 and 
the very effects of aging on the individual including physical senescence11.   
   Side effects of HAART known to adversely affect HRQOL include lipodystrophy, 
diarrhea, anemia, peripheral neuropathy, insulin resistance and metabolic syndrome, renal 
tubular toxicity, pancreatitis, and hypersensitivity reaction15-17. (Also see chapter 2). 
While side effects are not unique to a specific class of HAART medications, the protease 
inhibitors have been implicated as having greater adverse effects including morphological 
changes and metabolic disturbances18. To that end, we grouped we HAART into 
protease-inhibitor based HAART (PI-HAART) and non-protease inhibitor HAART (NPI-
HAART). For those not on HAART, we further differentiated between those who were 
off-medications (Off-HAART) from those who had never been on HAART (HAART-
naive).  
   In our earlier study (chapter 2), we did not find any statistically significant differences 
in physical or mental functional health among the HAART groups in the multivariate 
models although those in the NPI-HAART and HAART-naïve groups had significantly 
higher PCS scores compared to the PI-HAART group in univariate analyses. In this study 
we specifically investigated the treatment effect of  being on NPI-HAART compared to 
being on PI-HAART but did not find any statistically significant difference as evidenced 
by the lack of significant interaction between NPI-HAART and time (table 3.2.a) or near 
parallel lines of the treatment groups (figures 3.1.a. and 3.1.b). There were also no 
significant interactions among HAART-naive and Off-HAART and time. Furthermore, 
PCS scores were on average stable for the four groups over the period of follow-up. 
However, while there was no PCS score difference between the PI-HAART and Off-
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HAART groups, there were statistically significant differences in PCS scores in the 
HAART-naïve and NPI-HAART groups both in the univariate and multivariate models. 
Similarly, there were no significant treatment benefit of being in the other groups over 
PI-HAART in terms of MCS scores, and being in these groups did no lead to changes in 
MCS scores over time. Also, the MCS scores in NPI-HAART, HAART-naïve and Off-
HAART groups were not significantly different from those of PI-HAART.  
   In a five year longitudinal study of a French HIV-population on PI-HAART, 
Protopopescu et al, found that PCS scores improved in the first year following initiation 
of treatment but remained stable over the rest of the follow-up period19. Being that 
participants had already been on HAART for years before the HRQOL questionnaires 
were administered in our cohort, it was not entirely surprising that we did not see any 
initial improvement in PCS scores. Our findings of no significant treatment benefit of 
NPI-HAART over PI-HAART on participants HRQOL scores is different from the 
findings of others18,20,21 who reported improved quality of life in their studies. We note, 
however, that the studies by Potard et al18 and Campo et al21 involved treatment switch 
without the benefit of a concurrent PI-HAART comparison group while that by Fumaz et 
al20 involved 100 participants who had failed a PI-HAART regime before randomization 
into another PI-HAART or efavirenz based HAART.  
   Although PCS score of the HAART-naïve group was still higher than that of the PI-
HAART group in the multivariate model, those who were HAART naive showed an 
average decline in PCS scores by 0.5 points (p=0.5) over the follow-up period. This 
finding is not unexpected because in our cohort, participants are monitored regularly on a 
six-monthly interval22 for disease indicators (CD4 cell counts and viral loads), and those 
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with worsening disease indicators are placed on HAART. Therefore, the HAART-naive 
group may not reflect the expected downward trajectory in HRQOL1 because of the 
steady movement of participants in this group to the treatment arms (PI and NPI). By the 
same token, it may be argued that improvements in HRQOL may be blunted by additions 
of participants with less favorable HRQOL scores over time. The significant differences 
in PCS scores among the HAART groups may be explained by their baseline differences, 
residual confounding and confounding by indication since the PI-HAART group had 
lived with HIV-infection longer and had more comorbidities including AIDS at baseline. 
The Off-HAART group also had a relatively stable PCS scores over the period of follow-
up similar to the findings by others23,24 but different from the SMART trial which found a 
decline in HRQOL among those on CD4 count-guided treatment interruption25. Like the 
HAART-naïve group, participants with worsening disease indicators are also switched to 
either PI-HAART or NPI-HAART.  
   Another interesting finding in our current study was the interaction between time and 
medical comorbidity. While medical comorbidity was negatively predictive of PCS 
scores, we found that for every one year increment in duration from baseline, the 
presence of medical comorbidity led to improvement in PCS score by 0.7 points 
(p=0.005). One likely explanation for this is that those who develop medical 
comorbidities were likely to have had more contacts with the healthcare system and other 
specialists which may positively impact their PCS as their comorbid conditions improve 
or become stable. Furthermore, coping strategies used for their comorbidities may also 
help with their HIV-infection with net improvement in physical functioning. Similar to 
the findings by other investigators and in keeping with clinical experience, we also found 
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that lower CD4 counts19,26, AIDS diagnosis19,27, and mental comorbidities26,27 were 
negatively predictive of physical functional health on the long term. Increasing age was 
also a negative predictor of physical functional health similar to the findings of 
others1,19,26. Like in our baseline study, being married was negatively predictive of 
physical functional health. HIV duration although significant in the univariate model was 
not independently predictive of PCS score, a finding that is similar to our baseline study 
and that of Jia et al28,29. 
    Only three factors were independently predictive of mental functional health in our 
cohort, and these were CD4 count <200 cells/mm3, mental comorbidity and being 
African-American, and these findings were similar to our baseline study (chapter 2). 
Although the impact of mental comorbidity on mental functional health was not nearly as 
dramatic as we found in our baseline study (-4.36 vs. -6.15), it still remained the most 
significant predictor of MCS scores in our cohort (chapter 2). Based on our current and 
baseline studies, we believe that there is a need to aggressively address the mental health 
needs of HIV-infected military personnel by both clinicians and policy makers in order to 
improve their overall quality of life. 
   Some of the limitations of our current study include the high percentage of missing 
HRQOL measures. Of the 812 eligible participants at baseline, 626 (77%) had HRQOL 
measures by the end of first year of follow-up but at the end of administrative censorship 
in September of 2010, there were 362 (45%) participants left with HRQOL measures. 
Participants with missing HRQOL measures were due to non-response to or improperly 
completed self-administered questionnaire or loss to follow-up. This high percentage of 
dropout has the potential to bias our results but this is unlikely considering the similarity 
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of our current results to the baseline findings for the entire cohort. Also, the proportions 
of participants over the years did not seem to be affected by demographic characteristics, 
HIV-disease indicators or comorbidities (figures 3.3 to 3.11). When we compared those 
who did not respond to the questionnaire for the period, we did not find any differences 
by demographic characteristics or HIV-disease indicators but non-responders were less 
likely to have medical or mental comorbidity (data not shown). Investigators in a 
longitudinal French HIV cohort did not find any difference in their results between the 
traditional linear mixed random effects model (as in our current study) and the joint 
parameter-dependent selection model that accounted for non-ignorable dropout. We note 
here that the retention rate was much better with our cohort: 77% vs. 63.5% for the 
French study at the end of the first year of follow-up and 45% vs. 23.8% for the French 
study at the end of follow-up period.  
   Another limitation of our study is the predominantly male distribution of the cohort, 
which may limit the generalizability of our result. As we stated earlier, confounding by 
indication30, which tends to be a major drawback to most clinical epidemiologic studies 
evaluating treatment benefits, may partly explain the better physical functional health we 
observed in the HAART-naïve group over the PI-HAART group. Also, residual 
confounding may have contributed to better physical functional health observed for these 
groups in our current study. Some of the ways to address these short-comings will be 
either through randomization, which is impossible being an observational study, or by 
propensity scoring, which is beyond the scope of our current research efforts but may be 
the subject for future research.    
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    One of the important strengths of our study is the long follow-up period (over 4.5 
years) enabling us to determine the long term predictors of HRQOL in an observational 
study. To the best of our knowledge, this is the first study to evaluate the impact of 
specific HAART classes on HRQOL measures, including those who are HAART naïve 
and Off-HAART. Contrary to the view that PI-based HAART are associated with more 
adverse effects and so will be more detrimental to participants HRQOL measures, we did 
not find treatment benefit of NPI-based HAART over PI-HAART. Also, those on 
HAART in our cohort had stable HRQOL scores over the period of follow-up. Our study 
also shows that lower CD4 count and mental comorbidities were by far the most 
important modifiable risk factors affecting the overall HRQOL (PCS and MCS) of 
participants while AIDS, and medical comorbidities specifically affected physical 
functional health. Addressing these risk factors will help improve the functional health of 
participants. Further improvement in mental functional health could be achieved through 
such measures as social support and active coping as suggested by previous 
investigators26,28. Regular clinical monitoring of HIV-infected persons as well as testing 
for HIV disease indicators (CD4 count and plasma viral loads) are useful in deciding 
when to start HAART in the HAART naïve. Furthermore, these measures are useful in 
determining those doing well on their treatment modalities, as well as in individuals who 
are off medications from various reasons including drug toxicities. The relatively stable 
HRQOL scores in the HAART naïve and the Off-HAART groups over time therefore 
supports the current monitoring strategy of the NHS as those with ‘worsening’ HIV-
disease indicators are moved to either the PI or NPI treatment arms. However, because 
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this study is with a nested fixed cohort, further research on the entire dynamic cohort will 
be needed to corroborate these findings.    
3.5: Conclusion 
   In this observational study, we found that the effect of non-protease inhibitors on 
participants’ mean HRQOL scores was not significantly different from that of 
participants on the protease inhibitors. Also, there were no significant changes in 
HRQOL measures by HAART groups over the period of follow-up. The group 
differences in physical HRQOL scores is attributable to baseline measures, residual 
confounding and confounding by indication. We believe that to improve the functional 
health of participants, there is need to aggressively address the modifiable risk factors 
that predict low HRQOL especially mental comorbidity and lower CD4 count.  
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3.6: Tables 
Table 3.1a: Baseline Characteristics of Participants in 2006 
 
 
 
 
 
 
Characteristics N (%) 
Gender 
Male 
Female 
 
771 (94.95) 
41 (5.05) 
Race 
Non-Hispanic White 
Non-Hispanic African American 
Hispanic/Others 
 
387 (47.66) 
321 (39.53) 
104 (12.32) 
Rank 
Officer/Warrant Officer 
Enlisted 
Others (Retired/Civilians) 
 
61 (7.51) 
374 (46.06) 
377 (46.43) 
Married, Yes 270 (33.25) 
Medical Comorbidity, Yes 131 (16.13) 
Mental Comorbidity, Yes 219 (26.97) 
AIDS, Yes 82 (10.10) 
HAART 
PI-Based 
Non-PI-Based 
HAART-Naïve 
Off-HAART 
 
288 (35.47) 
318 (39.16) 
106 (13.05) 
100 (12.32) 
 Viral Load > 50 copies/mL 
Yes 
No 
Missing 
 
356 (43.84) 
455 (56.03) 
1 (0.12) 
CD4 Count Groups 
<200 cells/mm3 
200-499 cells/mm3 
       >499  cells/mm3 
Missing 
 
47 (5.79) 
322 (39.66) 
441 (54.31) 
2 (0.25) 
Age (years) – Median  (IQR) 42.00 (37.00 – 47.00) 
CD4 Count (x 106/L) – Median  (IQR) 524.00 (379.00 – 720.00) 
Plasma Viral Load (Log10) – Median  (IQR) 1.70 (1.70 – 3.56) 
Time from HIV Diagnosis (years) – Median (IQR) 10.00 (5.00 – 16.00) 
PCSS – Median (IQR)  54.41 (45.95 – 57.48) 
MCSS – Median (IQR) 50.77 (44.06 – 54.05) 
92 
 
Table 3.1.b: HAART groups of participants from 2006 to 2010 
 
 
 
 
 
 
TPWCQOL = Total Participants who Completed the SF-36 Questionnaire. Should equal sum of TP and MisVal. 
NPSNHSBNQ = Number of Participants still in the NHS Cohort but did not complete the SF-36 Questionnaire. Based on having CD4 count and/or pVL 
TP – Used = Total Participants Available for Statistical Analyses 
MisVal = Missing one or more covariates 
 
Table 3.2.a: Univariate Analyses for PCSS including Testing for Interaction Between HAART and Time 
 
Variable 
PCSS Model with Treatment Effect PCSS Model without Treatment Effect 
β SE 95%CI P-Value β SE 95%CI P-Value 
HAART 
HAART-Naïve 
Non-PI-Based-HAART 
Off-HAART 
PI-Based-HAART 
 
4.02 
2.02 
0.62 
Ref. 
 
0.98 
0.70 
0.93 
Ref. 
 
2.11 – 5.94 
0.65 – 3.38 
-1.33 – 2.56 
Ref. 
 
<.0001 
0.0038 
0.5346 
Ref. 
 
3.67 
2.11 
0.44 
Ref. 
 
0.64 
0.56 
0.73 
Ref. 
 
2.40 – 4.93 
1.01 – 3.20 
-1.00 – 1.88 
Ref. 
 
<.0001 
0.0002 
0.5437 
Ref. 
Time (One-Yearly Increment) -0.04 0.13 -0.31 – 0.22 0.7397 -0.09 0.08 -0.25 – 0.07 0.2653 
HAART*Time 
HAART-Naïve*Time 
Non-PI-Based-HAART*Time 
Off-HAART*Time 
PI-Based-HAART*Time 
 
-0.48 
-0.004 
0.03 
Ref. 
 
0.35 
0.18 
0.34 
Ref. 
 
-1.17 – 0.21 
-0.36 – 0.35 
-0.63 – 0.67 
Ref. 
 
0.49 
0.71 
0.68 
Ref. 
    
Intercept 49.59 0.54 48.54 – 50.64 <.0001 49.64 0.50 48.66 – 50.62 <.0001 
 
 
Year TPWCQOL NPSNHSBNQ MisValue   TP – Used Off-HAART HAART-Naive NPI-HAART PI-HAART 
2006 812 0 9 803 100 104 315 284 
2007 626 83 4 622 66 63 264 229 
2008 535 78 3 532 50 33 254 195 
2009 514 39 3 511 32 32 249 198 
2010 362 66 7 355 22 13 186 136 
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Table 3.2.b: Univariate Analyses for MCSS including Testing for Interaction Between HAART and Time 
 
Variable 
MCSS Model with Treatment Effect MCSS Model without Treatment Effect 
β SE 95%CI P-Value β SE 95%CI P-Value 
HAART 
HAART-Naïve 
Non-PI-Based-HAART 
Off-HAART 
PI-Based-HAART 
 
-1.54 
-0.01 
-1.91 
Ref. 
 
0.99 
0.70 
1.00 
Ref. 
 
-3.48 – 0.39 
-1.38 – 1.36 
-3.88 – 0.05 
Ref. 
 
0.1184 
0.9837 
0.0565 
Ref. 
 
-0.43 
0.30 
-0.69 
Ref. 
 
0.72 
0.49 
0.64 
Ref. 
 
-1.84 – 0.98 
-0.66 – 1.25 
-1.96 – 0.58 
Ref. 
 
0.5507 
0.5421 
0.2851 
Ref. 
Time (One-Yearly Increment) -0.04 0.14 -0.31 – 0.22 0.7467 0.09 0.08 -0.08 – 0.08 0.2926 
HAART*Time 
HAART-Naïve*Time 
Non-PI-Based-HAART*Time 
Off-HAART*Time 
PI-Based-HAART*Time 
 
0.56 
0.11 
0.53 
Ref. 
 
0.36 
0.18 
0.34 
Ref. 
 
-1.17 – 0.21 
-0.36 – 0.35 
-0.63 – 0.67 
Ref. 
 
0.1167 
0.5284 
0.1198 
Ref. 
    
Intercept 48.10 0.53 47.05 – 49.15 <.0001 47.76 0.45 46.87 – 48.65 <.0001 
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Table 3.3.a: Multivariate Predictors of Physical (PCSS) and Mental (MCSS) Component Summary Scores  
 
Variable 
PCSS Model Most Parsimonious PCSS Model 
β SE 95%CI P-Value β SE 95%CI P-Value 
HAART 
HAART-Naïve 
Non-PI-Based-HAART 
Off-HAART 
PI-Based-HAART 
 
1.52 
1.13 
0.26 
Ref. 
 
0.74 
0.48 
0.63 
Ref. 
 
0.08 – 2.97 
0.19 – 2.07 
-0.97 – 1.50 
Ref. 
 
0.0388 
0.0187 
0.6761 
Ref. 
 
1.55 
1.13 
0.25 
Ref. 
 
0.71 
0.47 
0.63 
Ref. 
 
0.15 – 2.95 
0.20 – 2.05 
-0.98 – 1.49 
Ref. 
 
0.0299 
0.0171 
0.6862 
Ref. 
Age (Years, 5-yearly Increment) -0.79 0.18 -1.14 – -0.43 <.0001 -0.83 0.15 -1.12 – -0.54 <.0001 
CD4 Category 
CD4 Count <200 
CD4 Count 200 – 499 
CD4 Count >499 
 
-2.61 
-0.90 
Ref 
 
0.86 
0.34 
Ref 
 
-4.30 – -0.92 
-1.57 – -0.23  
Ref 
 
0.0025 
0.0085 
Ref. 
 
-2.62 
-0.90 
Ref 
 
0.86 
0.34 
Ref 
 
-4.31 – -0.93 
-1.57 – -0.23  
Ref 
 
0.0024 
0.0084 
Ref. 
Duration of HIV (Years) 0.03 0.06 -0.08 – 0.14 0.6268     
AIDS -3.36 0.83 -4.98 – -1.74 <.0001 -3.38 0.81 -4.98 – -1.78 <.0001 
Medical Comorbidity -3.83 0.80 -5.41 – -2.25 <.0001 -3.80 0.80 -5.38 – -2.23 <.0001 
Mental Comorbidity -3.19 0.49 -4.16 – -2.23 <.0001 -3.24 0.48 -4.19 – -2.29 <.0001 
Married -0.98 0.45 -1.87 – -0.09 0.0318 -0.99 0.45 -1.88 – -0.11 0.0277 
Rank 
Civilian/Retired 
Enlisted 
Officer 
 
-1.67 
-0.91 
Ref. 
 
1.07 
1.05 
Ref. 
 
-3.76 – 0.42 
-2.98 – 1.16 
Ref. 
 
0.1178 
0.3892 
Ref. 
    
Medical Comorbidity*Time 0.73 0.21 0.33 – 1.14 0.0004 0.72 0.21 0.32 – 1.13 0.0005 
Intercept 60.28 1.80 56.75 – 63.80 <.0001 59.72 1.33 57.12 – 62.32 <.0001 
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Table 3.3.b: Multivariate Predictors of Mental Component Summary Scores (MCSS) 
 
Variable 
MCSS Model Most Parsimonious MCSS Model 
β SE 95%CI P-Value β SE 95%CI P-Value 
CD4 Category 
CD4 Count <200 
CD4 Count 200 – 499 
CD4 Count >499 
 
-2.34 
-0.55 
Ref. 
 
0.87 
0.35 
Ref. 
 
-4.06 – -0.63 
-1.23 – 0.13 
Ref. 
 
0.0074 
0.1153 
Ref. 
 
-2.42 
-0.57 
Ref 
 
0.87 
0.35 
Ref 
 
-4.13 – -0.71 
-1.24 – 0.11  
Ref 
 
0.0056 
0.1014 
Ref. 
Plasma Viral Load >50copies/mL -0.63 0.34 -1.29 – 0.04 0.0648 -0.61 0.34 -1.28 – 0.05  0.0717 
Medical Comorbidity -0.32 0.54 -1.34 – 0.70 0.5402     
Mental Comorbidity -4.26 0.49 -5.22 – -3.30 <.0001 -4.38 0.48 -5.32 – -3.43 <.0001 
Race/Ethnicity 
Non-Hispanic African-America 
Others 
Non-Hispanic White 
 
2.54 
0.87 
Ref. 
 
0.57 
0.83 
Ref. 
 
1.41 – 3.66 
-0.76 – 2.51  
Ref. 
 
<.0001 
0.2952 
Ref. 
 
2.45 
0.89 
Ref. 
 
0.56 
0.82 
Ref. 
 
1.35 – 3.56 
-0.73 – 2.50  
Ref. 
 
<.0001 
0.2832 
Ref. 
Rank 
Civilian/Retired 
Enlisted 
Officer 
 
-1.25 
-0.69 
Ref. 
 
1.03 
1.04 
Ref. 
 
-3.28 – 0.77 
-2.73 – 1.35 
Ref. 
 
0.2237 
0.5034 
Ref. 
    
Intercept 49.25 0.99 47.30 – 51.20 <.0001 48.37 0.49 47.41 – 49.34 <.0001 
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3.7: Figures 
 
 
Fig. 3.1.a: Physical Component Summary Scores Over Four Years of Follow-Up 
 
 
Fig. 3.1.b: Physical Component Summary Scores Over Four Years of Follow-Up: PI/NPI 
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Fig. 3.1.c: Physical Component Summary Scores Over Four Years of Follow-Up: PI/Naïve  
 
 
Fig. 3.1.d: Physical Component Summary Scores Over Four Years of Follow-Up: PI/Off  
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Fig. 3.2.a: Mental Component Summary Scores Over Four Years of Follow-Up 
 
 
Fig. 3.2.b: Mental Component Summary Scores Over Four Years of Follow-Up: PI/NPI 
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Fig. 3.2.c: Mental Component Summary Scores Over Four Years of Follow-Up: PI/Naïve 
 
 
Fig. 3.2.d: Mental Component Summary Scores Over Four Years of Follow-Up: PI/Off 
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Fig. 3.3: Age of Participants by Treatment Groups Over Four Years of Follow-Up 
 
 
Fig. 3.4: CD4 Count (cells/mm3) by Treatment Group Over Four Years of Follow-Up 
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Fig. 3.5: Plasma Viral Load (log10) by Treatment Group Over Four Years of Follow-Up 
 
 
Fig. 3.6:  Duration of HIV (Years) by Treatment Group Over Four Years of Follow-Up 
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Fig. 3.7: CD4 Categories by Treatment Group Over Four Years of Follow-Up  
 
 
Fig. 3.8: Viral Load Categories by Treatment Group Over Four Years of Follow-Up 
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Fig. 3.9: AIDS-Defining Illnesses by Treatment Group Over Four Years of Follow-Up 
 
 
Fig. 3.10: Medical Comorbidity by Treatment Group Over Four Years of Follow-Up 
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Fig. 3.11: Mental Comorbidity by Treatment Group Over Four Years of Follow-Up 
 
 
Fig. 3.12: Marital Status by Treatment Group Over Four Years of Follow-Up 
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Fig. 3.13: Race/Ethnicity by Treatment Group Over Four Years of Follow-Up 
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Chapter 4 
Health-Related Quality of Life and Risk of Hospitalization among HIV-
infected Individuals  
Abstract 
Objective: To determine if HRQOL scores were predictive of all-cause hospitalization in the NHS cohort. 
Methods: The RAND Short Form 36 (SF-36) was administered between 2006 and 2010 among members of 
the NHS cohort, and matched with participants’ hospitalization records over the same time period. 
Physical component summary (PCSS) and mental component summary (MCSS) scores were computed 
based on standard algorithms. We also generated terciles of PCSS and MCSS with the upper terciles as 
referent groups. Three separate Cox proportional hazard regression models were used to estimate the 
hazard of hospitalization for PCSS terciles, MCSS terciles, and combined PCSS and MCSS terciles while 
controlling for same set of demographic and clinical characteristics.  
Results: 21% of participants were hospitalized over the period of follow-up. The median and interquartile 
ranges (IQR) for terciles of PCSS were 41.8 (35.9-46.1), 54.6 (52.8-55.9), and 58.8 (57.9-59.8) for the 
lower, middle and upper terciles respectively. The median and IQR for terciles of MCSS were 39.7 (32.0-
43.9), 50.7 (49.0-51.8), and 55.3 (54.0-57.3) for the lower, middle and upper terciles respectively. The 
hazards of hospitalization were 2.12 times (95% CI: 1.59-2.84), 1.59 times (95% CI: 1.19-2.14) higher for 
the lower and middle terciles of PCSS compared to the upper PCSS tercile. The hazards of hospitalization 
were 1.33 times (95% CI: 1.02-1.73), 1.20 times (95% CI: 0.91-1.57) higher for the lower and middle 
terciles of MCSS compared to the upper MCSS tercile. Other predictors of hospitalization we CD4 count < 
200 cells/mm3 (HR= 2.84, 95% CI: 1.96, 4.12), CD4 count 200-349 cells/mm3 (HR= 1.67, 95% CI: 1.24, 
2.26), CD4 count >499 cells/mm3 (HR= 1.41, 95% CI: 1.09, 1.83), viral load >50 copies/mL (HR= 1.82, 
95% CI: 1.46, 2.26), being civilian/retired (HR= 2.04, 95% CI: 1.25, 3.34), and HIV-duration (HR= 0.94, 
95% CI: 0.93, 0.96). Mental comorbidity and AIDS diagnosis were also significant predictors of 
hospitalization in the PCSS and MCSS models but not in the combined model.   
Conclusion: Our study shows that both PCSS and MCSS were good prognostic tools for estimating the 
hazard of all-cause hospitalization in an HIV-infected population after controlling for demographic and 
clinical characteristics.   
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Chapter 4 
Health-Related Quality of Life and Risk of Hospitalization among HIV-
infected Individuals  
 
4.1: Introduction and Background 
   Although health-related quality of life (HRQOL) is primarily used as a patient-centered 
outcome measure to assess the individual’s overall functional health status and for 
evaluating therapeutic interventions in human immunodeficiency virus (HIV) infection 
and acquired immune deficiency syndrome (AIDS)1,2, few studies have also utilized 
HRQOL as a prognostic tool for predicting survival in people living with HIV/AIDS 
(PLWHA)3-6. These studies have shown that HRQOL is useful as a risk stratification tool 
in HIV-infected individuals both in clinical trials and observational studies. But with the 
declining mortality in PLWHA7-9, the use of HRQOL measure as a prognostic tool for 
mortality in HIV-infected individuals may not be very appealing to clinicians given the 
prolonged survival of PLWHA. The classification of HIV/AIDS as a chronic disease in 
the era of highly active antiretroviral therapy (HAART) from the fatal disease it used to 
be in the 1980s and early 1990s may also explain why very few studies have used 
HRQOL measures to prognosticate mortality in HIV-infected individuals.  
   With prolonged survival among PLWHA, the lack of cure on currently available 
treatment, and the steady incidence of HIV in the United States9 it means the prevalence 
of the disease and, by extension, the burden of the disease on the healthcare system will 
continue to rise. In order to mitigate the increasing burden of the disease on the 
healthcare system, it is important that PLWHA are clinically stable and in optimal 
functional health, free from medical/mental comorbidities or opportunistic infections, and 
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have minimal hospitalizations. Poor HRQOL measures have been associated with higher 
utilization of healthcare resources in other chronic diseases10-12. Also, in HIV-infected 
individuals, HRQOL has been shown to be associated with hospitalization and 
emergency department utilization5. In our cohort, the rate of hospitalization has been 
previously reported to be as high as 34%13. Given the high rate of hospitalization among 
our cohort, it is important for clinicians to know the factors that may predict 
hospitalization, especially modifiable risk factors, in the hope that appropriate 
interventions can be instituted with the ultimate goal of reducing hospitalizations among 
cohort members.     
   Both the content and construct validity of the Short Form 36 (SF-36) have been 
demonstrated in HIV studies of HRQOL in different settings but to the best of our 
knowledge this instrument has not been used in predictive studies in HIV-infected 
populations; the medical outcome studies (MOS) for HIV (MOS-HIV) questionnaire was 
used in two of the four previously cited studies to predict mortality4,6. In these studies, the 
authors concluded that the HRQOL is a useful tool for predicting mortality in HIV-
infected individuals. The other HRQOL instruments that have been used to predict 
survival in HIV-infected populations are the HIV Cost and Services Utilization Study 
(HCSUS) HRQOL instrument3 and the EuroQol5. This latter instrument was also used to 
predict hospitalization and emergency department utilization5. Previous investigators 
have argued that HRQOL, especially the physical functional health, may be a better 
measure of the impact of the disease progression and treatment  on the individual than 
that captured by clinical and laboratory measures including HIV disease indicators such 
as CD4 count. In this research, we investigate the usefulness of the Research and 
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Development (RAND) SF-36 in predicting hospitalization in our cohort. Because 
HRQOL reflects an individual’s overall physical and mental functional health status, we 
hypothesize that participants with lower HRQOL are more likely to be hospitalized 
compared to participants with higher HRQOL over the period of follow-up. We believe 
that the ability to predict hospitalization with HRQOL will be important as a risk 
stratification tool in clinical practice. 
4.2: Methods 
4.2.1: Study Cohort 
The U.S. Military HIV Natural History Study (NHS) is a prospective multicenter 
continuous enrollment observational cohort of HIV-infected active duty military 
personnel and other beneficiaries (spouses, adult dependents, and retired military 
personnel) from the Army, Navy/Marines and Air Force enrolled since 198614-17.  
Participants are followed at five medical centers in the United States.  Demographic data 
are collected at baseline and updated while medical and medication histories and standard 
laboratory studies are collected biannually. Blood samples obtained from participants in 
this cohort from scheduled visits are stored in a repository.  Demographic information 
captured includes race/ethnicity (Caucasian, African American, Hispanic or Puerto Rican, 
Mexican, Asian, or Pacific Islander, Native American or Alaskan native, or other), age, 
gender, active duty, retired or dependent, and rank in military. Although not captured in 
the NHS database, injection drug use (IDU) has been reported to be very rare in this 
cohort15,18.  All NHS participants provided informed consent, and approval for this 
research was obtained from the institutional review board at each participating site. 
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4.2.2: Study Participants  
The RAND Short Form 36 (SF-36) questionnaires were administered annually to the 
NHS participants from April 2006 to September 2010. However, a few participants had 
more than one completed questionnaire in a year, and for these participants the last 
completed questionnaire for that year was used. Baseline was defined as the first ever 
HRQOL measure irrespective of when the participant was enrolled in the NHS. We used 
the CD4 count and viral load values closest in time to the HRQOL measure used.  
4.2.3: Definitions and Variable Selections 
4.2.3.1: Hospitalization and Time from Completed Survey to Hospitalization 
   Participants’ dates of hospitalization, diagnosis at hospitalization, and number of days 
of hospitalization were retrieved from their hospital records and through participants’ 
interviews. The principal or first-listed diagnosis was considered for purposes of this 
study. Hospitalization was the outcome variable of interest. Participants hospitalized from 
April 2006 to September 2010 were considered for inclusion in the analyses. In order to 
establish a temporal relationship, we ensured that date of completed questionnaire 
preceded the date of hospitalization. Hospitalization was coded as ‘yes’ if participant was 
ever hospitalized after the first completed SF-36 questionnaire and ‘no’ if participant was 
never hospitalization after the first completed  questionnaire for the duration of the study. 
We used the initial hospitalization after the baseline HRQOL measure for the purposes of 
this study. Therefore, if a participant was hospitalized prior to his or her baseline HRQOL 
measure, but was not hospitalized after being enrolled into the study, that participant was 
considered not to have been hospitalized; however, if the participant had another  
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hospitalization after being enrolled in the study, then the participant was considered 
hospitalized.  
4.2.3.2: Health-Related Quality of Life Scores 
   The norm-based the physical component summary scores (PCSS) and mental 
component summary scores (MCSS) were computed from the eight health domains in the 
SF-36 questionnaire in line with the recommended scoring algorithm for the RAND 36-
item health survey 1.019,20. The PCS and MCS scores were categorized into terciles with 
the upper tercile being the reference group. PCS and MCS scores were the main 
explanatory variables. We used the PCS and MCS scores immediately prior to 
hospitalization and if missing the ones before that.   
4.2.3.3: Covariates  
      HAART was defined as a combination of at least three full dose antiretroviral agents 
similar to previous investigations for this cohort15. HAART treatment was divided into 
four groups: protease inhibitor-based HAART (PI-HAART), for HAART with at least 
one protease inhibitor in the combined HAART regimen; non-protease-inhibitor-based 
HAART (NPI-HAART), for HAART with no protease inhibitor in the combined 
HAART regimen; HAART-naïve group (HAART-N) for those who had never been on 
HAART, and Off-HAART/Non-HAART ART group, made up of those who were either 
off treatment or on non-HAART anti-retroviral therapy. Other covariates considered were 
gender (male/female), age (in increment of 5 years), military rank (officer/warrant 
officer, enlisted and civilian/retired),  marital status (married, not married), race/ethnicity 
(non-Hispanic white, non-Hispanic African-American, and Others), plasma viral load 
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(≤50 copies/ml, >50 copies/ml), CD4+ count (<350 cells/mm3, 350 – 499 cells/mm3 and 
>499 cells/mm3), medical comorbidity, mental comorbidity, AIDS-defining illnesses, and 
HIV duration. AIDS definition was in line with the 1993 Centers for Disease Control and 
Prevention criteria, with the exception of an isolated CD4 cell count <200 cells/mL as 
CD4 was analyzed separately. Medical co-morbidity referred to chronic medical 
conditions, and was classified as having no comorbidity or having one or more 
comorbidity. Mental comorbidity was classified similarly.  
4.2.3.4: Time-Varying and Time-Invariant Covariates  
With the exception of gender and race, all other variables were treated as time-varying 
covariates. For the time-invariant covariates, gender and race/ethnicity, we used the 
values of these covariates at baseline. For the time-dependent covariates the values of 
these covariates prior to the date of hospitalization or censorship were used.  
4.2.3.5: Follow-up Time  
   Follow-up began at baseline, which was the time participants were enrolled in the 
HRQOL study as described in section 4.2.2. Time from baseline to hospitalization was 
calculated by subtracting the date of admission from the HRQOL date at baseline. Time 
from baseline to censoring was calculated similarly. The date of administrative censoring 
was fixed at September 30, 2010. 
4.2.3.6: Censoring  
   There were five HRQOL measures (PCS and MCS scores) over the period of follow-
up, and participants who completed the five annual HRQOL measures were censored at 
September 30, 2010, the date of administrative censorship. For participants who were lost 
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to follow-up, we censored them 6 months after the date of their last HRQOL measure. 
For example, if a participant completed only the baseline HRQOL measure, the duration 
of follow-up for this  participant was placed at 6 months. By the same token, participants 
who had HRQOL measures for the baseline and second year of follow-up but not 
subsequently, the duration of follow-up was defined as the difference between the second 
HRQOL date and baseline HRQOL date plus six months. Similarly, censored participants 
who had HRQOL measures for the first to third year of study but not after, the duration of 
follow-up was defined as the difference between the third HRQOL date and baseline 
HRQOL date plus six months, and so forth.  
4.2.4: Inclusion and Exclusion Criteria 
All participants aged 18 years and above who completed the HRQOL survey 
questionnaires between 2006 and 2010 were included. 19 participants who had one or 
more missing values for covariates were excluded from the Cox regression analyses.   
4.2.5: Statistical Analyses 
   We summarized the characteristics of the participants based on their frequency 
distribution for count variables and the median and interquartile ranges for numeric 
variables. We conducted further descriptive statistics using the Kaplan-Meier analysis for 
categorized variables, and used the Tukey-Kramer adjustment for between group 
differences for the independent variables and covariates with more than two categories. 
The Cox regression model21 was used to estimate the hazard of hospitalization for 
participants. Because separate multivariate models are traditionally used for PCSS and 
MCSS when these variables are the outcome variables in research settings, we also used 
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them separately as independent variables in two different models while controlling for the 
same set of covariates which were significantly predictive of hospitalization in the 
univariate Cox regression analyses. We also constructed a third model in which both 
PCSS and MCSS were included in the model. To be eligible for inclusion into the 
multivariate model, the covariate must achieve a significance level of <0.2 in the 
univariate Cox regression model. For categorical variables with more than two categories 
we used the significance level of the global null hypothesis. Accordingly, race/ethnicity, 
age, gender, marital status, and medical comorbidity did not make it into the final models. 
In line with the model specifications, we first checked for non-proportionality using a 
graphical approach22. Specifically, we plotted the minus-natural-log-minus-natural-log 
survival curves of the categorized variables and examined the plots to see if they were 
‘parallel’ over the follow-up period22,23. We then conducted formal diagnostics to test for 
violation of the proportional hazard assumption using both the Schoenfeld residuals22-24 
and covariate-time interaction term as recommended21,24. All statistical analyses and 
graphs were performed using SAS 9.3 [SAS Institute Inc., Cary, NC]. 
4.3: Results 
   Out of the 1730 participants eligible for the study there were 370 (21.50%) hospital 
admissions (table 4.1). 19 participants had one or more missing values for one or more 
covariates. Our cohort was predominantly male (93%), with about equal representation 
from non-Hispanic Whites and African American (42% each). About 17% of participants 
had a medical comorbidity while 29% had mental comorbidity; 12% had a diagnosis of 
AIDS either in the past or currently. Slightly over 5% of the cohort had CD4 count <200 
cells per mm3 and over 56% had CD4 count >499 cells/mm3. 35% of participants had 
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plasma viral load copies greater 50 copies/mL. The lower and upper terciles had 572 
participants each while the middle tercile had 573 participants. The median PCS score of 
the lower PCSS tercile was 41.75 (interquartile range [IQR] 35.88-46.12) compared to 
54.55 (IQR, 52.78-55.87) for the middle tercile and 58.81 (IQR, 57.86-59.75) for the 
upper tercile. The median MCS score of the lower MCSS tercile was 39.71 (IQR, 31.96-
43.87) compared to 50.69 (IQR, 49.02-51.82) for the middle tercile and 55.25 (IQR, 
54.04-57.29). The Kaplan-Meier product-limit survival estimates for the terciles showed 
that there were statistically significant differences between all terciles of PCSS and 
between the lower tercile and other two MCSS terciles but not between the upper and 
middle terciles of MCSS (figures 4.1 and 4.3). Both terciles of PCSS and MCSS satisfied 
the proportional hazard assumption based on Schoenfeld residuals (figures 4.2 and 4.4).  
   In the unadjusted Cox regression model (table 4.2), participants in the lower PCSS 
tercile were 2.52 times at increased hazard of being hospitalized compared to upper PCSS 
tercile, and this hazard of hospitalization remained significant at 2.12 for this group even 
after adjusting for covariates (95% confidence interval [CI] 1.59-2.84). Please see the 
combined PCSS and MCSS model in table 4.3.a. The hazard of hospitalization among 
participants in the middle tercile of PCSS was 1.74 times more than for participants in the 
upper tercile of PCSS in the unadjusted model (95% CI, 1.31-2.33) and in the adjusted 
model the hazard of hospitalization was still increased by over 59% (95% CI 1.19-2.14). 
In the unadjusted model, participants in the lower MCSS tercile were 79% at increased 
hazard of being hospitalized compared to those in the upper MCSS tercile but this hazard 
fell to 33% in the adjusted combined model (95% CI 1.02-1.73). The hazard of 
hospitalization among participants was not significantly different between the middle and 
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upper terciles of MCSS in both the unadjusted (HR: 1.27, 95% CI 0.97-1.67) and 
adjusted (HR: 1.20, 95% CI 0.91-1.57) models.   
   The hazards of hospitalization were independently increased in participants with CD4 
count <200 cells/mm3, 200-349 cell/mm3 and 350-499 cell/mm3 by 2.84, 1.65, and 1.38 
times respectively when compared to those with CD4 count >499 cells/mm3. Also, 
having plasma viral load greater than 50 copies/mL, and being retired/civilian were 
independently associated with an increased hazard of hospitalization. Although the 
presence of mental comorbidity was not independently associated with an increased 
hazard of hospitalization in the combined model, it remained predictive of hospitalization 
in the individual PCSS (HR: 1.31, 95% CI 1.04-1.63) and MCSS models (HR: 1.30, 95% 
CI 1.04-1.64). While prior AIDS diagnosis was independently predictive of 
hospitalization in the MCSS model, it was not predictive of not predictive in either the 
PCSS or combined models. Every one year increment in time from HIV diagnosis led to 
a 5.6% reduced hazard of hospitalization ( 95% CI 0.93-0.96). Compared to those on PI-
HAART, participants on NPI-HAART had a 30% significantly reduced hazard of 
hospitalization in the unadjusted model but was no longer significant in the multivariate 
model. In the univariate model, being in the HAART-naïve or Off-HAART/Non-HAART 
ART groups were associated with increased hazard of hospitalization by 1.80 and 1.75 
times respectively but these were no longer significant in the adjusted models.    
4.4: Discussion 
   Our study shows that both physical and mental functional health status were 
independently predictive of the risk of hospitalization among HIV-infected individuals in 
our cohort even after adjusting for HIV disease markers, AIDS diagnosis and duration of 
119 
 
 
HIV infection. This novel finding supports both the discriminatory and predictive validity 
of the SF-36 with possible practical implications in both research and clinical settings. 
Some authors have argued that PCSS is both an inclusive and robust measure of health 
relevant to the individual’s well-being that may not be captured by common clinical and 
laboratory indicators3,4. Our findings support this claim. Furthermore, our study also 
shows that MCSS is also a useful predictive tool especially when the MCS score is low as 
was the case with the lower tercile of the cohort. The ability of MCSS to discriminatorily 
predict hospitalization was, however, much less compared to the PCSS in our study as 
evidenced by the magnitude of the parameter estimates, the clear dose-response 
relationship with PCSS and the comparable differences in tercile values for PCSS and 
MCSS.  
    It is instructive to note that while mental comorbidity was independently predictive of 
hospitalization in the individual PCSS and MCSS models, it was no longer predictive in 
the combined PCSS and MCSS model while MCS score remained predictive of 
hospitalization in the combined model, clearly showing that between MCS score and 
mental comorbidity MCS score was a better predictor of hospitalization. While this 
finding may not counter the view that that mental and psychiatric comorbidity primarily 
determines mental functional health25-27, something that is also supported by our research 
in this cohort (please see chapter 2), it is evident that beyond mental/psychiatric 
comorbidity, other factors not ordinarily captured clinically may also play a significant 
role in the mental functioning of the individual, similar to the argument put forward for 
physical functional health3,4.      
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   Our study also showed that CD4 count <200 cells/mm3, CD4 count 200 – 349 
cells/mm3, and CD4 count 350 – 499 cells/mm3 were respectively associated with 
increased hazard of hospitalization by 184%, 65% and 38% when compared to CD4 
count >499 cells/mm3. Somewhat similar to our findings, Crum-Ciaflone et al13, in an 
earlier work on this cohort, had found that CD4 count >499 cells/mm3 reduced the risk of 
hospitalization when compared to CD4 <350 cells/mm3 but they did not find any 
difference in the risk of hospitalization between CD4 count >499 cells/mm3 and CD4 
count  350-499 cells/mm3. Other investigators have also shown that lower CD4 counts is 
associated with hospitalization, especially when CD4 count falls below 20028-33. Viral 
load greater than 50 copies per ml was also associated with hospitalization in our cohort. 
Although the levels of dichotomization differed, Fielden et al33 also found that higher 
plasma viral load is associated with hospitalization while Mocroft et al28 demonstrated 
that in the last of three time points in their study, there was an increased odds of 
hospitalization for every log unit increase in plasma viral load. Although others had 
found AIDS diagnosis to be predictive of hospitalization28,33,34, we found this to be true 
for only our MCSS model but not in the PCSS or combined models. This shows that in 
our cohort, after account for physical functional health, prior AIDS diagnosis was no 
longer predictive of hospitalization. 
    Interestingly, longer HIV duration was predictive of a reduced hazard of 
hospitalization in our cohort. One plausible explanation for this finding may be that 
individuals with longer disease duration may be more experienced with dealing with 
symptoms (including subtle ones) associated with their infection, and are more likely to 
seek medical attention early enough before admission is warranted. In the unadjusted 
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models, those on non-PI based HAART appeared to have a reduced hazard of 
hospitalization while HAART-naïve and the Off-HAART/Non-HAART ART 
participants were at increased hazard of hospitalization when compared to those on PI-
HAART but these differences were not sustained in the multivariate models. Also, 
because the Off-HAART/Non-HAART ART group is quite a broad group, we conducted 
sensitivity analyses in which we excluded non-HAART ART and our results remained 
essentially the same. The finding that being civilian/retired was associated with over 
100% increased hazard of hospitalization in our cohort is not entirely surprising because 
to remain in active duty one has to be physically fit, and some medical or psychiatric 
conditions may have contributed to these participants being retired. 
    One major limitation of our study will be its generalizability within and outside HIV-
infected populations. Within HIV-infected populations, the male predominance may limit 
its generalizability but many HIV studies/cohorts in the United States are predominantly 
male, and so our findings should apply to similar HIV populations. While HRQOL 
measure may still be a useful tool for predicting hospitalization in non-HIV-infected 
populations, our findings may not necessarily be generalizable to them because the 
factors determining HRQOL differ between HIV-infected and non-HIV-infected 
populations. Finally, it is possible that some hospital admissions outside the military 
settings may not have been captured but we believe that the number of non-Military 
hospital admissions that were not captured will be small as we frequently conducted 
interviews to capture such admissions.  
   Our study adds to the nascent literature on the prognostic value of HRQOL, particularly 
SF-36, as a predictive tool in HIV-infected individuals. To the best of our knowledge, 
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only one study has looked at the association between HRQOL and hospitalization in 
HIV-infected individuals, and this study utilized the EuroQol and VAS to assess 
HRQOL. That findings were similar using different measures of QOL reinforces the 
validity of HRQOL as a predictor of hospitalization. Important strengths of our study 
include its large sample size and the heterogeneity of the cohort with regards to HIV 
disease indicators and other clinical parameters, such as medical and mental 
comorbidities. The well-established temporal sequence was another major advantage of 
this study. In sensitivity analyses, we excluded those who were admitted within 7 days of 
completing their HRQOL questionnaire, and our results were unchanged. Like the 
disease specific MOS-HIV, our study also showed that the generic SF-36 is a very 
important predictive tool in HIV-infected population, which should support its use in 
clinical and research settings. Furthermore, the predictive validity of the MOS-HIV in 
survival studies in HIV-populations was limited to the physical functional health in 
previous studies4,6, unlike ours in which mental functional health remained independently 
predictive of hospitalization even after controlling for physical functional health.    
   Although PCS and MCS scores predicted hospitalization in our study this does not 
imply causation, and the exact mechanism may deserve further elucidation and research. 
Yet, as others have noted, self-reported functional health status may capture a very broad 
range of obvious and subtle symptoms and signs that may be more indicative of disease 
progression beyond what may be clinically obvious. More so, the causes of 
hospitalization were very diversified, something previously noted in our cohort by other 
researchers13. One advantage HRQOL measures may have over HIV-disease indicators is 
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that HRQOL is also reflective of perceptions that may affect subsequent health-seeking 
behaviors and utilization of healthcare resources including preventive services4,35.  
   Summary scores of the SF-36 are also known to change with treatment and other 
important clinical parameters, and some have suggested that score change of 5 may be 
clinically and socially relevant36. As a predictive tool for survival, one group of 
investigators showed that every unit increase in PCS resulted in a 4% increased chances 
of survival in a predominantly white male HIV-infected population6 while another group 
of investigators showed that every 5 unit increment in PCS led to a 2% reduced hazard of 
death in a Dutch HIV cohort4. When we conducted our analyses using PCS and MCS 
scores as continuous variables in our models, we found that every unit increase in PCS  
and MCS scores respectively reduced the hazard of hospitalization by 12% and 6% in the 
combined model (table 4.3.b). So, for our cohort with wide ranges of PCS (16.66 to 
70.67) and MCS (8.56 to 67.60) scores, the SF-36 questionnaire is a very useful tool for 
predicting hospitalization.  
   The lifetime cost of HAART treatment continues to rise37 and this cost is greatly 
increased by hospitalizations33,37,38. The ability to predict hospital admissions beyond 
HIV disease indicators will be useful to clinicians treating HIV-infected individuals. The 
simultaneous prediction of hospitalization by HRQOL measures, HIV disease indicators 
and AIDS diagnosis further supports the concurrent validity of the SF-3639, an instrument 
that is self-administered and takes about 10 minutes to complete40. Furthermore, the 
median follow-up time for the non-hospitalized participants was 3.13 years (IQR, 1.53-
972) compared to the median follow-up time for hospitalized participants of 1.23 years 
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(IQR, 0.53-2.38) (table 4.1), which means that a yearly survey or even one survey every 
other year may suffice for this purpose.  
4.5: Conclusion 
   In summary we found several interesting and important findings. This study shows that 
both physical and mental function health are good prognostic tools for estimating the 
hazard of hospitalization in an HIV-infected population even after controlling for HIV 
disease indicators, and HIV duration. Also, our study supports the content, construct, and 
criterion-related (predictive and concurrent) validity of the SF-36. Considering the high 
cost of hospitalization in the United States, measures should be instituted to address the 
modifiable risk factors that may be associated with lower health related quality of life in 
HIV-infected individuals.   
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4.6: Tables 
 
Table 4.1: Characteristics of Participants 
 
Characteristics N (%) 
Hospitalized 
Yes 
No 
 
372 (21.50) 
1358 (78.50) 
Gender 
Male 
Female 
 
1610 (93.06) 
120 (6.94) 
Race 
Non-Hispanic White 
Non-Hispanic African  
Hispanic/Others 
 
723 (41.79) 
736 (42.54) 
271 (15.66) 
Rank 
Officer/Warrant Officer 
Enlisted 
Others (Retired/Civilians) 
Missing 
 
126 (7.28) 
900 (52.02) 
702 (40.58) 
2 (0.12) 
Marriage, Yes 564 (32.60) 
Medical Comorbidity, Yes 291 (16.82) 
Mental Comorbidity, Yes 501 (28.96) 
AIDS, Yes 207 (11.97 
HAART 
PI-Based 
Non-PI-Based 
HAART-Naïve 
Off-HAART 
Non-HAART ART 
 
471 (33.64) 
766 (44.28) 
243 (14.05) 
121 (6.99) 
18 (1.04) 
 Viral Load >50 copies/mL 
Yes 
No 
Missing 
 
606 (35.03) 
1120 (63.67) 
4 (0.23) 
CD4 Count Groups 
<200 cells/mm3  
200-349 cells/mm3 
350-499 cells/mm3 
>499 cells/mm3 
Missing 
 
94 (5.43) 
246 (14.22) 
412 (23.82) 
975 (56.36) 
3 (0.17) 
Age (years) – Median  (IQR) 42.00 (34.00 – 49.00) 
CD4 Count (x 106/L) – Median  (IQR) 538.00 (389.00 – 721.00) 
Viral Load (Log10) – Median  (IQR) 1.70 (1.68 – 2.28) 
Time from HIV Diagnosis (years) – Median (IQR) 10.00 (4.00 – 17.08) 
Duration of Follow-Up (Years, Overall) – Median (IQR) 
Hospitalized – Median (IQR) 
Not Hospitalized – Median (IQR) 
2.72 (1.04 – 3.81) 
1.23 (0.53 – 2.38) 
3.13 (1.53 – 3.97) 
Physical Component Summary Scores (PCSS) 
Lower Tercile –  Median  (IQR) 
Middle Tercile – Median  (IQR) 
Upper Tercile – Median  (IQR) 
 
41.75 (35.88-46.12) 
54.55 (52.78-55.87) 
58.81 (57.86-59.75) 
Mental Component Summary Scores (MCSS) 
Lower Tercile – Median  (IQR) 
Middle Tercile –  Median  (IQR) 
Upper Tercile – Median (IQR) 
 
39.71 (31.96-43.87) 
50.69 (49.02-51.82) 
55.25 (54.04-57.29) 
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Table 4.2: Univariate Cox Regression Model for Hazard of Hospitalization 
 
 
 
Variable Hazard 
Ratio 
95% CI P-Value 
Physical Component Summary Score (PCSS) 
Lower Tercile of PCSS 
Middle Tercile of PCSS 
Upper Tercile of PCSS 
 
2.52 
1.74 
1.0 
 
1.92 – 3.32 
1.31 – 2.33 
- 
 
<.0001 
0.0002 
- 
Mental Component Summary Score (MCSS) 
Lower Tercile of MCSS 
Middle Tercile of MCSS 
Upper Tercile of MCSS 
 
1.79 
1.27 
1.0 
 
1.39 – 2.30 
0.97 – 1.67 
- 
 
<.0001 
0.0783 
- 
Age (Years, Increment of 5 Years) 0.98 0.94 – 1.03 0.4971 
Gender (Male) 1.06 0.70 – 1.62 0.7877 
Marital Status (Married) 1.13 0.91 – 1.40 0.2586 
Race/Ethnicity 
Non-Hispanic African American 
Hispanic/Others 
Non-Hispanic Caucasian 
 
0.96 
0.86 
1.0 
 
0.77 – 1.19 
0.63 – 1.18 
- 
 
 0.7077 
 0.3495 
- 
Rank 
Civilian/Retired 
Enlisted 
Officers 
 
1.47 
1.22 
1.0 
 
0.93 – 2.35 
0.77 – 1.95 
- 
 
0.0962 
0.3922 
- 
CD4 Count  
CD4 Count <200 cells/mm3 
CD4 Count 200-349 cells/mm3 
CD4 Count 350-499 cells/mm3 
CD4 Count >499 cells/mm3 
 
3.89 
2.16 
1.55 
1.0 
 
2.78 – 5.44 
1.63 – 2.86 
1.20 – 2.00 
- 
 
<.0001 
<.0001 
0.0008 
- 
Viral Load >50 Copies/mL 2.36 1.92 – 2.89 <.0001 
Medical Comorbidity 1.05 0.81 – 1.36 0.7130 
Mental Comorbidity 1.43 1.16 – 1.76 0.0009 
AIDS 1.67 1.27 – 2.18 0.0002 
HIV Duration (Years) 0.98 0.96 – 0.99 0.0018 
HAART Treatment 
Non-PI Based HAART 
HAART-Naïve 
Off-HAART/Non-HAART ART 
PI Based HAART 
 
0.70 
1.80 
1.75 
1.0 
 
0.55 – 0.87 
1.33 – 2.43 
1.26 – 2.44 
- 
 
0.0033 
0.0002 
0.0008 
- 
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Table 4.3.a: Multivariate Cox Regression Model for Hazard of Hospitalization for Terciles of PCSS and MCSS  
Variable PCSS Model MCSS Model Combined PCSS and MCSS Model 
HR 95% CI P-Value HR 95% CI P-Value HR 95% CI P-Value 
PCSS 
Lower Tercile  
Middle Tercile 
Upper Tercile  
 
2.18 
1.62 
1.0 
 
1.64 – 2.90 
1.21 – 2.17 
- 
 
<.0001 
0.0013 
- 
    
2.12 
1.59 
1.0 
 
1.59 – 2.84 
1.19 – 2.14 
- 
 
<.0001 
0.0018 
- 
MCSS 
Lower Tercile 
Middle Tercile  
Upper Tercile 
    
1.44 
1.14 
1.0 
 
1.10 – 1.87 
0.87 – 1.49 
- 
 
0.0077 
0.3576 
- 
 
1.33 
1.20 
1.0 
 
1.02 – 1.73 
0.91 – 1.57 
- 
 
0.0374 
0.2010 
- 
CD4 Count  
<200 cells/mm3 
200-349 cells/mm3 
350-499 cells/mm3 
>499 cells/mm3 
 
2.84 
1.69 
1.41 
1.0 
 
1.96 – 4.12 
1.25 – 2.27 
1.09 – 1.82 
 - 
 
<.0001 
0.0006 
0.0099 
- 
 
2.99 
1.67  
1.37 
1.0 
 
2.06 – 4.33 
1.24 – 2.25 
1.05 – 1.77 
- 
 
<.0001 
0.0007 
0.0184 
- 
 
2.84 
1.67 
1.41 
1.0 
 
1.96 – 4.12 
1.24 – 2.26 
1.09 – 1.83 
- 
 
<.0001 
0.0007 
0.0094 
- 
Viral Load >50 Copies/mL 1.83 1.47 – 2.28 <.0001 1.88 1.51 – 2.34 <.0001 1.82 1.46 – 2.26 <.0001 
Mental Comorbidity 1.31 1.04 – 1.63 0.0195 1.30 1.04 – 1.64 0.0237 1.23 0.98 – 1.55 0.0741 
AIDS 1.35 1.00 – 1.83 0.0512 1.47 1.09 – 1.99 0.0129 1.34 0.99 – 1.81 0.0608 
Rank 
Civilian/Retired 
Enlisted 
Officer 
 
2.06 
1.18 
1.0 
 
1.26 – 3.37 
0.74 – 1.88 
- 
 
0.0038 
0.4864 
- 
 
2.16 
1.17 
1.0 
 
1.32 – 3.52 
0.73 – 1.86 
- 
 
0.0022 
0.5145 
- 
 
2.04 
1.19 
- 
 
1.25 – 3.34 
0.74 – 1.89 
- 
 
0.0044 
0.4755 
- 
HIV Duration (Years) 0.94 0.92 – 0.96 <.0001 0.94 0.93 – 0.96 <.0001 0.94 0.93 – 0.96 <.0001 
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Table 4.3.b: Multivariate Cox Regression Model for Hazard of Hospitalization (PCSS and MCSS Continuous)  
Variable PCSS Model MCSS Model Combined PCSS and MCSS 
Model 
HR 95% CI P-Value HR 95% CI P-Value HR 95% CI P-Value 
PCSS, 5 Unit Increments 0.87 0.83 – 0.92 <.0001    0.88 0.84 – 0.93 <.0001 
MCSS, 5 Unit Increments    0.91 0.87 – 0.96 0.0007 0.94 0.89 – 0.99 0.0169 
CD4 Count  
<200 cells/mm3 
200-349 cells/mm3 
350-499 cells/mm3 
>499 cells/mm3 
 
2.76 
1.66 
1.38 
1.0 
 
1.90 – 4.01 
1.23 – 2.23 
1.07 – 1.80 
 - 
 
<.0001 
0.0009 
0.0133 
- 
 
2.96 
1.67 
 1.37 
1.0 
 
2.04 – 4.29 
1.24 – 2.25 
1.05 – 1.77 
- 
 
<.0001 
0.0007 
0.0188 
- 
 
2.73 
1.65 
1.38 
1.0 
 
1.88 – 3.97 
1.22 – 2.23 
1.07 – 1.79 
- 
 
<.0001 
0.0010 
0.0139 
- 
Viral Load >50 Copies/mL 1.86 1.49 – 2.32 <.0001 1.89 1.52 – 2.36 <.0001 1.86 1.49 – 2.31 <.0001 
Mental Comorbidity 1.31 1.05 – 1.64 0.0185 1.28 1.02 – 1.61 0.0360 1.23 0.97 – 1.54 0.0867 
AIDS 1.34 0.99 – 1.82 0.0624 1.48 1.09 – 2.00 0.0120 1.34 0.99 – 1.82 0.0596 
Rank 
Civilian/Retired 
Enlisted 
Officer 
 
2.21 
1.28 
1.0 
 
1.35 – 3.61 
0.80 – 2.04 
- 
 
0.0016 
0.3087 
- 
 
2.14 
1.16 
1.0 
 
1.31 – 3.49 
0.73 – 1.85 
- 
 
0.0024 
0.5240 
- 
 
2.15 
1.27 
- 
 
1.32 – 3.52 
0.79 – 2.02 
- 
 
0.0023 
0.3244 
- 
HIV Duration (Years) 0.94 0.92 – 0.96 <.0001 0.95 0.93 – 0.96 <.0001 0.94 0.93 – 0.96 <.0001 
 
 
 
 
 
4.7: Figures 
 
 
Fig. 4.1: Kaplan-Meier Survival Curve for Physical Component Summary Score (PCSS) 
 
 
Fig. 4.2: Minus-Log-Minus-Log Survival Curve for Physical Component Summary Score (PCSS) 
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Fig. 4.3: Kaplan-Meier Survival Curve for Mental Component Summary Score (MCSS) 
 
 
Fig. 4.4: Minus-Log-Minus-Log Survival Curve for Mental Component Summary Score (MCSS) 
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Chapter 5 
Conclusions and Recommendations 
5.1: Conclusions  
  With the introduction of highly active anti-retroviral therapy (HAART), infection with 
human immunodeficiency virus (HIV) has evolved from being a progressive fatal illness 
to a manageable chronic disease. However, the improved control of HIV with HAART is 
associated with adverse drug effects. Also, as people living with HIV (PLWH) grow 
older they are faced with greater burden of age-associated diseases, such as diabetes, 
cardiovascular and renal diseases all of which may affect the quality of life of PLWH. 
Health-related quality of life (HRQOL) is a patient-centered outcome measure that has 
the potential to improve care by assessing and monitoring treatment effects, enhancing 
communication between patient and provider, and tracking changes in functional status 
over time1. Furthermore, HRQOL provides valuable information to policy makers and 
administrators on the efficiency, effectiveness and cost-benefit ratios of healthcare 
programs2,3. The pharmaceutical industry and regulatory agencies also rely on HRQOL to 
evaluate the effectiveness and treatment benefit of new drugs2-5.  
   The importance of HRQOL in HIV is underscored by its relationship to biologic 
markers of HIV disease progression6-9, disease burden10, survival11-14, and health care 
utilization13,15,16. It is not surprising therefore that research on HRQOL has dramatically 
increased over the last 3 to 4 decades17, and particularly so for HRQOL in the HIV-
infected population for the past 2 decades18. Yet, comparison of HRQOL studies is 
difficult because of varying instruments used, period under study (pre-HAART versus 
HAART era), HRQOL dimensions studied (health domain scores vs. summary scores vs. 
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overall HRQOL), whether or not the instrument is disease specific or generic, the 
research setting (clinical trial vs. non-clinical trial) and the population studied (men, 
women, high or low income countries). Often, the research questions addressed by 
different investigators make it impossible to provide an overview and assess the status of 
HRQOL research in HIV18. Of the 825 articles Drewes et al selected in their descriptive 
study of HRQOL in HIV-infected persons they found 122 of these to be instrument 
studies, 265 interventional studies and the remaining 465 correlational studies18. 
However, Gakhar et al included only 26 studies in their 2003 review of articles on 
HRQOL, HIV and anti-retroviral therapy (ART). Degroote et al reviewing journal 
articles published in high-income countries prior to July 2013 included 49 studies3. To be 
included in their review, the study should have included either the overall HRQOL 
measure or the two summary measures (physical/mental health summary scores)3. Cohort 
studies on HRQOL are even fewer. For example, Jin et al in a systematic review of 
cohort studies on HRQOL in HIV-infected patients on anti-retroviral therapy included 
only 8 studies published prior to December 2012 out of 1,675 potentially relevant 
citations19. To be included in this study, four criteria had to be met, viz: (i) be a cohort 
study; (ii) the patients initiated combination anti-retroviral therapy at baseline; (iii) 
presented QOL data at baseline; and (iv) follow-up for more than 12 weeks. 
   In the light of the aforementioned, our work comes as a useful addition to HRQOL 
studies in HIV-infected individuals in the HAART era. We have not only corroborated 
current knowledge but have extended it. Furthermore, our work clearly shows the need to 
have an expanded explanatory model on the relationship between HRQOL, HIV and 
HAART especially on the long term. Before we delve further into conceptual models on 
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HIV, HAART and HRQOL, we will highlight some pertinent findings in our studies and 
use those as reference points in our discussion as we find suitable.   
   We found that the physical functional health of our cohort was slightly better than that 
of the United States’ general population while the mental functional health of our cohort 
was slightly worse than that of the US general population. Both our cohort’s physical and 
mental functional health were worse than that of the United States Military Millennium 
Cohort but the difference mental functional health was much wider (>5 points). Our study 
further confirmed the SF-36 as a reliable instrument for measuring the eight domain 
scores as evident by the high Cronbach’s alpha (see chapter 1). Important factors that 
were negatively associated with physical HRQOL at baseline were CD4 count <200 
cells/mm3, medical and mental comorbidities, increasing age, and AIDS. Other factors 
that were negatively associated with physical functional health were being enlisted or 
civilians/retired, and being married. Factors that were negatively associated with mental 
functional health were CD4 count <200 cells/mm3 and mental comorbidity while being 
African American and increasing age were positively associated with mental functional 
health.  
   In our longitudinal study, we found that being on a non-protease inhibitor HAART 
(NPI-HAART) did not provide any treatment benefit over being on a protease inhibitor 
HAART (PI-HAART). Although participants who were HAART naïve or Off-HAART 
could freely move into either the NPI-HAART or PI-HAART groups based on their 
disease progression, we did not find being on PI-HAART to have treatment benefit over 
being HAART-naïve or Off-HAART. Furthermore, we found that being on any HAART 
group (PI-HAART, NPI-HAART, HAART-Naïve, and Off-HAART) did not result in 
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significant HRQOL changes over the period of follow-up in our multivariate models. 
However, being HAART-Naïve or on NPI-HAART were positively predictive of 
physical functional health. We believe this group differences may be due to residual 
confounding, the lack of randomization or confounding by indication20. The other factors 
independently predictive of physical functional health were all negative predictors and 
they include CD4 count of <200 cells/mm3, CD4 count 200-499 cells/mm3, medical and 
mental comorbidities, AIDS diagnosis, increasing age and being married. Over the period 
of follow-up, having a medical comorbidity led to improvement in physical functional 
health. Factors independently predictive of mental functional health were CD4 count 
<200 cells/mm3 or mental comorbidity while being African American was positively 
predictive of mental functional health. There were no differences in mental functional 
health by HAART groups. 
   As a predictive tool we also found that both physical (PCS) and mental (MCS) 
component summary scores were predictive of hospitalization in our cohort even after 
adjusting for demographic and HIV-disease indicators with a clear dose-response 
relationship for PCS groups. Similar to PCS groups, there was a dose-response 
relationship between CD4 count and the hazard of hospitalization, with CD4 count <200 
cells/mm3 being most predictive of this risk. Other factors in our model that were 
predictive of hospitalization were plasma viral load (>50 copies/mL), AIDS diagnosis, 
and mental comorbidity. Duration of HIV infection was associated with reduced hazard 
of hospitalization. It was interesting to note that while pVL was predictive of 
hospitalization it was neither independently associated with HRQOL in the baseline study 
nor predictive of HRQOL in the longitudinal study. While the study by Call et al7 found 
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pVL to be independently associated with PCS, it is difficult to compare that study with 
ours because of the difference in categorizing pVL. For example, the lowest pVL 
category in their study was ≤5,000 copies/mL compared to ours of <50 copies/mL. 
Another study that clearly showed a relationship between pVL and HRQOL was that by 
Gill et al6 but this study, beyond the difference in categorization of pVL, did not provide 
summary scores making comparison difficult. While the work by Preau et al used 
summary scores, their pVL cut-point was ≤400 copies/mL9. This difficulty in comparing 
plasma viral load in HRQOL/HIV research cuts across the literature as technological 
advancement led to fever viral copies being detected per mL of plasma. We avoided the 
use of the term ‘detectable’ for even within our cohort that term had applied to varying 
cut points over the years (<400copies/mL, <50 copies/mL and 48 copies/mL). That being 
said, and as we noted earlier in chapter 2, several studies in the late HAART era did not 
find an association between pVL and HRQOL2,21-24. 
   The relationship between CD4 count and physical functional health is better established 
both in cross-sectional and longitudinal studies7,9,10,21,23,25-27. Yet, as others have noted the 
impact of ART on CD4 count is more evident in those with CD4 count <200 cells per 
cubic millimeter28. In our cohort we did not find differences between CD4 count 200-499 
cells/mm3 and CD4 count >499 cells/mm3 at baseline but found the CD4 count 200-499 
cells/mm3 group had a slightly lower PCS scores over the period of follow-up similar to 
the findings by others21. Current recommendations on HAART initiation by the 
Department of Health and Human Services (DHHS) is for all HIV-infected individuals to 
start HAART irrespective of the level of CD4 count although the strength of the 
recommendation varies by CD4 groups29. While the recommendation for HAART 
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initiation for those with CD4 count >499 cells/mm3 is based on expert opinion, the 
recommendation for HAART initiation in the those with CD4 count 350-500 cells/mm3 is 
based on evidence from observational studies29. On the other hand, the World Health 
Organization30 recommends starting ART at CD4 count <500 cells/mm3. Unfortunately, 
these recommendations for HAART initiation were anchored solely on evidence that 
early ART initiation delayed progression to AIDS and reduced mortality29,30 without 
taking into consideration the impact of HAART on HRQOL31, which may actually affect 
HAART use on the long term. Burgoyne and Tran in their review of HRQOL in HIV-
infected individuals in the HAART era cautioned on the need to balance prolonging life 
with the quality of life of the infected individual31. Perhaps the Strategic Timing of Anti-
Retroviral Treatment (START) trial, which recently published its baseline HRQOL 
findings, may help determine the optimum time to initiate HAART in the antiretroviral-
naïve HIV-infected persons32. The relationship between CD4 count and mental functional 
health is less defined with many studies finding no association while a few, like ours, 
found lower CD4 count to be associated with mental functional health9,26,33.  
   A fundamental question that begs for answer in HRQOL research is: what is the clinical 
implication of HRQOL scores? When should the clinician pay particular attention to a 
patient based on his HRQOL scores? To answer this question some researchers have used 
the recommended using change in effect size34-36 in describing changes in HRQOL scores 
in their longitudinal studies37. One approach in calculating effect size is to divide the 
differences in mean of the of the HRQOL scores at the different time points by pooled 
standard deviation of the means37. Others suggest using the baseline standard deviation 
instead36. Cohen suggested the use certain thresholds to determine the clinically 
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important differences with 0.2, 0.5 and 0.7 considered small (SCID), moderate (MCID), 
and large (SCID) clinically important differences (CID)34. Apart from the paucity of 
literature on the subject, its application in HRQOL research is limited36. In our current 
work for example, while covariates (with the exception of medical comorbidity) did not 
result in changes in HRQOL measures over time they still remained significant long-term 
predictors of the individual’s perceived health. We will therefore take a look at another 
approach used by other investigators6,10.  
   In their work, Gill et al6 calibrated effect sizes by substituting known clinical conditions 
(acute diarrhea and clinical depression) for estimating effect sizes of these conditions on 
the HRQOL domain score. We note here that the use of the term ‘effect size’ is different 
from how Cohen used it, and refers to the magnitude of the beta coefficient (β) in the 
regression model in line with the use of the term by Ellis in his book, Essential Guide to 
Effect Sizes38. Substituting acute diarrhea and clinical depression in their multivariate 
models led to a score difference in physical functioning (PF) score by -4.6 (p = .03) and -
6.5 (p = .003) respectively. On the other hand, the score differences in PF for CD4 count 
<200 cells/mm3, pVL (log10), and HAART use were respectively -8.8, -7.7, and -5.4
6. For 
their participants, having a CD4 count <200 cells/mm3 was worse than having clinical 
depression or being on HAART was worse than having acute diarrhea! Similar arguments 
were put forward by Lorenz et al10. Hopman et al have suggested that HRQOL domain 
scores of 5 and above or summary scores (PCS and MCS) of 2 to 3 may be clinically and 
socially relevant39. This suggestion is in fact corroborated in our multivariate analyses 
(chapters 2 and 3). It may also be important to consider the baseline score for the cohort 
as reflected by the intercept for the model since a difference in score of 3 from 42 to 39 
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may be more useful clinically than a difference in score of 5 from 63 to 58. While score 
differences of 2 - 3 and above from covariates that are modifiable risk factors may 
warrant intervention, attention should also be placed on non-modifiable risk factors with 
summary score differences in that range as they may constitute a special risk group. In 
our baseline study for example, being civilian/retired was associated with a 3.3 point 
decrement in perceived physical health making them a possible risk group. In chapter 4, 
we see that being civilian/retired increased the hazard of hospitalization by over 100% 
even after adjusting for the other covariates including PCS and MCS.  
   But beyond the clinician, policy makers and administrators may also be interested in 
risk stratification in order to identify areas for possible intervention, and the cost-benefit 
analyses of which intervention to choose based on limited budget. Information sort by the 
health care administrator or a policy maker may not be very different from that sort by 
the clinician although the goal for such an inquiry may be different. Let us assume that a 
retired military personnel (PCS score = -2.5) with post-traumatic disorder (PCS score =  
-3.5) also has problems with housing but after seeing his PCP he is placed on therapy, 
referred to a psychiatrist, and his housing issues are resolved through the help of 
administrators. Suppose also that based on these measures his PCS score improves by 3, 
then we may have reduced his chances of hospitalization by 7.2% (please see chapter 4, 
table 4.3.b). If a 7.2% reduction in hospitalization across board leads to lessening of the 
clinicians workload with better quality services then this will be considered clinically 
significant40. From the economic point of view, if providing ancillary services to retired 
military personnel on the one hand leads to a significant reduction in hospitalization 
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resulting in a net budgetary gain, then the administrator and policy makers should have 
benefitted from the investment.  
   HRQOL measures should be seen as a predictor and not a cause of hospitalization. 
Attempts to provide explanatory models should be directed at fully understanding the 
factors contributing to HRQOL including those not well established. The conceptual 
model put forward by Wilson and Cleary was an important effort in that direction41. 
These authors expounded a conceptual model linking clinical variables to HRQOL. The 
model basically traces the cause to the biologic or physiologic process that results in a 
symptom status which could in turn affect functional status. Functional status then results 
in certain general health perceptions that affect the HRQOL of the individual. They also 
conceptualized the interplay between environmental factors and the individual’s 
characteristics on the one hand and the clinical variables and HRQOL variables on the 
other (please see figure 5.1). The conceptual model expounded by Vidrine et al42 is also 
appealing as it takes into account the role latent variables may play in HRQOL. Variables 
that are more likely to be affected by concerns on social desirability, such as alcohol use 
and smoking, may be better analyzed using structural equation modeling42. More recently 
the link between inflammatory markers and HRQOL seem to gaining attention in certain 
quarters, especially with psychiatric conditions such as depression43 and post-traumatic 
stress disorder44, and end stage renal disease45. While there appears to be a correlation 
between inflammatory markers and depression/PTSD44, the evidence of such a 
relationship with end stage renal disease is lacking45. For inflammatory markers to be 
fully accepted as an explanatory model for HRQOL measures, first there has to be 
consistent association between common inflammatory markers (C-reactive protein 
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[CRP], tumor necrosis factor [TNF], and the interleukins [IL-1, IL-6]) and HRQOL, and 
two, a temporal sequence clearly showing that the inflammatory markers preceded the 
HRQOL outcome. Even then, the inflammatory markers would have to directly influence 
functional status well before routinely observed or measured symptoms appear. This is 
akin to having HRQOL serving as a screening test, pointing to the disease before it is 
obvious.  
   The impact of age and age-associated comorbidities on HIV-infected persons further 
complicates the relationship between HIV, HAART and HRQOL. It is estimated that by 
2015, the number of older adults (defined as ≥50 years) would have reached 50%46. 
Although only 17% of our cohort fall into the older age group, age showed a positive 
linear relationship with physical functional health both in the baseline and longitudinal 
studies and an inverse relationship with mental functional health at baseline. Age is 
associated with increased vulnerability towards more rapidly advancing disease, 
including AIDS-defining illness, HIV-associated neuro-cognitive disorders, and mortality 
due to immune senescence and differential response to HAART47-50. Common 
comorbidities affecting HRQOL in HIV-infected persons include diabetes, cardiovascular 
and renal diseases, and cancers47 (also see chapter 1). While there is increased 
comorbidity burden associated with age47, the relationship could be more complex. For 
example, we noticed an improvement in PCS scores over the period of follow-up in those 
with medical comorbidity (chapter 3). How much of this positive impact is a reflection of 
the healthcare system is unknown. In our cohort by far the most important psychiatric 
comorbidity is depression. 
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   Finally, one would expect significant variations in scores over time given the dynamic 
and subjective nature of HRQOL measures but that was not the case with our longitudinal 
study (chapter 3). Others have reported similar stability in HRQOL scores with long-term 
follow-up33,51. For our cohort, possible reasons for this would be the free movement of 
participants across groups especially the HAART-naïve and the Off-HAART groups to 
the PI-HAART and NPI-HAART groups, but even the PI-HAART and NPI-HAART 
groups crossed over. Descriptive analyses showed that between the first and second year 
there were 72 such cross overs, 41 between the second and third year and 31 for both the 
3rd/4th and 4th/5th years. These cross-overs were basically influenced by HIV-disease 
markers (CD4 count and plasma viral load) but factors such as drug toxicities, and HIV-
resistance strains may have played a role. As time passes, the perception of the individual 
may change and his or her priorities (values/goals) may also change, and these have the 
potential to keep scores stable or fluctuate only slightly over time as they may allocate 
higher scores to health domains they had previously scored low and low scores to 
domains they previously scored high. This adaptation of the individual to his changing 
health situation is what has been described as response shift52-54. Rapkin53 defines 
response shift in QOL as a ‘deviation of an observed score from some expected value, 
associated with a change in the way that the individual appraises QOL’. For response 
shift to occur, three criteria must be fulfilled: (i) a change in the respondent’s internal 
standards of measurement resulting in scale recalibration; (ii) a change in the 
respondents values or the importance of the component domains constituting the target 
construct; and (iii) a redefinition of the target construct or reconceptualization52,54. 
Although response shift offers an attractive model to explain stability in HRQOL scores 
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over time, its evaluation often requires qualitative research53,54. One clue to possible 
presence of response shift in a multivariate regression model may be the degree of 
variances in the model and the presence of significant interaction term affecting the 
HRQOL score53. In our longitudinal models, the relative smallness of the error terms in 
the treatment groups (PI/NPI) compared to the non-treatment groups (Naïve/Off), and the 
significant effect of comorbidity*time interaction term are perhaps the best clue of the 
presence of response shift (figures 3.1.a-d and 3.2.a-d; tables 3.2.a, 3.2.b, 3.3.a). In 
concluding we will note that while some domain measures in the HRQOL assessment, 
such as general health perception, are affected by response shift, others, such as physical 
functioning, which ask questions about accomplishment of specific tasks, are not affected 
by response shift.  
5.2: Recommendations 
   A few instruments have been recommended for use in clinical settings including 
clinical trials1,55. Grossman et al1 recommended two generic instruments, the linear 
analogue self-assessment questionnaire (LASA), the SF-12 for their brevity, or the MOS-
HIV in clinical setting. On the other hand Clayson et al55 recommended the EQ-5D, the 
SF-36, health utilities index (HUI), functional assessment of HIV infection (FAHI) and 
MOS-HIV. Clayson et al based their recommendation on (1) content validity for physical 
function, social/role function and mental health/emotional well-being, (2) practicality 
(self-administered,  taking ≤ 15 minutes with ≤ 50 items), (3) psychometric properties 
(dimensionality, reliability, validity, and responsiveness), and (4) the availability of 
normative data and/or population-based preference weights13. Based on the results of our 
studies (chapters 1, 2, 3, and 4), in which we used the summary scores both as outcome 
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as well as explanatory variables, our findings strongly support the use of SF-36 in clinical 
practice. The predictive, discriminative and concurrent validity makes it very suitable for 
use in risk stratification in clinical and research settings. We have clearly seen from our 
study the need to address the mental health needs of HIV-infected military personnel. To 
do so will need a commitment on the part of both administrators and clinicians. 
Furthermore, a multi-disciplinary approach may be more beneficial. Because completing 
the SF-36 questionnaire may take some valuable time during office visits, we encourage 
its completion well prior to patients clinical encounters with their primary care 
physicians/providers. Following this reasoning, we encourage the use of secured patients’ 
portal in the electronic health records (EHR) system, which should be readily 
incorporated into their health records. With the passage of the Health Information 
Technology for Economic and Clinical Health (HITECH) Act of 200956 and the other 
incentives programs by the Centers for Medicare and Medicaid (CMS), such as 
Meaningful Use of the EHR57, we believe it will be much easier to incorporate these 
measures now than it was in the past. Taking the HRQOL survey ahead of their annual 
comprehensive physical examination may make it more acceptable to patients. On the 
part of developers of the instrument, we encourage the development of SF-36 application 
that is user friendly. This app should allow for both domain and summary scores to be 
calculated, at least for the provider specific SF-36 app. In that case, the information in the 
patient-specific app should be transferable to the clinician-specific app. We believe such 
measures are likely to make incorporating HRQOL measurement in clinical practice 
more acceptable to practitioners.  
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   We recommend future research using the SF-36 or other instruments to separately 
report both the physical component summary scores (PCSS) and mental component 
summary scores (MCSS), rather than the global or overall HRQOL scores. This is 
because the summary scores (PCSS and MCSS) capture different attributes in the 
individual or participants32 (chapters 2, 3, and 4). Also, it facilitates comparisons of 
results across different HIV-infected populations, and across groups with different 
medical conditions but even more importantly with general US population, therefore 
enabling us to gauge the burden of HIV on the individual. Reporting of only the eight 
health domain scores without inclusion of the summary scores should be discouraged. 
That being said, we encourage further subscale (or domain) analyses in order to fully 
understand which domains are primarily affected in the summary scores, which might be 
important in respect to specific interventions. This could still be done for our cohort. 
   Further support for the use of the SF-36 is based on the increasing burden of medical 
and psychiatric comorbidities among HIV-infected persons. We believe its use may 
provide more advantages than the use of HIV-disease specific instruments under these 
circumstances. With HAART being increasingly started at higher CD4 counts, it is 
unlikely that routine clinical assessment of the infected individual based on HIV-disease 
indicators (CD4 count and viral loads) will provide the needed information on patient 
satisfaction with treatment, and assessment of HRQOL may offer that opportunity. While 
HIV-infection can now be classified as a chronic disease, such as hypertension, diabetes 
and coronary artery disease, we must not fail to lose sight of the fact that HIV is still an 
infectious disease, and that the infected individual may engage in risk taking behaviors 
over time. Efforts should therefore be made to always assess the individual’s overall 
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well-being and motivational level, and we believe measurement of HRQOL provides that 
opportunity.
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